Anti-MSR1 antibodies and methods of use thereof

Anti-MSR1 antibodies and antibody-drug conjugates target MSR1-expressing cells to address side effects and bioavailability issues in existing therapies, offering effective treatments for conditions like atherosclerosis and bacterial infections.

JP7590871B2Active Publication Date: 2024-11-27REGENERON PHARMACEUTICALS INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2020562649
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-03-20
Filing Date
2019-05-08
Publication Date
2024-11-27
Estimated Expiration
2039-05-08

AI Technical Summary

Technical Problem

Current therapies for conditions such as atherosclerosis, Alzheimer's disease, and inflammatory diseases face challenges due to undesirable side effects from off-target modulation of LXR and glucocorticoid receptors, and the limited bioavailability of rifamycins, necessitating the development of targeted therapies that minimize these issues.

Method used

Development of anti-MSR1 antibodies and antibody-drug conjugates that specifically target MSR1-expressing cells, allowing for targeted modulation of LXR and glucocorticoid receptors, and conjugation of rifamycins to minimize side effects.

Benefits of technology

The anti-MSR1 antibodies and conjugates provide targeted therapy, reducing side effects and improving bioavailability, effectively treating conditions like atherosclerosis and bacterial infections while minimizing off-target impacts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590871001153
    Figure 0007590871001153
  • Figure 0007590871001154
    Figure 0007590871001154
  • Figure 0007590871001155
    Figure 0007590871001155
Patent Text Reader

Abstract

Provided herein are antibodies and antigen-binding fragments that bind to MSR1, and methods of using the same. In certain embodiments, the antibodies bind to human MSR1 with high affinity. In certain embodiments, the antibodies bind to MSR1 without blocking modified LDL binding to MSR1, or block the binding by less than 90%. In some embodiments, the antibodies bind to cell surface-expressed MSR1 and are internalized. The antibodies of the present invention may be fully human. The present invention includes anti-MSR1 antibodies or antigen-binding fragments thereof conjugated to a drug or therapeutic compound. [Selection diagram] Figure 21
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application claims priority to U.S. Provisional Application No. 62 / 669,276, filed May 9, 2018, U.S. Provisional Application No. 62 / 678,200, filed May 30, 2018, U.S. Provisional Application No. 62 / 769,946, filed November 20, 2018, U.S. Provisional Application No. 62 / 789,987, filed January 8, 2019, and U.S. Provisional Application No. 62 / 821,362, filed March 20, 2019, which are incorporated by reference in their entireties for all purposes.

[0002] FIELD OF THE INVENTION The present invention relates to antibodies and antigen-binding fragments thereof that specifically bind to the trimeric membrane glycoprotein receptor (MSR1) and modulate MSR1 signaling, as well as antibody-drug conjugates of such antibodies, and methods of use thereof.

[0003] (Sequence Listing) A copy of the Sequence Listing is being submitted contemporaneously herewith via EFS-Web as a hardcopy of the ASCII format Sequence Listing with filename 114581.00244_ST25.TXT, created on May 30, 2018, and approximately 165 kilobytes in size. The Sequence Listing contained in this hardcopy ASCII format document is a part of the present specification and is incorporated herein by reference in its entirety. [Background technology]

[0004] (background) Macrophage scavenger receptor 1 (MSR1) is a single-span trimeric type II membrane glycoprotein pattern recognition receptor that mediates the uptake of a series of negatively charged / polyanionic ligands, including modified low-density lipoprotein (LDL) (Krieger, M., 1994. Annu. Rev. Biochem. 63:601-637; Platt, N. and S. Gordon, 2001. J. Clin. Invest. 108(5):649-654) and advanced glycation end products of bovine serum albumin (AGE-BSA) (Smedsrod et al., 1997. Biochem. J. 322(Pt 2):567-573). The MSR1 receptor has been implicated in many macrophage-related physiological and pathological processes, including atherosclerosis, Alzheimer's disease, and host defense.

[0005] MSR1 expression was initially thought to be macrophage-specific. However, it has recently been shown to be present on various classes of dendritic cells (Herber et al., 2010. Nat. Med. 16(8): 880-886). Furthermore, MSR1 appears to be expressed in endothelial cells and smooth muscle cells. It is internalized via coated pits on the cell surface, releases its ligand at acidic pH, and then recycles from the trans-Golgi apparatus back to the cell surface (Doi et al., 1994. Journal of Biological Chemistry; Mori, T. 1994. Lab Invest.). This promotes the conversion of monocyte-derived macrophages to foam cells, a key step in the progression of atherosclerosis.

[0006] MSR1 isoforms 1 and 2 are functional receptors that mediate the endocytosis of modified low-density lipoprotein (LDL). MSR1 isoform 3 can bind modified LDL (acetyl-LDL) but does not appear to be able to internalize the bound complex. However, MSR1 also binds to a wide variety of ligands other than modified LDL. These ligands include β-amyloid protein, molecular chaperones, extracellular matrix proteins, advanced glycation end products, apoptotic cells, and activated B cells.

[0007] Liver X receptors (LXRs) include LXRα and LXRβ, ligand-dependent transcription factors that regulate the expression of genes involved in cholesterol, lipid, and glucose homeostasis, inflammation, and innate immunity. LXRα is highly expressed in the liver, intestine, adipose tissue, and differentiated macrophages; LXRβ is widely expressed. LXRs have diverse biological functions, including (i) stimulating the expression of cholesterol transporters, such as ABCA1 and ABCG1 (both of which mediate cellular cholesterol efflux); and (ii) negatively regulating macrophage inflammatory gene expression through the suppression of NF-kB activation. LXRs have also been implicated in atherosclerosis, proliferative disorders, neurodegenerative disorders, and inflammation. Proliferative disorders include melanoma, lung cancer, oral squamous cell carcinoma, and prostate cancer (Pencheva et al., 2004; Wu et al., 2015; Kaneko et al., 2015; Chuu et al., 2006). Neurodegenerative disorders include Alzheimer's disease and myelin gene expression (Terwel et al., 2011; Sandoval-Hernandez et al., 2016; Meffre et al., 2014). Inflammation includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, and arthritis (Anderson et al., 2011; Huang et al., 2015; Cui et al., 2012). Macrophage LXRs are known to have anti-atherogenic activity. LXR agonists are believed to be able to (i) inhibit the initiation and slow the progression of atherosclerosis; (ii) attenuate atherosclerosis and stabilize established atherosclerotic lesions; and (iii) reduce lesion macrophage content through apoptosis.

[0008] The therapeutic efficacy of small molecule LXR modulators is limited, for example, by undesired LXR modulation in non-target cells and / or low bioavailability. Modulation of LXR in non-target cells can result in undesirable side effects, and low bioavailability can be caused by a number of reasons, including, but not limited to, low solubility, which further exacerbates the inadequate therapeutic range of treatment. The development of ADCs containing LXR modulators would enable target-specific LXR modulation, thereby avoiding side effects caused by off-target LXR modulation. Furthermore, such ADCs would provide improved modulation of biological targets, improved bioavailability, and an improved therapeutic range. Therefore, there remains a continuing need for effective treatment of, for example, metabolic diseases, using antibody-drug conjugates of LXR modulators.

[0009] Glucocorticoids (GCs) are small-molecule steroids that bind to the glucocorticoid receptor (GR) and are widely used in anti-inflammatory and immunosuppressive therapy. However, due to the ubiquitous expression of glucocorticoid receptors in many cell types, glucocorticoid therapy is compromised by toxicity to most organ systems. Therefore, there is a need for both novel glucocorticoids and novel therapies that minimize the side effects resulting from glucocorticoid administration, particularly those resulting from activation of the glucocorticoid receptor in non-target cells.

[0010] Rifamycins form a subclass of the ansamycin antibiotic family with a spectrum of activity against Gram-positive and Gram-negative bacteria and are commonly prescribed antimycobacterial drugs for the treatment of tuberculosis, leprosy, and / or Mycobacterium avium complex (MAC). The rifamycin group of antibiotics includes "classical" rifamycins and rifamycin derivatives, such as rifampicin (or rifampin), rifabutin, rifapentine, rifalazil, and rifaximin. The increasing occurrence of antibiotic-resistant bacterial strains (e.g., methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA)), and multidrug-resistant Mycobacterium tuberculosis, particularly in hospital settings, is an ongoing problem. More effective rifamycin analogs are needed. Rifamycins are moderate to strong inducers of the cytochrome P450 enzyme system (particularly CYP3A4), which can result in reduced bioavailability and enhanced clearance of some coadministered drugs that undergo metabolism by this enzyme (particularly CYP3A4). Such interactions may be delayed in onset but persist beyond rifamycin coadministration. Rifampin can also induce the P-glycoprotein (P-gp) multidrug efflux transporter. Novel therapies are needed that minimize side effects resulting from rifamycin administration, particularly those caused by activation of the cytochrome P450 enzyme system.

[0011] As disclosed in this application, MSR antibodies can provide a means for specific targeting of therapeutic molecules, such as LXR agonists, steroids, and rifamycins, to minimize undesirable side effects caused by systemic administration of such compounds. Summary of the Invention

[0012] (overview) Provided herein are antibodies, antigen-binding fragments of the antibodies, and antibody-drug conjugates thereof that bind to the membrane glycoprotein receptor known as MSR1. The antibodies are useful, inter alia, for targeting cells that express MSR1, such as macrophage cells. The anti-MSR1 antibodies and antigen-binding portions thereof can be used alone in their unmodified form or can be included as part of an antibody-drug conjugate.

[0013] The antibodies disclosed herein can be full length (e.g., IgG1 or IgG4 antibodies) or can comprise only the antigen-binding portion (e.g., Fab, F(ab')2, or scFv fragments) and can be modified to affect functionality, e.g., to abolish residual effector function (Reddy et al., 2000, J. Immunol. 164:1925-1933).

[0014] Embodiments of anti-MSR1 antibodies disclosed herein are listed in Tables 4 and 5. Table 4 shows the amino acid sequence identifiers of the heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), and light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of exemplary anti-MSR1 antibodies. Table 5 shows the nucleic acid sequence identifiers of the HCVR, LCVR, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of exemplary anti-MSR1 antibodies.

[0015] Provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising an HCVR comprising an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0016] Also provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising an LCVR comprising an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0017] Also provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising an HCVR and LCVR amino acid sequence pair (HCVR / LCVR) comprising any of the HCVR amino acid sequences listed in Table 4 paired with any of the LCVR amino acid sequences listed in Table 4. Certain embodiments relate to an antibody or antigen-binding fragment thereof comprising an HCVR / LCVR amino acid sequence pair included in any of the exemplary anti-MSR1 antibodies listed in Table 4. In some embodiments, the HCVR / LCVR amino acid sequence pair is: 2 / 10, 34 / 42 , 50 / 58; 98 / 106 , and 290 / 298 is selected from the group consisting of:

[0018] Provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0019] Also provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0020] Also provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0021] Provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising a light chain CDR1 (LCDR1) comprising an amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0022] Also provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising a light chain CDR2 (LCDR2) comprising an amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0023] Also provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising a light chain CDR3 (LCDR3) comprising an amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table 4, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity.

[0024] Also provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising an HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3) comprising any of the HCDR3 amino acid sequences listed in Table 4 paired with any of the LCDR3 amino acid sequences listed in Table 4. Certain embodiments relate to an antibody or antigen-binding fragment thereof comprising an HCDR3 / LCDR3 amino acid sequence pair included in any of the exemplary anti-MSR1 antibodies listed in Table 4. In some embodiments, the HCDR3 / LCDR3 amino acid sequence pair is selected from the group consisting of: 8 / 16, 40 / 48, 56 / 64; 96 / 104, and 288 / 296.

[0025] Provided herein are antibodies or antigen-binding fragments thereof that specifically bind to MSR1, comprising six CDR pairs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in any of the exemplary anti-MSR1 antibodies listed in Table 4. In certain embodiments, the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence pairs are: 4-6-8-12-14-16; 36-38-40-44-46-48; 52-54-56-60-62-64; 100-102-104-108-110-112 , and 292-294-296-300-302-304 is selected from the group consisting of:

[0026] In a related embodiment, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in the HCVR / LCVR amino acid sequence pair defined by any of the exemplary anti-MSR1 antibodies listed in Table 4. For example, the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising 2 / 10, 34 / 42 , 50 / 58, 98 / 106 , and 290 / 298The present invention also includes an antibody or antigen-binding fragment thereof that specifically binds to MSR1, comprising an HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence pair contained in an HCVR / LCVR amino acid sequence pair selected from the group consisting of:. Methods and techniques for identifying CDRs contained in HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the specific HCVR and / or LCVR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify CDR boundaries include, for example, the Kabat definition, the Chothia definition, and the AbM definition. Generally, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. See, e.g., Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989). Public databases are also available for identifying CDR sequences within antibodies.

[0027] Also provided herein are nucleic acid molecules encoding anti-MSR1 antibodies or portions thereof. For example, provided herein are nucleic acid molecules encoding any of the HCVR amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0028] Also provided herein are nucleic acid molecules encoding any of the LCVR amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0029] Also provided herein is a nucleic acid molecule encoding any of the HCDR1 amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR1 nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0030] Also provided herein are nucleic acid molecules encoding any of the HCDR2 amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR2 nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0031] Also provided herein are nucleic acid molecules encoding any of the HCDR3 amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR3 nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0032] Also provided herein is a nucleic acid molecule encoding any of the LCDR1 amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR1 nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0033] Also provided herein are nucleic acid molecules encoding any of the LCDR2 amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR2 nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0034] Also provided herein are nucleic acid molecules encoding any of the LCDR3 amino acid sequences listed in Table 4; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR3 nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0035] Also provided herein is a nucleic acid molecule encoding an HCVR, wherein the HCVR comprises a set of three CDRs (i.e., HCDR1-HCDR2-HCDR3), wherein the HCDR1-HCDR2-HCDR3 amino acid sequence set is as defined by any of the exemplary anti-MSR1 antibodies listed in Table 4.

[0036] Also provided herein is a nucleic acid molecule encoding an LCVR, wherein the LCVR comprises a set of three CDRs (i.e., LCDR1-LCDR2-LCDR3), wherein the LCDR1-LCDR2-LCDR3 amino acid sequence set is as defined by any of the exemplary anti-MSR1 antibodies listed in Table 4.

[0037] Also provided herein are nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises the amino acid sequence of any of the HCVR amino acid sequences listed in Table 4, and the LCVR comprises the amino acid sequence of any of the LCVR amino acid sequences listed in Table 4. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 5, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto. In certain embodiments according to this aspect of the invention, the nucleic acid molecule encodes an HCVR and an LCVR, wherein both the HCVR and LCVR are derived from the same anti-MSR1 antibody listed in Table 4.

[0038] Also provided herein are recombinant expression vectors capable of expressing polypeptides comprising the heavy or light chain variable regions of anti-MSR1 antibodies. For example, embodiments include recombinant expression vectors comprising any of the nucleic acid molecules described above, i.e., nucleic acid molecules encoding any of the HCVR, LCVR, and / or CDR sequences set forth in Table 4. Also included within the scope of the invention are host cells into which such vectors have been introduced, as well as methods for producing antibodies or antibody fragments by culturing the host cells under conditions permissive for their production, and for recovering the antibodies and antibody fragments so produced.

[0039] Provided herein are anti-MSR1 antibodies with modified glycosylation patterns. In some embodiments, modifications to remove undesired glycosylation sites can be useful, for example, to enhance antibody-dependent cellular cytotoxicity (ADCC) function (see Shield et al. (2002) JBC 277:26733). In some embodiments, modifications to provide antibodies lacking fucose moieties present on the oligosaccharide chains can be useful, for example, to enhance antibody-dependent cellular cytotoxicity (ADCC) function. In other applications, galactosylation modifications can be performed to modify complement-dependent cytotoxicity (CDC).

[0040] In another aspect, provided herein is a pharmaceutical composition comprising a recombinant human antibody or fragment thereof that specifically binds to MSR1 and a pharmaceutically acceptable carrier. In a related aspect, an embodiment relates to a composition that is a combination of an anti-MSR1 antibody and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with the anti-MSR1 antibody. Also provided herein are antibody-drug conjugates (ADCs) comprising an anti-MSR1 antibody conjugated to a drug or therapeutic agent. Exemplary combination therapies, co-formulations, and ADCs comprising anti-MSR1 antibodies are disclosed elsewhere herein.

[0041] Also provided herein are antibody-drug conjugates (ADCs) comprising an anti-MSR1 antibody or an MSR1 antigen-binding fragment thereof conjugated to a drug or therapeutic agent. Also provided herein are reactive linker-payloads useful for generating ADCs. Further provided herein are modified anti-MSR1 antibodies and modified MSR1 antigen-binding fragments useful for generating ADCs.

[0042] Also provided herein is a therapeutic method comprising administering to a subject in need thereof an anti-MSR1 antibody, an antigen-binding portion of the MSR1 antibody, or an ADC comprising the anti-MSR1 antibody or its antigen-binding fragment. The therapeutic method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the anti-MSR1 antibody, an antigen-binding portion of the MSR1 antibody, or an ADC comprising the anti-MSR1 antibody or its antigen-binding fragment. The disorder to be treated is any disease or condition that can be improved, ameliorated, inhibited, or prevented by targeting MSR1. In some embodiments, the disease or condition is a proliferative disease, metabolic disease, inflammatory disease, neurodegenerative disease, or a disease, disorder, or condition associated with glucocorticoid receptor signaling. In some embodiments, the disease or condition is atherosclerosis. In some embodiments, the disease, disorder, or condition associated with glucocorticoid receptor signaling is an inflammatory disease, disorder, or condition. In some such embodiments, side effects associated with administration of the unconjugated steroid payload of the compound are reduced.Also provided herein are therapeutic methods comprising administering an anti-MSR1 antibody, an antigen-binding portion of an MSR1 antibody, or an ADC comprising the anti-MSR1 antibody or MSR1-antigen-binding fragment thereof, for treating and / or preventing a bacterial infection in a subject.

[0043] Provided herein is the use of an anti-MSR1 antibody, an antigen-binding portion of an MSR1 antibody, or an ADC comprising an anti-MSR1 antibody or its MSR1 antigen-binding fragment, described herein, for the treatment of any disease, disorder, or condition described herein.

[0044] Also provided herein is a therapeutic method for treating, arresting, or ameliorating atherosclerosis, comprising administering to a subject in need thereof an anti-MSR1 antibody, an antigen-binding portion of the MSR1 antibody, or an ADC comprising the anti-MSR1 antibody or its MSR1 antigen-binding fragment. The therapeutic method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the anti-MSR1 antibody, the antigen-binding portion of the MSR1 antibody, or an ADC comprising the anti-MSR1 antibody or its MSR1 antigen-binding fragment.

[0045] Other embodiments will become apparent from a review of the following detailed description. [Brief explanation of the drawings]

[0046] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1] FIG. 1 provides the synthetic scheme for P1 and P2B.

[0047] [Figure 2] Figure 2 provides the synthetic scheme for LP1.

[0048] [Figure 3] Figure 3 provides the synthetic scheme for LP2.

[0049] [Figure 4] Figure 4 provides the synthetic scheme for LP5.

[0050] [Figure 5] Figure 5 provides a synthetic scheme for LP6.

[0051] [Figure 6] Figure 6 provides the synthetic scheme for LP18.

[0052] [Figure 7] Figure 7 provides a synthetic scheme for LP4.

[0053] [Figure 8] Figure 8 provides the synthetic scheme for LP11.

[0054] [Figure 9] Figure 9 provides a synthetic scheme for LP9.

[0055] [Figure 10] Figure 10 provides the synthetic scheme for LP12.

[0056] [Figure 11] Figure 11 provides the synthetic scheme for P3 and P4.

[0057] [Figure 12] Figure 12 provides the synthetic scheme for LP3.

[0058] [Figure 13] Figure 13 provides a synthetic scheme for LP13.

[0059] [Figure 14] Figure 14 provides a synthetic scheme for LP14.

[0060] [Figure 15] Figure 15 provides the synthetic scheme for LP15.

[0061] [Figure 16] Figure 16 provides a synthetic scheme for antibody-drug conjugates (ADCs).

[0062] [Figure 17] FIG. 17 is a line graph showing the percentage of dose-dependent cholesterol efflux in THP-1 macrophages for an exemplary MSR1 antibody-LXR conjugate, its unconjugated counterpart, an isotype control-steroid conjugate, and the corresponding free payload.

[0063] [Figure 18] FIG. 18 provides a series of bar graphs showing the effect of an exemplary MSR1 antibody-LXR agonist conjugate and its unconjugated counterpart on serum lipid levels in a mouse model of atherosclerosis.

[0064] [Figure 19] Figure 19 provides a series of bar graphs showing the effect of an exemplary MSR1 antibody-LXR agonist conjugate and its unconjugated counterpart on lesion lipid area and macrophage (CD68) content in a mouse model of atherosclerosis.

[0065] [Figure 20] FIG. 20 provides a series of bar graphs showing the effects of an exemplary MSR1 antibody-LXR agonist conjugate and its unconjugated counterpart on hepatic triglyceride and cholesterol levels in a mouse model of atherosclerosis.

[0066] [Figure 21] FIG. 21 provides a series of bar graphs showing the effect of an exemplary MSR1 antibody-LXR agonist conjugate and its unconjugated counterpart on de novo lipogenesis in a mouse model of atherosclerosis.

[0067] [Figure 22] Figure 22 provides a synthesis scheme for budesonide-spacer containing reactive groups: suc-acid (compound 1c), carbamate analogs (1d, 1e), THP-analogs (1g and 1h), glucose analogs (1i and 1j), phosphate analogs (1k and 1l), and a commercially available phosphate analog (1m).

[0068] [Figure 23]FIG. 23 provides the payloads, compounds, and synthetic schemes for bis-octahydrophenanthrenecarboxamides P3B-P9B.

[0069] [Figure 24] FIG. 24 provides the payloads, compounds, and synthetic schemes for bis-octahydrophenanthrenecarboxamides P10B-P11B.

[0070] [Figure 25] FIG. 25 provides a synthetic scheme for linkers and linker payloads LP1B-LP5B.

[0071] [Figure 26] Figure 26 provides a synthesis scheme for linker and linker payload LP6B.

[0072] [Figure 27] Figure 27 provides a synthesis scheme for the linker and linker payload LP7B.

[0073] [Figure 28] Figure 28 provides a synthesis scheme for the linker and linker payload LP8B.

[0074] [Figure 29] Figure 29 provides a synthesis scheme for the linker and linker payload LP9B.

[0075] [Figure 30] FIG. 30 provides a synthesis scheme for the linker and linker payloads LP10B and LP11B.

[0076] [Figure 31] FIG. 31 provides a synthetic scheme for payload 12B, linker, and linker payload LP12B.

[0077] [Figure 32] FIG. 32 provides a synthetic scheme for cyclodextrin-azide 105a.

[0078] [Figure 33] Figure 33 provides a synthetic scheme for azido-PEG4-taurine 105b.

[0079] [Figure 34] Figure 34 provides a synthetic scheme for maltose-azide 105c.

[0080] [Figure 35] FIG. 35 is a plot of the results of a Staphylococcus aureus growth inhibition assay performed with rifamycin analogs.

[0081] [Figure 36] FIG. 36 is a bar graph of the results of an S. aureus intracellular killing assay performed with rifamycin analogs.

[0082] [Figure 37] FIG. 37 is a plot of the results of an S. aureus intracellular killing assay performed with rifamycin analogs. DETAILED DESCRIPTION OF THE INVENTION

[0083] (Detailed explanation) Before describing the present invention, it is to be understood that the present invention is not limited to the particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0084] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.As used herein, the term "about" when used in relation to a specific recited numerical value means that the value may differ from the recited value by no more than 1%.For example, as used herein, the expression "about 100" includes 99 and 101 and all values ​​therebetween (for example, 99.1, 99.2, 99.3, 99.4, etc.).

[0085] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications, and non-patent publications mentioned herein are hereby incorporated by reference in their entirety.

[0086] (definition) As used herein, the terms "MSR1," "hMSR1," and the like refer to a human single-pass trimeric type II membrane glycoprotein pattern recognition receptor comprising (i) the amino acid sequence set forth in NCBI Accession No. NP_002436.1, (ii) the amino acid sequence set forth in NCBI Accession No. NP_619729.1, and / or (iii) the amino acid sequence set forth in NCBI Accession No. NP_619730.1, which represent various types and isoforms of class A macrophage scavenger receptors. The term "MSR1" encompasses both monomeric and multimeric MSR1 molecules. As used herein, the term "monomeric human MSR1" refers to an MSR1 protein or portion thereof that does not contain or possess a multimerization domain and exists as a single MSR1 molecule under normal conditions without being directly physically connected to another MSR1 molecule. An exemplary monomeric MSR1 molecule is the molecule designated herein as "His-hMSR1," which comprises the amino acid sequence of SEQ ID NO: 393 (see, eg, Example 3 herein).

[0087] All references herein to proteins, polypeptides, and protein fragments are intended to refer to the human version of the respective protein, polypeptide, or protein fragment, unless expressly identified as being derived from a non-human species. Thus, the term "MSR1" refers to human MSR1 unless identified as being derived from a non-human species, e.g., "mouse MSR1," "monkey MSR1," etc.

[0088] As used herein, the phrase "cell surface-expressed MSR1" refers to one or more MSR1 proteins, or extracellular domains thereof, expressed on the surface of a cell in vitro or in vivo, such that at least a portion of the MSR1 protein is exposed on the extracellular surface of the cell membrane and accessible to the antigen-binding portion of an antibody. "Cell surface-expressed MSR1" can comprise or consist of an MSR1 protein expressed on the surface of a cell that normally expresses the MSR1 protein. Alternatively, "cell surface-expressed MSR1" can comprise or consist of an MSR1 protein expressed on the surface of a cell that does not normally express human MSR1 on its surface but has been artificially modified to express MSR1 on its surface.

[0089] As used herein, the term "anti-MSR1 antibody" includes monovalent antibodies having a single specificity, as well as bispecific antibodies comprising a first arm that binds to MSR1 and a second arm that binds to a second (target) antigen, wherein the anti-MSR1 arm comprises any of the HCVR / LCVR or CDR sequences listed in Table 4 herein. The term "anti-MSR1 antibody" also includes antibody-drug conjugates (ADCs) comprising an anti-MSR1 antibody or an antigen-binding portion thereof conjugated to a drug or therapeutic agent. The term "anti-MSR1 antibody" also includes antibody-radionuclide conjugates (ARCs) comprising an anti-MSR1 antibody or an antigen-binding portion thereof conjugated to a radionuclide.

[0090] As used herein, the term "antibody" refers to any antigen-binding molecule or molecular complex that contains at least one complementarity-determining region (CDR) that specifically binds to or interacts with a specific antigen (e.g., MSR1). The term "antibody" includes immunoglobulin molecules, which contain four polypeptide chains: two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and multimers thereof (e.g., IgM). Each heavy chain contains a heavy chain variable region (referred to herein as HCVR or V). H The heavy chain constant region comprises three domains: C H 1. C H 2, and C H Each light chain comprises a light chain variable region (herein LCVR or V L The light chain constant region comprises one domain (C L 1) V H and V L The regions can be further subdivided into regions of hypervariability called complementarity-determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs). H and V L is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In various embodiments of the present invention, the FRs of an anti-MSR1 antibody (or an antigen-binding portion thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence can be defined based on a comparative analysis of two or more CDRs.

[0091] The term "antibody," as used herein, also includes antigen-binding fragments of intact antibody molecules. As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, include any naturally occurring, enzymatically derived, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be obtained from intact antibody molecules using any suitable standard technique, such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable domains and, optionally, constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized. DNA can be sequenced and manipulated chemically or using molecular biology techniques, for example, to place one or more variable and / or constant domains in a suitable configuration, or to introduce codons, generate cysteine ​​residues, modify, add, or delete amino acids, etc.

[0092] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable regions of an antibody (e.g., isolated complementarity-determining regions (CDRs) such as CDR3 peptides), or constrained FR3-CDR3-FR4 peptides. Other engineered molecules, such as domain-specific antibodies, single-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed by the term "antigen-binding fragment" as used herein.

[0093] Antigen-binding fragments of antibodies typically contain at least one variable domain, which may be of any size or amino acid composition and typically contains at least one CDR adjacent to or in-frame with one or more framework sequences. H Domain is V L In the antigen-binding fragment associated with the domain, V H Domains and V L The domains may be in any suitable arrangement relative to each other. For example, the variable region may be a dimer and the V H -V H , V H -V L , or V L -V L Alternatively, the antigen-binding fragment of an antibody may contain a dimer of monomeric V H or V L It may contain domains.

[0094] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary arrangements of variable and constant domains that may be found in an antigen-binding fragment of an antibody of the invention include: (i) V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3;(vi)V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -C H 2;(x)V L -C H 3;(xi)VL -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C L In any arrangement of variable and constant domains, including any of the exemplary arrangements above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60, or more) amino acids that create a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Furthermore, antigen-binding fragments of antibodies of the present invention may comprise non-covalently associated variable and / or constant domains and / or one or more monomeric V H Or V L The variable and constant domains may comprise homodimers or heterodimers (or other multimers) of any of the above variable and constant domain arrangements non-covalently associated (e.g., by disulfide bonds) with the domains.

[0095] Like intact antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies typically comprise at least two different variable domains, where each variable domain can specifically bind to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in connection with the antigen-binding fragments of antibodies of the invention using routine techniques available in the art.

[0096] The antibodies of the present invention can function via complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). "Complement-dependent cytotoxicity" (CDC) refers to the lysis of antigen-expressing cells by the antibodies of the present invention in the presence of complement. "Antibody-dependent cell-mediated cytotoxicity" (ADCC) refers to a cell-mediated reaction in which nonspecific cytotoxic cells expressing Fc receptors (FcRs) (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibodies on target cells, thereby resulting in lysis of the target cells. CDC and ADCC can be measured using assays that are well known and available in the art (see, e.g., U.S. Pat. Nos. 5,500,362 and 5,821,337, and Clynes et al. (1998) Proc. Natl. Acad. Sci. (USA) 95:652-656). The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, the isotype of the antibody can be selected based on whether it is desirable for the antibody to mediate cytotoxicity.

[0097] In certain embodiments, the anti-MSR1 antibodies disclosed herein are human antibodies. As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the present invention may include, for example, amino acid residues in the CDRs, particularly CDR3, that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by in vitro random or site-specific mutagenesis or in vivo somatic mutation). However, as used herein, the term "human antibody" is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0098] The antibodies disclosed herein may, in some embodiments, be recombinant human antibodies. As used herein, the term "recombinant human antibody" is intended to include all human antibodies prepared, expressed, generated, or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or antibodies prepared, expressed, generated, or isolated by any other means involving splicing of human immunoglobulin gene sequences into other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or in vivo somatic mutagenesis when animals transgenic for human Ig sequences are used), thus reducing the V of the recombinant antibody. H and V L The amino acid sequence of the region is human germline V H and V L A sequence that is derived from and related to a sequence, but that may not naturally occur within the human antibody germline repertoire in vivo.

[0099] Human antibodies can exist in two forms related to hinge heterogeneity. In one form, the immunoglobulin molecule contains a stable four-chain construct of approximately 150-160 kDa in which dimers are linked by interchain heavy chain disulfide bonds. In the second form, the dimers are not linked by interchain disulfide bonds, forming a molecule of approximately 75-80 kDa composed of covalently linked light and heavy chains (half antibodies). These forms are extremely difficult to separate, even after affinity purification.

[0100] The frequency of occurrence of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the antibody hinge region isotype. A single amino acid substitution in the hinge region of a human IgG4 hinge can significantly reduce the occurrence of the second form to the level normally observed with a human IgG1 hinge (Angal et al. (1993) Molecular Immunology 30:105). The embodiments disclosed herein utilize a hinge, C H 2 or C H Included are antibodies with one or more mutations in the three regions, which may be desirable, for example, to improve the yield of the desired antibody form in production.

[0101] The antibodies disclosed herein may be isolated antibodies. As used herein, an "isolated antibody" refers to an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which it naturally occurs or is naturally produced, is an "isolated antibody" for purposes of the present invention. Isolated antibodies also include antibodies in situ within recombinant cells. An isolated antibody is an antibody that has been subjected to at least one purification or isolation step. In certain embodiments, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0102] The anti-MSR1 antibodies disclosed herein can contain one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences from which the antibody was derived. Such mutations can be readily identified by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. Embodiments include antibodies and antigen-binding fragments thereof derived from any of the amino acid sequences disclosed herein in which one or more amino acids in one or more framework and / or CDR regions have been mutated to the corresponding residue in the germline sequence from which the antibody was derived, or to the corresponding residue in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, one skilled in the art can readily generate numerous antibodies and antigen-binding fragments containing one or more individual germline mutations or combinations thereof. In certain embodiments, V H and / or V LAll framework and / or CDR residues within a domain are mutated back to the residues found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only mutated residues found in the first eight amino acids of FR1 or the last eight amino acids of FR4, or only mutated residues found in CDR1, CDR2, or CDR3. In other embodiments, one or more of the framework and / or CDR residues are mutated to the corresponding residue in a different germline sequence (i.e., a germline sequence different from the germline sequence from which the antibody was originally derived). Furthermore, the antibodies of the present invention can contain any combination of two or more germline mutations within the framework and / or CDR regions, e.g., in which certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residue in a different germline sequence. Once obtained, antibodies and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as, for example, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the scope of the embodiments disclosed herein.

[0103] Embodiments also include anti-MSR1 antibodies comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein with one or more conservative substitutions. For example, embodiments include anti-MSR1 antibodies having HCVR, LCVR, and / or CDR amino acid sequences with no more than 10, no more than 8, no more than 6, no more than 4, etc., conservative amino acid substitutions relative to any of the sets of HCVR, LCVR, and / or CDR amino acid sequences set forth in, e.g., Table 4 herein.

[0104] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule, known as the paratope. A single antigen can have multiple epitopes. Thus, different antibodies may bind to different portions of the antigen and have different biological effects. Epitopes can be either conformational or linear. Conformational epitopes arise from spatially juxtaposed amino acids from different segments of a linear polypeptide chain. Linear epitopes are those that arise from adjacent amino acid residues in a polypeptide chain. In some situations, an epitope can include a saccharide, phosphoryl, or sulfonyl moiety on an antigen.

[0105] The terms "substantial identity" or "substantially identical" when referring to a nucleic acid or fragment thereof indicates that when optimally aligned, with appropriate nucleotide insertions or deletions, with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 95%, more preferably at least about 96%, 97%, 98%, or 99% of the nucleotide bases, as measured by any well-known sequence identity algorithm, e.g., FASTA, BLAST, or GAP, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule, in certain instances, encodes a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

[0106] When applied to polypeptides, the terms "substantial similarity" or "substantially similar" mean that two peptide sequences share at least 95% sequence identity, and even more preferably at least 98% or 99% sequence identity, when optimally aligned, for example, by the programs GAP or BESTFIT using default gap weights. Preferably, non-identical residue positions differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or similarity can be adjusted upward to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331. Examples of groups of amino acids with side chains of similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartic acid and glutamic acid; and (7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-probability matrix disclosed in Gonnet et al. (1992) Science 256: 1443-1445. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-probability matrix.

[0107] Sequence similarity of polypeptides, also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, GCG software includes programs such as GAP and BESTFIT, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, e.g., homologous polypeptides from different species, or between a wild-type protein and its mutants. See, e.g., GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of highest overlap between the query and search sequences (Pearson, 2000, supra). Another preferred algorithm for comparing the sequences of the present invention to a database containing a large number of sequences from various organisms is the computer program BLAST, particularly BLASTP or TBLASTN, with default parameters. See, e.g., Altschul (1990) J. Mol. Biol. 215:403-410 and Altschul (1997) Nucleic Acids Res. 25:3389-402.

[0108] When referring to the compounds provided herein, the following terms have the following meanings unless otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In the event that there are multiple definitions for terms provided herein, these definitions prevail unless stated otherwise.

[0109] As used herein, the terms "a" or "an" mean one or more, unless the context clearly indicates otherwise.

[0110] As used herein, "alkyl" refers to a monovalent and saturated hydrocarbon radical moiety. Alkyl is optionally substituted and can be linear, branched, or cyclic, i.e., cycloalkyl. Alkyl includes radicals having 1 to 20 carbon atoms, i.e., C 1-20 Alkyl; a radical having 1 to 12 carbon atoms, i.e., C 1-12 Alkyl; a radical having 1 to 8 carbon atoms, i.e., C 1-8 Alkyl; a radical having 1 to 6 carbon atoms, i.e., C 1-6 alkyl; and radicals having 1 to 3 carbon atoms, i.e., C 1-3 Examples of alkyl moieties include, but are not limited to, alkyl. Examples of alkyl moieties include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, i-butyl, pentyl moieties, hexyl moieties, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of pentyl moieties include, but are not limited to, n-pentyl and i-pentyl. Examples of hexyl moieties include, but are not limited to, n-hexyl.

[0111] As used herein, "alkylene" refers to a divalent alkyl group. Unless otherwise specified, alkylene includes, but is not limited to, 1 to 20 carbon atoms. Alkylene groups are optionally substituted as described herein for alkyl. In some embodiments, alkylene is unsubstituted. In some embodiments, alkylene is a divalent branched alkyl group.

[0112] The term "amino" means --NH.sub.2.

[0113] The term "alkylamino," as used herein, unless otherwise specified, refers to the group -NHR', where R' is C as defined herein. 1-10 In some or any embodiments, alkylamino is C1-6 It is alkylamino.

[0114] The term "dialkylamino," as used herein, unless otherwise specified, refers to the group -NR'R', where each R' is independently a C as defined herein. 1-10 In some or any embodiments, dialkylamino is di-C 1-6 It is alkylamino.

[0115] The term "aminoalkyl," as used herein, unless otherwise specified, refers to an alkyl group, as defined herein, substituted with one or more amino groups. In some or any embodiments, an aminoalkyl is an alkyl group substituted with one -NH group (e.g., -R'(NH), where R' is -C, as defined herein). 1-10 In some or any embodiments, an aminoalkyl is an alkyl group substituted with two —NH groups. In some embodiments, an “aminoalkyl” is an aminoC 1-6 It is alkyl.

[0116] "Alkylaminoalkyl," as used herein, unless otherwise specified, refers to an alkyl group, as defined herein, substituted with one or more alkylamino groups, as defined herein. In some embodiments, "alkylaminoalkyl" refers to a C 1-6 Alkylamino C 1-6 In some embodiments, each alkyl in the alkylaminoalkyl is independently selected.

[0117] "Dialkylaminoalkyl," as used herein, unless otherwise specified, refers to an alkyl group, as defined herein, substituted with one or more dialkylamino groups, as defined herein. In some embodiments, "dialkylaminoalkyl" refers to a di-C 1-6 Alkylamino C 1-6In some embodiments, each alkyl in the dialkylaminoalkyl is independently selected.

[0118] As used herein, the terms "O-amino acid" or "HO-amino acid" refer to an amino acid in which the natural amino group at the N-terminus of the amino acid or amino acid sequence has been replaced with an oxygen or a hydroxyl group, respectively. For example, "O-AAAA" or "HO-AAAA" refers to an amino acid sequence (AAAA) in which the natural amino group at the N-terminus has been replaced with an oxygen or a hydroxyl group, respectively (e.g., [ka] where each R is an amino acid side chain). Similarly, the term "O-amino acid residue" or "HO-amino acid residue" refers to the chemical moiety in a compound that remains after a chemical reaction. For example, "O-amino acid residue" or "HO-amino acid residue" refers to the product of amide or peptide coupling of an O-amino acid or an HO-amino acid with a suitable coupling partner; where, for example, a water molecule is displaced after amide or peptide coupling of the O-amino acid or the HO-amino acid, resulting in a product with the O-amino acid residue or the HO-amino acid residue incorporated therein.

[0119] A designation of an amino acid or amino acid residue without specifying its stereochemistry is intended to encompass L-amino acids, D-amino acids, or racemic mixtures thereof.

[0120] As used herein, "haloalkyl" refers to an alkyl, as defined above, wherein the alkyl contains at least one substituent selected from a halogen, e.g., fluorine (F), chlorine (Cl), bromine (Br), or iodine (I). Examples of haloalkyl include, but are not limited to, -CF, -CHCF, -CClF, and -CCl.

[0121] As used herein, "alkenyl" refers to a monovalent hydrocarbon radical moiety containing at least two carbon atoms and one or more non-aromatic carbon-carbon double bonds. Alkenyl is optionally substituted and can be linear, branched, or cyclic. Alkenyl includes radicals having 2 to 20 carbon atoms, i.e., C 2-20 Alkenyl; a radical having 2 to 12 carbon atoms, i.e., C 2-12 Alkenyl; a radical having 2 to 8 carbon atoms, i.e., C 2-8 Alkenyl; a radical having 2 to 6 carbon atoms, i.e., C 2-6 alkenyl; and radicals having 2 to 4 carbon atoms, i.e., C 2-4 Examples of alkenyl moieties include, but are not limited to, vinyl, propenyl, butenyl, and cyclohexenyl.

[0122] As used herein, "alkynyl" refers to a monovalent hydrocarbon radical moiety containing at least two carbon atoms and one or more carbon-carbon triple bonds. Alkynyl is optionally substituted and can be linear, branched, or cyclic. Alkynyl includes radicals having 2 to 20 carbon atoms, i.e., C 2-20 Alkynyl; a radical having 2 to 12 carbon atoms, i.e., C 2-12 Alkynyl; a radical having 2 to 8 carbon atoms, i.e., C 2-8 Alkynyl; a radical having 2 to 6 carbon atoms, i.e., C 2-6 alkynyl; and radicals having 2 to 4 carbon atoms, i.e., C 2-4 Examples of alkynyl moieties include, but are not limited to, ethynyl, propynyl, and butynyl.

[0123] As used herein, "alkoxy" refers to a monovalent and saturated hydrocarbon radical moiety, where the hydrocarbon contains a single bond to an oxygen atom and the radical is located on the oxygen atom, e.g., in the case of ethoxy, CH3CH2-O·. An alkoxy substituent is attached to the compound it substitutes through the oxygen atom of the alkoxy substituent. An alkoxy is optionally substituted and can be linear, branched, or cyclic, i.e., cycloalkoxy. Alkoxy includes those having 1 to 20 carbon atoms, i.e., C 1-20 Alkoxy; having 1 to 12 carbon atoms, i.e., C 1-12 Alkoxy; having 1 to 8 carbon atoms, i.e., C 1-8 Alkoxy; having 1 to 6 carbon atoms, i.e., C 1-6 Alkoxy; and those having 1 to 3 carbon atoms, i.e., C 1-3 Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, i-butoxy, a pentoxy moiety, a hexoxy moiety, cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexoxy.

[0124] As used herein, "haloalkoxy" refers to an alkoxy, as defined above, wherein the alkoxy contains at least one substituent selected from a halogen, e.g., F, Cl, Br, or I.

[0125] As used herein, "aryl" refers to a monovalent moiety that is a radical of an aromatic compound whose ring atoms are carbon atoms. Aryl is optionally substituted and can be monocyclic or polycyclic, e.g., bicyclic or tricyclic. Examples of aryl moieties include those having 6 to 20 ring carbon atoms, i.e., C 6-20 Aryl; having 6 to 15 ring carbon atoms, i.e., C 6-15 Aryl and those having 6 to 10 ring carbon atoms, i.e., C6-10 Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, and pyrenyl.

[0126] As used herein, "arylalkyl" refers to a monovalent moiety that is a radical of an alkyl compound, where the alkyl compound is substituted with an aromatic substituent, i.e., the aromatic compound contains a single bond to the alkyl group and the radical is located on the alkyl group. An arylalkyl group is attached to the depicted chemical structure via the alkyl group. An arylalkyl group can be a group having a structure, e.g., [ka] (wherein B is an aromatic moiety, e.g., phenyl). Arylalkyl is optionally substituted, i.e., the aryl group and / or the alkyl group can be substituted as disclosed herein. Examples of arylalkyl include, but are not limited to, benzyl.

[0127] As used herein, "alkylaryl" refers to a monovalent moiety that is a radical of an aryl compound, where the aryl compound is substituted with an alkyl substituent, i.e., the aryl compound contains a single bond to an alkyl group and the radical is located on the aryl group. The alkylaryl group is attached to the depicted chemical structure via the aryl group. The alkylaryl is a group that can be represented by a structure, e.g., [ka] (wherein B is an aromatic moiety, e.g., phenyl). Alkylaryl is optionally substituted, i.e., the aryl group and / or the alkyl group can be substituted as disclosed herein. Examples of alkylaryl include, but are not limited to, toluyl.

[0128] As used herein, "aryloxy" refers to a monovalent moiety that is a radical of an aromatic compound whose ring atoms are carbon atoms and the ring is substituted with an oxygen radical, i.e., the aromatic compound contains a single bond to an oxygen atom and the radical is located on the oxygen atom, e.g., in the case of phenoxy, [ka] The aryloxy substituent is attached to the compound it substitutes through this oxygen atom. The aryloxy is optionally substituted. Aryloxy refers to radicals having 6 to 20 ring carbon atoms, i.e., C 6-20 Aryloxy; having 6 to 15 ring carbon atoms, i.e., C 6-15 aryloxy and those having 6 to 10 ring carbon atoms, i.e., C 6-10 Examples of aryloxy moieties include, but are not limited to, phenoxy, naphthoxy, and anthroxy.

[0129] As used herein, "R a R b "N-aryloxy" refers to a group in which the ring atoms are carbon atoms and the ring is free of at least one R a R b refers to a monovalent moiety that is a radical of an aromatic compound substituted with an N-substituent and at least one oxygen radical, i.e., the aromatic compound is R a R b It contains a single bond to the N-substituent and a single bond to the oxygen atom, and the radical is located on the oxygen atom, for example: [ka] R a R b The N-aryloxy substituent is attached to the compound it substitutes through this oxygen atom. a R b N-aryloxy is optionally substituted. a Rb N-aryloxy includes those having 6 to 20 ring carbon atoms, for example, C 6-20 (R a R b N) n -aryloxy, having 6 to 15 ring carbon atoms, e.g., C 6-15 (R a R b N) n -aryloxy and those having 6 to 10 ring carbon atoms, e.g., C 6-10 (R a R b N) n -aryloxy (where n is R a R b N- represents the number of substituents), but is not limited to these. a R b Examples of N-aryloxy moieties include 4-(dimethyl-amino)-phenoxy, [ka] These include, but are not limited to:

[0130] As used herein, "arylene" refers to a divalent moiety of an aromatic compound in which the only ring atoms are carbon atoms. Arylenes are optionally substituted and can be monocyclic or polycyclic, e.g., bicyclic or tricyclic. Examples of arylene moieties include those having 6 to 20 ring carbon atoms, i.e., C 6-20 Arylene; having 6 to 15 ring carbon atoms, i.e., C 6-15 Arylene and those having 6 to 10 ring carbon atoms, i.e., C 6-10 Examples include, but are not limited to, arylene.

[0131] As used herein, "heteroalkyl" refers to an alkyl in which one or more carbon atoms are replaced by a heteroatom. As used herein, "heteroalkenyl" refers to an alkenyl in which one or more carbon atoms are replaced by a heteroatom. As used herein, "heteroalkynyl" refers to an alkenyl in which one or more carbon atoms are replaced by a heteroatom. Suitable heteroatoms include, but are not limited to, nitrogen, oxygen, and sulfur atoms. Heteroalkyls are optionally substituted. Examples of heteroalkyl moieties include, but are not limited to, aminoalkyl, sulfonylalkyl, and sulfinylalkyl. Examples of heteroalkyl moieties also include, but are not limited to, methylamino, methylsulfonyl, and methylsulfinyl.

[0132] As used herein, "heteroaryl" refers to a monovalent moiety that is a radical of an aromatic compound whose ring atoms contain carbon atoms and at least one oxygen, sulfur, nitrogen, or phosphorus atom. Examples of heteroaryl moieties include, but are not limited to, those having 5 to 20 ring atoms; 5 to 15 ring atoms; and 5 to 10 ring atoms. Heteroaryls are optionally substituted.

[0133] As used herein, "heteroarylene" refers to an arylene in which one or more carbon ring atoms of the aromatic ring is replaced with an oxygen, sulfur, nitrogen, or phosphorus atom. Heteroarylene is optionally substituted.

[0134] As used herein, "heterocycloalkyl" refers to a cycloalkyl in which one or more carbon atoms are replaced with a heteroatom. Suitable heteroatoms include, but are not limited to, nitrogen, oxygen, and sulfur atoms. The heterocycloalkyl is optionally substituted. Examples of heterocycloalkyl moieties include, but are not limited to, morpholinyl, piperidinyl, tetrahydropyranyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, dioxolanyl, dithiolanyl, oxanyl, or thianyl.

[0135] As used herein, "N-containing heterocycloalkyl" refers to a cycloalkyl in which one or more carbon atoms are replaced with a heteroatom, and at least one heteroatom is a nitrogen atom. Suitable heteroatoms other than nitrogen include, but are not limited to, oxygen and sulfur atoms. N-containing heterocycloalkyls are optionally substituted. Examples of N-containing heterocycloalkyl moieties include, but are not limited to, morpholinyl, piperidinyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, or thiazolidinyl.

[0136] As used herein, "optionally substituted" when used to describe a radical moiety, such as optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylene, and optionally substituted heteroarylene, means that such moiety is optionally bonded to one or more substituents. Examples of such substituents include halo, cyano, nitro, optionally substituted haloalkyl, azido, epoxy, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, [ka] (where R A , R B , and R C is independently at each occurrence a hydrogen atom, alkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, heteroalkyl, heteroaryl, or heterocycloalkyl, or R A and R B

[0049] Examples include, but are not limited to, the following: together with the atoms to which they are attached, form a saturated or unsaturated carbocyclic ring, wherein the ring is optionally substituted and one or more ring atoms are optionally substituted with a heteroatom. In certain embodiments, when the radical moiety is optionally substituted with an optionally substituted heteroaryl, an optionally substituted heterocycloalkyl, or an optionally substituted saturated or unsaturated carbocyclic ring, the substituents on the optionally substituted heteroaryl, the optionally substituted heterocycloalkyl, or the optionally substituted saturated or unsaturated carbocyclic ring, if substituted, are not substituted with a substituent that is further optionally substituted with a further substituent. In some embodiments, when a group described herein is optionally substituted, the substituents attached to the group are not substituted unless otherwise specified.

[0137] As used herein, "O-glucose" refers to a monovalent moiety attached through the exocyclic glucose oxygen atom. Suitable O-glucose moieties include, but are not limited to: [ka] These include:

[0138] As used herein, "O-PEG" n " refers to a monovalent moiety attached through a terminal oxygen atom, where n is 1 to 100. For example, when n is 1, O-PEGn is -O-CH2CH2OH; when n is 2, O-PEGn is -O-CH2CHO-CH2CH2OH; and when n is 3, O-PEGn is -O-CH2CHO-CH2CHO-CH2CH2OH.

[0139] As used herein, "binding agent" refers to any molecule, e.g., a protein or antibody, that can bind with specificity to a given binding partner, e.g., an antigen.

[0140] As used herein, "linker" refers to a divalent, trivalent, or multivalent moiety that covalently attaches a binding agent to one or more compounds described herein, e.g., a payload compound described herein and / or a hydrophilic group.

[0141] As used herein, "connector group" or "connector group residue" refers to any group that can facilitate the release of a payload. Suitable connector groups facilitate the release of a divalent or multivalent attached payload back to its original, unconjugated form with little or no derivatization. Examples of connector groups include: [ka] or derivatives thereof. In another example, the connector group is [ka] is.

[0142] In a further example, the connector group is a self-immolative group. "Self-immolative group" refers to any such group known to those of skill in the art. In certain embodiments, the self-immolative group is p-aminobenzyloxycarbonyl (PAB / PABC), i.e., [ka] Those skilled in the art will recognize that a self-immolative group can undergo a chemical reaction that releases the payload from the remaining atoms of the linker.

[0143] As used herein, a "connecting linker" (L 2The term "connecting linker(s)" refers to a divalent group that is cleavable or non-cleavable. A cleavable linker is a linker that is cleaved by intracellular metabolism after internalization, for example, by cleavage via hydrolysis, reduction, or enzymatic reaction. A non-cleavable linker is a linker that releases the attached payload via lysosomal degradation of the antibody after internalization. Suitable connecting linkers include, but are not limited to, acid-labile linkers, hydrolytically labile linkers, enzyme-cleavable linkers, reduction-labile linkers, and non-cleavable linkers. Suitable linkers include glucuronides, succinimide-thioethers, polyethylene glycol (PEG) units, hydrazones, mal-caproyl units, disulfide units (e.g., -SS-, -SC(R 1b R 2b )-(where R 1b and R 2b are independently hydrogen or hydrocarbyl), carbamate units, para-amino-benzyl units (PAB), phosphate units, e.g., mono-, bis-, or tris-phosphate units, and peptide units, e.g., peptide units containing 2, 3, 4, 5, 6, 7, 8, or more amino acid residues, including, but not limited to, valine-citrulline residue units. As used herein, "caproyl" refers to the group -(CH)-C(O)-.

[0144] As used herein, the phrase "reactive group" ("RG") refers to a functional group or moiety that reacts with a reactive portion of an antibody, modified antibody, or antigen-binding fragment thereof. In certain embodiments, a "reactive group" is a functional group or moiety (e.g., maleimide or NHS ester) that reacts with a cysteine ​​or lysine residue of an antibody or antigen-binding fragment thereof. In certain embodiments, a "reactive group" is a functional group or moiety that can undergo a click chemistry reaction. In some embodiments of the click chemistry reaction, the reactive group comprises an alkyne that can undergo a 1,3 cycloaddition reaction with an azide. Such suitable reactive groups include, but are not limited to, strained alkynes, e.g., those suitable for strain-promoted alkyne-azide cycloaddition (SPAAC), cycloalkynes, e.g., cyclooctynes, benz-annulated alkynes, and alkynes that can undergo a 1,3 cycloaddition reaction with an alkyne in the absence of a copper catalyst. Suitable alkynes include DIBAC (wherein the -C(O)CHCHC(O)- moiety of the DIBAC moiety is L and / or L 2 DIBO (wherein the -O- moiety of the DIBO moiety can be L and / or L 2 BARAC (where the BARAC part [ka] The part is L and / or L 2 DIFO (wherein the -O- moiety can be L and / or L 2(which can be represented by the formula: ), substituted alkynes such as fluorinated alkynes, aza-cycloalkynes, BCN, and derivatives thereof, are also included, but are not limited to. Linker-payloads containing such reactive groups are useful for conjugating antibodies functionalized with azide groups. Such functionalized antibodies include antibodies functionalized with azide-polyethylene glycol groups. In certain embodiments, such functionalized antibodies are obtained by reacting an antibody containing at least one glutamine residue, for example, heavy chain Q295 (EU numbering), with a compound according to the formula H2N-LL-N3 (wherein LL is a divalent polyethylene glycol group) in the presence of the enzyme transglutaminase.

[0145] In some embodiments, the reactive group (RG) is an alkyne, e.g., [ka] which can be converted via click chemistry to azides, e.g. [ka] to produce a click chemistry reaction product, e.g., [ka] In some embodiments, the reactive group is an alkyne, e.g., [ka] (wherein L and / or L 2 includes -OCHC(O)-), which can be converted via click chemistry to an azide, e.g. [ka] to produce a click chemistry reaction product, e.g., [ka] In some embodiments, the reactive group can form an alkyne, e.g., [ka] which can be converted via click chemistry to azides, e.g. [ka] to produce a click chemistry reaction product, e.g., [ka] In some embodiments, the reactive group is a functional group, e.g., [ka] which reacts with cysteine ​​residues on an antibody or antigen-binding fragment thereof to form a bond therewith, e.g., [ka] (where Ab represents an antibody or antigen-binding fragment thereof, and S represents the S atom on a cysteine ​​residue through which the functional group is attached to the Ab). In some embodiments, the reactive group is a functional group, e.g., [ka] which reacts with lysine residues on an antibody or antigen-binding fragment thereof to conjugate therewith, e.g., [ka] (where Ab represents an antibody or antigen-binding fragment thereof, and N represents the N atom on a lysine or amino-terminal residue through which the functional group is attached to the Ab). In some examples, the reactive group is [ka] which reacts with two thiols (e.g., thiols on two different chains) of an antibody or antigen-binding fragment thereof to form a bond therewith, e.g., [ka] In some instances, the reactive group forms [ka] which reacts with two thiols (e.g., thiols on two different chains) of an antibody or antigen-binding fragment thereof to form a bond therewith, e.g., [ka] Form.

[0146] As used herein, the phrase "reactive group residue" refers to the product of the reaction of a functional group in a linker moiety with a reactive moiety of a binder (BA), including the product of click chemistry. The reactive group residue is formed by the reaction of a reactive group on an amino acid of the binder and is attached to the binder (e.g., antibody) and the linker. In some embodiments, the reactive group residue comprises 1,2,3-tetrazole, i.e., the group formed by the reaction of an alkyne with an azide. In some embodiments, the reactive group residue is [ka] where S represents the S atom on the cysteine ​​residue through which (a) binds to the Ab; and [ka] with a cysteine ​​residue on the antibody or antigen-binding fragment thereof. In some embodiments, the reactive group residue is [ka] where N represents the N atom on the lysine residue and a functional group such as [ka] with a lysine residue on the antibody or antigen-binding fragment thereof. One skilled in the art will recognize that the reactive group residue portion can be derived from the reactive group, the antibody, or both. In some instances, the reactive group residue is [ka] where S represents the S atom on a cysteine ​​residue and is a functional group [ka] with cysteine ​​residues on the antibody or antigen-binding fragment thereof.

[0147] As used herein, "pharmaceutically acceptable salt" refers to any salt suitable for administration to a patient. Suitable salts include, but are not limited to, those disclosed in Berge et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1, which is incorporated herein by reference. Examples of salts include, but are not limited to, acid-derived, base-derived amines, organic amines, inorganic amines, and alkali or alkaline earth metal salts, including, but not limited to, calcium salts, magnesium salts, potassium salts, sodium salts, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. In some instances, the payloads described herein (e.g., the rifamycin analogs described herein) contain a tertiary amine, where the nitrogen atom in the tertiary amine is the atom through which the payload is attached to the linker or linker-spacer. In such instances, the bond between the tertiary amine and the payload results in a quaternary amine in the linker-payload molecule. The positive charge on the quaternary amine can be counterbalanced by a counterion (e.g., chloro, bromo, iodo, or other suitably charged moiety, such as those described above).

[0148] Certain groups, moieties, substituents, and atoms are shown with a wavy line. The wavy line can cross a bond or bonds or can cap a bond or bonds. The wavy line indicates the atom through which the group, moiety, substituent, or atom is bonded. For example, the propyl group shown below: [ka] A phenyl group substituted with has the following structure: [ka] 。

[0149] As used herein, "amide synthesis conditions" refers to reaction conditions suitable for achieving amide formation, for example, by reaction of a carboxylic acid, an activated carboxylic acid, or an acyl halide with an amine. In some examples, "amide synthesis conditions" refers to reaction conditions suitable for achieving amide bond formation between a carboxylic acid and an amine. In some of these examples, the carboxylic acid is first converted to an activated carboxylic acid, and then the activated carboxylic acid is reacted with an amine to form an amide. Suitable conditions for achieving amide formation include, but are not limited to, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), and the like. Fluorophosphate (PyAOP), Bromotripyrrolidinophosphonium hexafluorophosphate (PyBrOP), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium These include, but are not limited to, those that utilize reagents to achieve the reaction of carboxylic acids with amines, including 3-oxide hexafluorophosphate (HATU), N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide (EDC), 2-chloro-1,3-dimethylimidazolidinium hexafluorophosphate (CIP), 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), and carbonyldiimidazole (CDI). In some instances, the carboxylic acid is first converted to an activated carboxylic ester, which is then treated with an amine to form an amide bond.In some embodiments, a carboxylic acid is treated with a reagent. The reagent activates the carboxylic acid by deprotonating the carboxylic acid and then forming a product complex with the deprotonated carboxylic acid as a result of nucleophilic attack by the deprotonated carboxylic acid on the protonated reagent. The activated carboxylic acid ester of the particular carboxylic acid is then more susceptible to nucleophilic attack by amines than before the carboxylic acid was activated. This results in amide bond formation. The carboxylic acid is therefore described as activated. Exemplary reagents include DCC and DIC.

[0150] "Amino acid" or "amino acid residue" refers, in some embodiments, to naturally occurring amino acids. In other embodiments, an amino acid or amino acid residue refers to naturally occurring amino acids and / or unnatural amino acids (e.g., β-amino acids (β 3 and β 2 ), homo-amino acids, proline and pyruvate derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, and / or N-methyl amino acids, or any other commercially available unnatural amino acids (e.g., unnatural amino acids available from Sigma-Aldrich). In other embodiments, the amino acid residue may be a residue having a side chain that participates in a transglutaminase-mediated reaction, e.g., a transglutaminase-mediated reaction of an amino acid side chain with a primary amine. For example, the reaction of asparagine and / or glutamine side chains with primary amines is used for the preparation of certain ADCs described herein. In certain embodiments, such functionalized antibodies are obtained by reacting an antibody comprising at least one glutamine residue, e.g., a heavy chain Q295 (EU numbering), with a compound according to the formula H2N-LL-N3, where LL is a divalent polyethylene glycol group, in the presence of the enzyme transglutaminase.

[0151] As used herein, "taurine" refers to a reagent [ka] or base [ka] (where, [ka] indicates the atom through which taurine is attached to the adjacent group in the formula).

[0152] As used herein, "stereoisomeric forms" or "stereoisomers" refer to the relative spatial orientation of different groups in a compound. Stereoisomeric forms include enantiomers, diastereomers, and / or mixtures thereof.

[0153] As used herein, "positional isomer," "positional isomers," or "mixture of positional isomers" refers to the product of a 1,3-cycloaddition or strain-promoted alkyne-azide cycloaddition (SPAAC) reaction, otherwise known as a click reaction, derived from a suitable azide (e.g., an -N3, or PEG-N3 derivatized antibody) treated with a suitable alkyne. In certain embodiments, for example, positional isomers and mixtures of positional isomers are characterized by the click reaction products shown below: [ka] .

[0154] By way of example only, the positional isomers of compound A1′, i.e., compounds A2′, A3′, A4′, are shown below, where each [ka] is the bond with the binder; and each [ka] Here is the binding with the payload: [ka] .

[0155] (Anti-MSR1 antibodies containing Fc variants) In some embodiments, provided herein are anti-MSR1 antibodies comprising an Fc domain containing one or more mutations that enhance or reduce antibody binding to the FcRn receptor at acidic pH, e.g., as compared to neutral pH. For example, provided herein are antibodies comprising an Fc domain containing one or more mutations that enhance or reduce antibody binding to the FcRn receptor at acidic pH, e.g., as compared to neutral pH. H 2 or C H An anti-MSR1 antibody containing a mutation in region 3, which increases the affinity of the Fc domain for FcRn in an acidic environment (e.g., in endosomes, where the pH ranges from about 5.5 to about 6.0). Such a mutation can result in an increased serum half-life of the antibody when administered to an animal. Non-limiting examples of such Fc modifications include, for example, modifications at positions 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T); or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., H / F or Y); or modifications at positions 250 and / or 428; or modifications at positions 307 or 308 (e.g., 308F, V308F) and 434. In one embodiment, the modifications include a 428L (e.g., M428L) and a 434S (e.g., N434S) modification; a 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modification; a 433K (e.g., H433K) and a 434 (e.g., 434Y) modification; a 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modification; a 250Q and 428L modification (e.g., T250Q and M428L); and a 307 and / or 308 modification (e.g., 308F or 308P).

[0156] For example, embodiments include anti-MSR1 antibodies comprising an Fc domain comprising one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T, and 256E (e.g., M252Y, S254T, and T256E); 428L and 434S (e.g., M428L and N434S); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the foregoing Fc domain mutations, and other mutations in antibody variable domains disclosed herein, are contemplated within the scope of the present invention.

[0157] (Biological characteristics of antibodies) Embodiments include antibodies and antigen-binding fragments thereof that bind to human MSR1 with high affinity. For example, the present invention provides antibodies and antigen-binding fragments thereof that bind to the human MSR1 extracellular domain expressed with an N-terminal nonahistidine tag (e.g., His9-hMSR1) with a K of less than about 10 nM, as measured by surface plasmon resonance at 25°C or 37°C using, for example, the assay format defined in Example 3 herein, or a substantially similar assay. D In some embodiments, the anti-MSR1 antibodies have a K of less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, or less than about 10 pM at 37°C, as measured by surface plasmon resonance using, for example, the assay format defined in Example 3 herein, or a substantially similar assay. DIn some embodiments, the anti-MSR1 antibodies disclosed herein have a K of less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, or less than about 20 pM at 25°C, as measured by surface plasmon resonance using the assay format defined in Example 3 herein, or a substantially similar assay. D It binds to human MSR1.

[0158] Embodiments also include antibodies and antigen-binding fragments thereof that bind to monkey MSR1 with high affinity. For example, disclosed herein are antibodies and antigen-binding fragments thereof that have a K of less than about 20 nM, as measured by surface plasmon resonance at 25° C. or 37° C. using, for example, the assay format defined in Example 3 herein, or a substantially similar assay. D and binds to the monkey MSR1 extracellular domain (e.g., HMM-mfMSR1) expressed with an N-terminal myc-myc-hexahistidine tag. According to one embodiment, the antibody has a cytoplasmic affinity of less than about 20 nM, less than about 18 pM, less than about 15 nM, less than about 12 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 5 nM, less than about 5 nM, less than about 6 ... a K of less than 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, or less than about 10 pM DThe present invention provides an anti-MSR1 antibody that binds to monkey MSR1 at a specific site. In some embodiments, the anti-MSR1 antibodies provided herein have a K of less than about 12 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, or less than about 20 pM at 25°C as measured by surface plasmon resonance using the assay format defined in Example 3 herein, or a substantially similar assay. D It binds to monkey MSR1.

[0159] The present invention provides compounds having a dissociation half-life (t) of greater than about 5 minutes, as measured, for example, by surface plasmon resonance at 25° C. or 37° C. using the assay format defined in Example 3 herein, or a substantially similar assay. 1 Also included are antibodies and antigen-binding fragments thereof that bind to the human MSR1 extracellular domain (e.g., His9-hMSR1) expressed with an N-terminal nonahistidine tag at 37° C., at a temperature of greater than about 4 minutes, greater than about 5 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, greater than about 70 minutes, greater than about 80 minutes, greater than about 90 minutes, greater than about 120 minutes, greater than about 150 minutes, greater than about 180 minutes, greater than about 210 minutes, greater than about 240 minutes, or longer, as measured by surface plasmon resonance using the assay format defined in Example 3 herein, or a substantially similar assay. 1 Anti-MSR1 antibodies that bind to human MSR1 at / 2 are provided.

[0160] Embodiments also include antibodies and antigen-binding fragments thereof that can bind with high affinity to the monkey MSR1 extracellular domain (e.g., HMM-mfMSR1) expressed with an N-terminal myc-myc-hexahistidine tag. For example, the present invention provides antibodies and antigen-binding fragments thereof that have a K of less than about 20 nM, as measured by surface plasmon resonance at 25° C. or 37° C. using, for example, the assay format defined in Example 3 herein, or a substantially similar assay. D The antibody contains an anti-MSR1 antibody that binds to HMM-mfMSR1. According to certain embodiments, the K is less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 150 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, or less than about 50 pM at 37°C as measured by surface plasmon resonance using the assay format defined in Example 3 herein, or a substantially similar assay. D The present invention provides an anti-MSR1 antibody that binds to HMM-mfMSR1 at In some embodiments, the anti-MSR1 antibodies disclosed herein have a K of less than about 12 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 150 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, or less than about 50 pM at 25°C as measured by surface plasmon resonance using the assay format defined in Example 3 herein, or a substantially similar assay. D binds to HMM-mfMSR1.

[0161] Embodiments include those having a dissociation half-life (t) of greater than about 55 minutes, as measured by surface plasmon resonance at 25° C. or 37° C. using, for example, the assay format defined in Example 3 herein, or a substantially similar assay. 1 Also included are antibodies and antigen-binding fragments thereof that bind to the monkey MSR1 extracellular domain (e.g., HMM-mfMSR1) expressed with an N-terminal myc-myc-hexahistidine tag at 37° C., at a temperature of 120° C. / 2 (Figure 2). According to certain embodiments, the antibodies and antigen-binding fragments thereof have a t of greater than about 1 minute, greater than about 2 minutes, greater than about 3 minutes, greater than about 4 minutes, greater than about 5 minutes, greater than about 6 minutes, greater than about 8 minutes, greater than about 10 minutes, greater than about 12 minutes, greater than about 14 minutes, greater than about 16 minutes, greater than about 18 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, greater than about 70 minutes, greater than about 80 minutes, greater than about 90 minutes, greater than about 120 minutes, greater than about 150 minutes, greater than about 180 minutes, greater than about 210 minutes, or longer, at 37° C., as measured by surface plasmon resonance using the assay format defined in Example 3 herein, or a substantially similar assay. 1 Anti-MSR1 antibodies that bind to dimeric human MSR1 at / 2 are provided.

[0162] Embodiments also include antibodies and antigen-binding fragments thereof that bind to modified cell surface-expressed hMSR1 at a binding ratio of at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 12-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, or more, of modified hMSR1-expressing cells to non-expressing cells, as measured, for example, by an antibody binding assay using the assay format defined in Example 5 herein, or a substantially similar assay. In some embodiments, provided herein are antibodies that bind to cells with endogenously expressed hMSR1 at a binding ratio of at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, or at least about 12-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, or more, of endogenously hMSR1-expressing cells to non-expressing cells, as measured by, for example, an antibody binding assay using the assay format defined in Example 5 herein, or a substantially similar assay. In some embodiments, the MSR1 antibodies or antigen-binding fragments disclosed herein bind to modified cell surface-expressed mouse MSR1 at a binding ratio of at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 12-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, or more, of cells expressing modified mouse MSR1 to cells not expressing modified mouse MSR1, as measured by, e.g., an antibody binding assay using the assay format defined in Example 5 herein, or a substantially similar assay.

[0163] Embodiments also include antibodies and antigen-binding fragments thereof that bind to MSR1 and exhibit less than about 95% maximal inhibition of modified low-density lipoprotein (LDL) uptake in cells expressing human MSR1. For example, embodiments include antibodies and antigen-binding fragments thereof that exhibit an IC of less than about 6.1 nM when measured using a ligand uptake assay using the assay format defined in Example 8 herein, or a substantially similar assay. 50 and exhibits less than about 95% maximal inhibition of uptake of modified LDL (e.g., oxidized or acetylated) in cells expressing human MSR1. According to certain embodiments, the antibodies have an IC of less than about 6.1 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1.5 nM, less than about 1.4 nM, less than about 1.3 nM, less than about 1.2 nM, less than about 1.0 nM, less than about 900 pM, less than about 800 pM, less than about 600 pM, less than about 400 pM, less than about 200 pM, less than about 100 pM, less than about 80 pM, less than about 60 pM, less than about 40 pM, or less than about 20 pM, when measured using a ligand uptake assay using the assay format defined in Example 8 herein, or a substantially similar assay. 50 and anti-MSR1 antibodies that exhibit maximal inhibition of modified LDL uptake in cells expressing human MSR1 by less than about 95%.

[0164] In some embodiments, the anti-MSR1 antibody has an IC of less than about 6.1 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1.5 nM, less than about 1.4 nM, less than about 1.3 nM, less than about 1.2 nM, less than about 1.0 nM, less than about 900 pM, less than about 800 pM, less than about 600 pM, less than about 400 pM, less than about 200 pM, less than about 100 pM, less than about 80 pM, less than about 60 pM, less than about 40 pM, or less than about 20 pM, when measured using a ligand uptake assay using the assay format defined in Example 8 herein, or a substantially similar assay. 50 shows a maximal inhibition of modified LDL uptake of approximately 90% in cells expressing human MSR1.

[0165] In some embodiments, the anti-MSR1 antibody has an IC of less than about 6.1 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1.5 nM, less than about 1.4 nM, less than about 1.3 nM, less than about 1.2 nM, less than about 1.0 nM, less than about 900 pM, less than about 800 pM, less than about 600 pM, less than about 400 pM, less than about 200 pM, less than about 100 pM, less than about 80 pM, less than about 60 pM, less than about 40 pM, or less than about 20 pM, when measured using a ligand uptake assay using the assay format defined in Example 8 herein, or a substantially similar assay. 50 shows a maximal inhibition of modified LDL uptake of less than about 75% in cells expressing human MSR1.

[0166] In some embodiments, the anti-MSR1 antibody has an IC of less than about 6.1 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1.5 nM, less than about 1.4 nM, less than about 1.3 nM, less than about 1.2 nM, less than about 1.0 nM, less than about 900 pM, less than about 800 pM, less than about 600 pM, less than about 400 pM, less than about 200 pM, less than about 100 pM, less than about 80 pM, less than about 60 pM, less than about 40 pM, or less than about 20 pM, when measured using a ligand uptake assay using the assay format defined in Example 8 herein, or a substantially similar assay. 50 shows a maximal inhibition of modified LDL uptake of less than about 60% in cells expressing human MSR1.

[0167] In some embodiments, the anti-MSR1 antibody has an IC of less than about 6.1 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1.5 nM, less than about 1.4 nM, less than about 1.3 nM, less than about 1.2 nM, less than about 1.0 nM, less than about 900 pM, less than about 800 pM, less than about 600 pM, less than about 400 pM, less than about 200 pM, less than about 100 pM, less than about 80 pM, less than about 60 pM, less than about 40 pM, or less than about 20 pM, when measured using a ligand uptake assay using the assay format defined in Example 8 herein, or a substantially similar assay. 50shows a maximal inhibition of modified LDL uptake of less than about 50% in cells expressing human MSR1.

[0168] Embodiments also include antibodies and antigen-binding fragments thereof that bind to cell surface-expressed MSR1 and are internalized by the cells. For example, provided herein are antibodies that bind to cell surface-expressed MSR1 on THP-1 cells and become internalized by the cells. For example, the present disclosure includes an anti-MSR1 antibody that binds to cell surface-expressed MSR1 on THP-1 cells and becomes internalized by the cells at a relative percentage of at least about 10%, as measured using chemiluminescence with the assay format defined in Example 9 herein, or a substantially similar assay. In certain embodiments, an anti-MSR1 antibody that binds to cell surface-expressed MSR1 on THP-1 cells and becomes internalized by the cells at a relative percentage of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%, as measured using chemiluminescence with the assay format defined in Example 9 herein, or a substantially similar assay.

[0169] The antibodies disclosed herein can possess one or more of the above biological characteristics, or any combination thereof. The foregoing list of biological characteristics of the antibodies disclosed herein is not intended to be exhaustive. Other biological characteristics of the antibodies disclosed herein will be apparent to those skilled in the art upon review of this disclosure, including the working examples herein.

[0170] (Antibody-drug conjugates (ADCs)) Provided herein are antibody-drug conjugates (ADCs) comprising an anti-MSR1 antibody or an antigen-binding fragment thereof conjugated to a drug or therapeutic agent. In some embodiments, the therapeutic agent is a liver X receptor (LXR) agonist or a steroid. Also provided herein are reactive linker-payloads useful for generating ADCs. Further provided herein are modified anti-MSR1 antibodies and modified MSR1 antigen-binding fragments useful for generating ADCs.

[0171] ADCs typically have the formula (I): BA-[(L) 0-1 -PA] n wherein BA is a binding agent, for example, an anti-MSR1 antibody, or an MSR1 antigen-binding fragment thereof. L is a linker, as described in detail below. PA is a payload. Suitable payloads include any small molecule whose delivery to MSR1 can provide a therapeutic benefit. In certain embodiments, the payload can be, for example, a steroid, an LXR modulator, or a rifamycin analog. Useful payloads are described in detail below. wherein n is an integer from 1 to 30, for example, 1 to 4, e.g., 2 or 4. Each L-PA is covalently bound to a functional group of PA. In certain embodiments, each L-PA is covalently bound to a lysine side chain, a cysteine ​​side chain, a glutamine side chain, or the amino terminus of BA.

[0172] Techniques and linkers for conjugation to residues of antibodies or antigen-binding fragments are known in the art. Exemplary amino acid additions that can be used in connection with this embodiment include, for example, lysine (see, e.g., US 5,208,020; US 2010 / 0129314; Hollander et al., Bioconjugate Chem., 2008, 19:358-361; WO 2005 / 089808; US 5,714,586; US 2013 / 0101546; and US 2012 / 0585592), cysteine ​​(see, e.g., US 2007 / 0258987; WO 2013 / 055993; WO 2013 / 055990; WO 2013 / 053873; WO 2013 / 053872; WO 2011 / 130598; US No. 2013 / 0101546; and US Pat. No. 7,750,116), selenocysteine ​​(see, e.g., WO 2008 / 122039; and Hofer et al., Proc. Natl. Acad. Sci., USA, 2008, 105: 12451-12456), formylglycine (see, e.g., Carrico et al., Nat. Chem. Biol., 2007, 3:321-322; Agarwal et al., Proc. Natl. Acad. Sci., USA, 2013, 110:46-51; and Rabuka et al., Nat. Protocols, 2012, 10:1052-1067), unnatural amino acids (see, e.g., WO 2013 / 068874 and WO 2012 / 166559), as well as acidic amino acids (see, for example, WO 2012 / 05982).Linkers can also be conjugated to antigen-binding proteins via attachment to carbohydrate (see, e.g., US 2008 / 0305497, WO 2014 / 065661, and Ryan et al., Food & Agriculture Immunol., 2001, 13: 127-130) and disulfide linkers (see, e.g., WO 2013 / 085925, WO 2010 / 010324, WO 2011 / 018611, and Shaunak et al., Nat. Chem. Biol., 2006, 2:312-313). Site-specific conjugation techniques can also be used to direct conjugation to specific residues on an antibody or antigen-binding protein (see, e.g., Schumacher et al., J Clin Immunol (2016) 36(Suppl 1): 100), including, but not limited to, transglutaminase-mediated glutamine conjugation (see, e.g., Schibli, Angew Chemie Inter Ed. 2010, 49, 9995).

[0173] Linkers can be conjugated to one or more glutamine residues via transglutaminase-based chemical enzymatic conjugation (see, e.g., Dennler et al., Bioconjugate Chem. 2014, 25, 569-578 and WO 2017 / 147542). For example, one or more glutamine residues of an antibody can be coupled to a primary amine compound in the presence of transglutaminase. Briefly, in some embodiments, an antibody having a glutamine residue (e.g., Gln295 residue) is treated with a primary amine compound, described in more detail below, in the presence of the enzyme transglutaminase. Primary amine compounds include payloads or linker-payloads, which directly provide antibody-drug conjugates via transglutaminase-mediated coupling. Primary amine compounds also include linkers and spacers that are functionalized with reactive groups that can subsequently react with additional compounds to synthesize antibody-drug conjugates. Antibodies containing glutamine residues can be isolated from natural sources or modified to contain one or more glutamine residues. Techniques for artificially creating glutamine residues in antibody polypeptide chains (glutaminyl-modified antibodies or antigen-binding molecules) are within the capabilities of those skilled in the art. In some embodiments, the antibodies are aglycosylated.

[0174] In certain embodiments, the antibody or glutaminyl-modified antibody or antigen-binding molecule comprises at least one glutamine residue in at least one polypeptide chain sequence. In certain embodiments, the antibody or glutaminyl-modified antibody or antigen-binding molecule comprises two heavy chain polypeptides, each having one Gln295 residue. In further embodiments, the antibody or glutaminyl-modified antibody or antigen-binding molecule comprises one or more glutamine residues at a site other than heavy chain 295. In some embodiments, antibodies can be prepared by site-directed mutagenesis to insert glutamine residues at a site without impairing antibody function or binding. For example, included herein are antibodies bearing the Asn297Gln (N297Q) mutation described herein. In some embodiments, antibodies with the Gln295 residue and / or the N297Q mutation contain one or more additional native glutamine residues in their variable regions that are accessible to transglutaminase and therefore can be conjugated to a linker or linker-payload. An exemplary native glutamine residue can be found, for example, at Q55 of the light chain. In such cases, the antibody conjugated via transglutaminase can have a higher than expected DAR value (e.g., a DAR higher than 4). Any such antibody can be isolated from a natural or artificial source.

[0175] Primary amine compounds useful for transglutaminase-mediated coupling of glutamine-containing antibodies (or antigen-binding compounds) can be any primary amine compound deemed useful by those skilled in the art. Typically, primary amine compounds have the formula HN-R, where R can be any group compatible with the antibody and reaction conditions. In certain embodiments, R is alkyl, substituted alkyl, heteroalkyl, or substituted heteroalkyl.

[0176] In some embodiments, the primary amine compound comprises a reactive group or a protected reactive group. Useful reactive groups include azides, alkynes, cycloalkynes, thiols, alcohols, ketones, aldehydes, acids, esters, hydrides, and the like. La J Do, a D R hmm, and amine. In certain embodiments, the reactive group is selected from the group consisting of azide, alkyne, sulfhydryl, cycloalkyne, aldehyde, and carboxyl.

[0177] In some embodiments, the primary amine compound is of the formula HN-LL-X, where LL is a divalent spacer and X is a reactive group or a protected reactive group. In certain embodiments, LL is a divalent polyethylene glycol (PEG) group. In some embodiments, X is selected from the group consisting of -SH, -N, alkyne, aldehyde, and tetrazole. In certain embodiments, X is -N.

[0178] In certain embodiments, the primary amine compound is according to one of the following formulas: H2N-(CH2) n -X; H2N-(CH2CH2O) n -(CH2) p -X; H2N-(CH2) n -N(H)C(O)-(CH2) m -X; H2N-(CH2CH2O) n -N(H)C(O)-(CH2CHO) m -(CH2) p -X; H2N-(CH2) n -C(O)N(H)-(CH2) m -X; H2N-(CH2CH2O) n -C(O)N(H)-(CH2CH2O) m -(CH2) p -X; H2N-(CH2) n-N(H)C(O)-(CH2CHO) m -(CH2) p -X; H2N-(CH2CH2O) n -N(H)C(O)-(CH2) m -X; H2N-(CH2) n -C(O)N(H)-(CH2CH2O) m -(CH2) p -X; and H2N-(CH2CH2O) n -C(O)N(H)-(CH2) m -X; (wherein n is an integer selected from 1 to 12; m is an integer selected from 0 to 12; p is an integer selected from 0 to 2; and X is -SH, -N3, -C≡CH, -C(O)H, tetrazole, and [ka] (selected from the group consisting of:

[0179] In the above, either the alkyl or alkylene (i.e., -CH2-) group can be, for example, C 1-8 It may be optionally substituted with alkyl, methylformyl, or -SO3H. In certain embodiments, the alkyl group is unsubstituted.

[0180] In some embodiments, the primary amine compound is: [ka] is selected from the group consisting of:

[0181] In certain embodiments, the primary amine compound is [ka] is.

[0182] Exemplary conditions for the above reactions are provided in the Examples below.

[0183] Thus, provided herein are modified anti-MSR1 antibodies and antigen-binding fragments thereof linked to one or more primary amine compounds. In certain embodiments, provided herein are modified anti-MSR1 antibodies and antigen-binding fragments thereof according to the following formula: [ka] .

[0184] In this formula, BA is an anti-MSR1 antibody or an antigen-binding fragment thereof. The variable n is an integer from 1 to 30. In certain embodiments, n is from 1 to the number of glutamine residues in BA. In certain embodiments, n is from 1 to 4. In certain embodiments, n is 1, 2, 3, or 4. In some embodiments, n is 2. In some embodiments, n is 4. The modified anti-MSR1 antibodies and antigen-binding fragments thereof are useful, for example, for linking one or more L-PA molecules to form ADCs.

[0185] In some embodiments, the BA contains two or four glutamine residues. In some embodiments, the BA contains a Q295 residue. In some embodiments, the BA contains an N297Q mutation. In some embodiments, the BA contains Q295 and N297Q. In such embodiments, the BA can be a dimer, so that the BA has four glutamine residues for conjugation to the L-PA moiety.

[0186] (compound) In one aspect, provided herein is an antibody-drug conjugate comprising any antibody or antigen-binding fragment thereof described herein conjugated to a compound and / or a payload moiety, optionally via a linker or linker-spacer.

[0187] In one group of embodiments, the compound and / or the antibody-drug conjugate has the structure of Formula (I): [ka] (In the formula: BA is a binder; L is a linker; PA is a payload moiety selected from the group consisting of a steroid residue, an LXR modulator residue, or a rifamycin analog residue; and The subscript n is an integer from 1 to 30.

[0188] In one group of embodiments, the compounds and / or antibody-drug conjugates described above and herein have the structure of formula (IA): [ka] (In the formula, SP 1 is absent or a spacer; RG 1 is a reactive group residue; AA 1 is absent or a bivalent or trivalent linker comprising an amino acid residue optionally bonded directly or indirectly to a group HG; AA 2 is absent or a dipeptide, tripeptide, or tetrapeptide residue; Q, if present, is a connector group residue; SP is absent or a spacer; and HG, if present, is a hydrophilic group).

[0189] In one group of embodiments, the compounds and / or antibody-drug conjugates described above and herein have the structure of formula (IB-1): [ka] (In the formula, SP 1 is absent or a spacer; RG 1 is a reactive group residue; Q, if present, [ka] and SP is absent or a spacer; where: [ka] indicates the atom through which the referred group is attached to the adjacent group in the formula).

[0190] In one group of embodiments, the compounds and / or antibody-drug conjugates described above and herein have the structure of formula (IB-2): [ka] (In the formula, SP 1 is absent or a spacer; RG 1 is a reactive group residue; AA 1 is absent or a bivalent or trivalent linker comprising an amino acid residue optionally bonded directly or indirectly to a group HG; AA 2 is absent or a dipeptide, tripeptide, or tetrapeptide residue; Q, if present, [ka] and; SP is absent or a spacer; and HG, if present, [ka] where: [ka] indicates the atom through which the referred group is attached to the adjacent group in the formula).

[0191] In a group of embodiments, the compounds and / or antibody-drug conjugates described above and herein have the structure of Formula (IC), Formula (ID), or Formula (IE): [ka] (In the formula, SP 1 is absent or a spacer; RG 1 is a reactive group residue; SP 2 is absent or a spacer; RG 2 is a reactive group residue; AA 1 is a bivalent or trivalent linker comprising an amino acid residue; AA 2 is a dipeptide, tripeptide, or tetrapeptide residue; Q, if present, [ka] and; SP is absent or a spacer; and HG is [ka] (It is).

[0192] where: [ka] indicates the atom through which the referenced group is attached to the adjacent group in the formula. In some or any of the examples of any of the compounds and / or antibody-drug conjugates above and herein, AA 1 -AA 2 is according to formula (LL1): [ka] (In the formula, R AA1 , R AA2 , and R AA3 are each independently at least one of which is -(RG 2 )-SP 2 -HG, -(RG 2 )-HG, or an amino acid side chain linked to HG; [ka] AA through it 1 -AA 2 indicates the atom that is bonded to the adjacent group in the formula. In some such embodiments, R AA1 is a lysine, glutamine, glutamic acid, or aspartic acid side chain attached directly or indirectly to HG, and R AA2 and R AA3 are either valine and alanine or valine and citrulline side chains, respectively.

[0193] In some or any of the examples of any of the compounds and / or antibody-drug conjugates described above and herein, AA 1 -AA 2 teeth, [ka] where: [ka] AA through it 1 -AA 2 indicates the atom bonded to the adjacent group in the formula.

[0194] In some or any of the examples of any of the compounds and / or antibody-drug conjugates described above and herein, RG 1 and R.G. 2 The residues are, independently in each case: [ka] selected from the group consisting of: where: [ka] Through it, the RG 1 or RG 2 The residue indicates the atom that is attached to the adjacent group in the formula.

[0195] In some or any of the examples of any of the compounds and / or antibody-drug conjugates described above and herein, SP, SP 1 , and SP 2 is, independently in each instance, absent or C 1-6 Alkylene, -NH-, -S-, -O-, -C(O)-, (-CH2-CH2-O) e , -NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, (glycine)4-serine, and combinations thereof, wherein subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8.

[0196] In some or any of the examples of any of the compounds and / or antibody-drug conjugates described above and herein, n is an integer from 1 to 10, 1 to 8, 1 to 6, 1 to 4, or n is 1, 2, 3, or 4.

[0197] In some or any of the examples of any of the compounds, linker-payload, and / or antibody-drug conjugates described above and herein, [ka] teeth, [ka] TIFF0007590871000070.tif230170TIFF0007590871000071.tif223170TIFF0007590871000072.tif181170TIFF0007590871000073.tif214170.

[0198] In some or any of the embodiments of any of the compounds and / or antibody-drug conjugates described above and herein, the antibody or antigen-binding fragment thereof is conjugated to a steroid payload via a linker or linker-spacer.

[0199] In some or any of the embodiments of any of the compounds and / or antibody-drug conjugates described above and herein, the antibody or antigen-binding fragment thereof is conjugated to the LXR modulator payload via a linker.

[0200] In some or any of the embodiments of any of the compounds and / or antibody-drug conjugates described above and herein, the antibody or antigen-binding fragment thereof is conjugated to a rifamycin analog payload via a linker.

[0201] (payload) Formula (I) BA-[L-PA] nIn the present invention, the PA can be any payload that is deemed useful. Such payloads include small molecules that provide a therapeutic benefit through their delivery via MSR1. In certain embodiments, the PA is a residue of a molecule selected from the group consisting of a steroid, an LXR modulator, or a rifamycin analog. In some cases, the PA is a steroid. In some cases, the PA is an LXR modulator. In some cases, the PA is an LXR agonist. In some embodiments, the PA is an LXR antagonist. Exemplary LXR modulator payloads are described, for example, in U.S. Application No. 62 / 508,327, filed May 18, 2017, entitled "BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF," published as US 2018 / 0334426, which is incorporated herein by reference in its entirety. In some examples, the PA is a rifamycin analog, including any of the rifamycin analogs described herein. In some examples, the PA is a rifamycin analog having the following structure: [ka] .

[0202] In certain embodiments, the payload in the compound of Formula (I) is a glucocorticoid according to Formula (A): or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof; [ka] (In the formula, R 1 and R 2 are independently -H, alkyl, alkyl-C(O)-O-, -OH, or halo; or R 1 and R 2 together, [ka] Forming where R 4 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; wherein the alkyl, aryl, arylalkyl, and N-containing heterocycloalkyl are independently in each occurrence -NR Aa R Ab optionally substituted with; R 3 is -OH, R Z -C(O)-X-, heteroalkyl, piperidinyl, -NR Aa R Ab , -oxyaryl-NR Aa R Ab , or -Z-A'(R P ) t and; R Z is alkyl; X is O or NR Aa and; Z is S, S(O), S(O)2, SO2NR Aa , O, C(O)NR Aa , C(O), or NR Aa and; A' is aryl, arylalkyl, or heteroaryl; R P is independently in each occurrence halo, optionally substituted alkyl, —OH, or —NR Aa R Ab and; R Aa and R Ab is independently at each occurrence —H, optionally substituted alkyl, or optionally substituted aryl; the subscript a is an integer from 0 to 19; and t is an integer from 1 to 3; however: (1)R 1 is —OH, or (b) R 1 and R 2 together, [ka] (where R 4 is C 1-9 Alkyl or [ka] ) is formed, R 3 is not -OH(a), and (2)R 3 teeth, [ka] Not and R 5A and R 5B are each independently a halo or a hydrogen atom; where the group R 3 or R 4 is attached to the linker).

[0203] In some such embodiments, R 3 is NH. In some other such embodiments, R 3 teeth, [ka] where: [ka] is R 3 indicates the atom bonded to the adjacent group in formula (I).

[0204] In some embodiments, the PA is a steroid. Exemplary steroid payloads are described, for example, in U.S. Application No. 62 / 614,905, filed January 8, 2018, entitled "STEROIDS AND ANTIBODY CONJUGATES THEREOF," and U.S. Application No. 15 / 806,197, filed November 7, 2017, entitled "STEROIDS AND PROTEIN-CONJUGATES THEREOF," published as US 2018 / 0155389, each of which is incorporated herein by reference in its entirety. In some embodiments, the PA is [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In certain embodiments according to any of Formulas 1110-1140, R 3 is -O-aryl, -NR Aa R Ab , -Alkylene-NR Aa R Ab , -X-arylene-Y-NR Aa R Ab , -X-heteroarylene-Y-NR Aa R Ab or N-containing heterocycloalkyl; where X is absent, —N—, —CH—, or —O—; where Y is absent or —CH—; and R 4 is alkyl, aryl, alkylaryl, or arylalkyl. In certain embodiments, R 3 is -O-arylene-NR Aa R Ab , -O-heteroarylene-NR Aa R Ab wherein the aryl or heteroaryl is optionally substituted with halogen, deuterium, hydroxyl, or methoxyl. In certain embodiments, R 3 is -O-phenyl-NR Aa R Ab , -O-heteroarylene-NRAa R Ab wherein phenyl or heteroaryl is optionally substituted with halogen or deuterium. In certain embodiments, R 4 is n-propyl. In certain embodiments, R Aa and R Ab are each independently hydrogen or alkyl. In certain embodiments, R Aa and R Ab In one embodiment, one of the PAs is replaced with a bond to a linker (e.g., L or LL). [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In certain embodiments, PA is [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In certain embodiments, PA is [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In certain embodiments, PA is [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In certain embodiments, PA is [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In certain embodiments, PA is [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In such embodiments, the wavy line indicates the bond to the linker (e.g., L or LL).

[0205] In certain embodiments, PA comprises the following residues: [ka] TIFF0007590871000090.tif206170TIFF0007590871000091.tif95170, or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, a primary or secondary amine is linked to the linker L to form a linker payload, which is linked to the BA to form the conjugate. One of skill in the art will recognize that the above compounds can be linked to L having a bond to a primary or secondary amine group in place of H.

[0206] In some embodiments, the anti-MSR1 antibodies described herein: [ka] is conjugated to

[0207] In some embodiments, the antibody-drug conjugate described herein comprises a steroid payload, wherein the steroid payload is: [ka] or a mixture thereof.

[0208] In one embodiment, the PA comprises: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the PA is: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the PA is: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.

[0209] In one embodiment, the PA comprises: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the PA is: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the PA is: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.

[0210] In certain embodiments, the PA is a liver X receptor (LXR) modulator. In certain embodiments, the PA is according to Formula (B) or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof: [ka] (In the formula, W is -CH2-, -N(H)-, or -O-; R B1 is -H, -OH, -NH2, alkyl, or -OP(O)(OR 6 )2; R B2 -H, -OH, -CH2NH2, R B3 , R B4 , R B5 , or -OR B5 where R B1 and R B2 is not simultaneously -H; R B3 is -N(R 6 )2; R B4is -XYZ; X is selected from the group consisting of -O- and -N(H)-; Y is selected from the group consisting of alkylene, substituted alkylene (including but not limited to, oxo-substituted (i.e., =0)), heteroalkylene, and substituted heteroalkylene (including but not limited to, oxo-substituted (i.e., =0)); Z is selected from the group consisting of -OH and -NH; R B5 is alkyl, heterocycloalkyl, or substituted heterocycloalkyl, where each heterocycloalkyl or substituted heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from nitrogen and oxygen and contains at least one -OH and -CHOH substituent or at least one primary or secondary nitrogen, e.g., O-glucose; Each R 6 is, in each occurrence, —H, an amino acid residue, an N-alkyl amino acid residue, a peptide, or an alkyl; and Each R 7 are independently halo, C 1-6 Alkyl, C 1-6 Alkoxy, -CN, O-glucose, O-amino acid residues, and O-PEG b where each subscript b is an integer from 0 to 3; where the group R B1 , R B2 , or R 7 is attached to the linker).

[0211] In certain embodiments, R B1 or R B2 is replaced by a bond to a linker (e.g., L or LL).

[0212] In one embodiment, the PA comprises: [ka] is selected from.

[0213] In certain embodiments, [ka] The wavy line in the middle indicates a bond to a linker (eg, L or LL).

[0214] In some embodiments, the payload of formula (B) is: [ka] TIFF0007590871000104.tif234170 or a pharmaceutically acceptable stereoisomeric form thereof.

[0215] In one embodiment, the PA comprises: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.

[0216] In one embodiment, the PA comprises: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.

[0217] In one embodiment, the PA comprises: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof.

[0218] In some embodiments, the anti-MSR1 antibodies described herein: [ka] It is conjugated to

[0219] In some embodiments, the PA is a liver X receptor (LXR) modulator according to Formula (B-1) or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof: [ka] (In the formula, R B1 is -N(H)R 8 or -N(R 9 )2; R B2 is -N(H)R 8 and; Each R 8 is independently in each occurrence hydrogen, an amino acid residue, an N-alkyl amino acid residue, a peptide residue, a biodegradable moiety, or an alkyl; R 9 is alkyl, aryl, arylalkyl, heterocycloalkyl, or substituted heterocycloalkyl, where each heterocycloalkyl or substituted heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from nitrogen and oxygen, and when substituted, contains at least one of —OH and —CHOH, or contains at least one primary or secondary nitrogen; Each R 7 are independently halo, C 1-6 Alkyl, C 1-6 Alkoxy, -CN, O-glucose, O-amino acid residue, or O-PEG b (wherein each subscript b is an integer from 0 to 3); where the group R B1 , R B2 , or R 7 is attached to the linker).

[0220] In some examples, the compound of formula (B-1) is: [ka] TIFF0007590871000111.tif188170TIFF0007590871000112.tif232170TIFF0007590871000113.tif55170 or a pharmaceutically acceptable salt or solvate thereof.

[0221] In certain embodiments, R B1 or R B2 is replaced by a bond to a linker (e.g., L or LL).

[0222] In one embodiment, the PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the PA is: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the PA is: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In certain embodiments, the PA is: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In one embodiment, the PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In one embodiment, the PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In one embodiment, the PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In one embodiment, the PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In one embodiment, the PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some such embodiments, the carboxylic acid group of P10B is attached to the linker via an amide bond as shown above. In certain embodiments, PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. In some such embodiments, the carboxylic acid group of P11B is attached to the linker via an amide bond as shown above. In certain embodiments, PA is [ka] or a pharmaceutically acceptable salt or stereoisomer thereof. For any embodiment described in this paragraph, [ka] The wavy line in the middle indicates a bond to a linker (eg, L or LL) as described above.

[0223] In a group of embodiments, provided herein are compounds of formula (III) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: [ka] (In the formula: R 34is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; Both R x is hydrogen; and SP is —C(O)—C—C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1 -(where X 1 is attached to L' in formula (III), -C(O)-N(H)-(C-C 10 -alkylene)-S- (wherein S is attached to L' in formula (III)), -C(O)-N(C 1-6 Alkyl)-(C1-C 10 -alkylene)-S- (wherein S is attached to L' in formula (III)), [ka] (wherein the point of attachment to the right (i.e., at N) is to L' in formula (III)), -CH2-NH- (wherein N is attached to L' in formula (III)), [ka] (wherein N is attached to L' in formula (III) and Ar is an optionally substituted arylene or an optionally substituted heteroarylene), -(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (III), -C(O)-(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (III) and each of C1-C 10 -alkylene optionally substituted independently with one or more hydroxy), -C(O)-N(R35 )-C1-C 10 -Alkylene-C(O)NH-X 2 -(where X 2 is attached to L' in formula (III), or [ka] (where X 4 is attached to L' in formula (III); or Both R x is fluoro; and SP is —C(O)—C—C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1b -(where X 1b is attached to L in formula (III), -C(O)-N(H)-(C-C 10 -alkylene)-X 1b -(where X 1b is attached to L' in formula (III), [ka] (wherein the point of attachment to the right (i.e., at N) is to L' in formula (III)), -CH2-NH- (wherein N is attached to L' in formula (III)), [ka] (wherein N is attached to L' in formula (III) and Ar is an optionally substituted arylene or an optionally substituted heteroarylene), -(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (III), -C(O)-(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR50a -(where NR 50a is attached to L' in formula (III) and each of C1-C 10 -alkylene optionally substituted independently with one or more hydroxy), -C(O)-N(R 35 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -(where X 2 is attached to L' in formula (III), or [ka] (where X 4 is attached to L' in formula (III); and X 1 is -N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 is -CH2- or X 3 is -CH2-O-(C1-C 10 -alkylene)-C(O)- (wherein C(O) is X 4 (attached to a 3 is -C(O)-; X 4 is -O-; R 35 is H, -OH, -OCH3, or C 1-6 is alkyl; R 50 and R 50a are independently hydrogen or C1-C6-alkyl; R d , R e , and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CHOR g where each R g is independently —CHC(O)OH or —CHC(O)O(alkyl); and mm is 0 or 1; n is an integer selected from 1 to 30; L' is a linker; and BA is a binder).

[0224] In some embodiments, in the compound of Formula (III), both R x is hydrogen, and SP, BA, L', R 34 and n are as described herein in some or any embodiments. In some embodiments, in compounds of Formula (III), both R x is fluoro, and SP, BA, L', R 34 and n is as described herein in some or any embodiments. In some embodiments, R 34 is of the R-configuration. In some embodiments, R 34 is in the S-configuration. In some embodiments, R 34 is a mixture of R- and S-configurations. In some embodiments, R 34 is a mixture of R- and S-configurations, where the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0225] In some embodiments, the compound is of Formula (III), wherein: Both R x is hydrogen; and SP is —C(O)—C—C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1 -(where X 1 is attached to L' in formula (III), -C(O)-N(H)-(C-C 10 -alkylene)-S- (wherein S is attached to L' in formula (III)), -C(O)-N(C 1-6 Alkyl)-(C1-C 10-alkylene)-S- (wherein S is attached to L' in formula (III)), -(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (III), -C(O)-(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (III) and each of C1-C 10 -alkylene optionally substituted independently with one or more hydroxy), -C(O)-N(R 5 )-C1-C 10 -Alkylene-C(O)NH-X 2 -(where X 2 is attached to L' in formula (III), or [ka] (where X 4 is attached to L' in formula (III); or Both R x is fluoro; and SP is —C(O)—N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1b -(where X 1b is attached to L' in formula (III), -C(O)-N(H)-(C-C 10 -alkylene)-X 1b -(where X 1b is attached to L' in formula (III), [ka] (wherein the point of attachment to the right (i.e., at N) is to L' in formula (III)), -(C1-C 10 -alkylene)-NR 50C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (III), -C(O)-(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (III) and each of C1-C 10 -alkylene optionally substituted independently with one or more hydroxy), or -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -(where X 2 is attached to L' in formula (III).

[0226] In some embodiments, the compound of Formula (I) is a compound of Formula (3000) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof: BA-(L′-SP-D) n Expression(3000) (In the formula, D is a) [ka] (wherein both R x is hydrogen; R 34 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is —C(O)—C—C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1 -(where X 1 is attached to L' in formula (3000), -C(O)-N(H)-(C1-C 10 -alkylene)-S- (wherein S is attached to L' in formula (3000)), -C(O)-N(C 1-6Alkyl)-(C1-C 10 -alkylene)-S- (wherein S is attached to L' in formula (3000)), [ka] (wherein the point of attachment to the right (i.e., at N) is to L' in formula (3000)), -CH2-NH- (wherein N is attached to L' in formula (3000)), [ka] wherein N is attached to L′ in formula (3000), and Ar is an optionally substituted arylene (in some embodiments, [ka] ) or optionally substituted heteroarylene), -(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (3000), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (3000), and each C1-C 10 -alkylene is optionally substituted independently with one or more hydroxy), -C(O)-N(R 35 )-C1-C 10 -Alkylene-C(O)NH-X 2 -(where X 2 is attached to L' in formula (3000), or [ka] (where X 4 is attached to L' in formula (3000); or Here, both R in formula (a) x is fluoro; R 34 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is —C(O)—C—C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1b -(where X 1b is attached to L' in formula (3000), -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -(where X 1b is added to L' in formula (3000), [ka] (wherein the point of attachment to the right (i.e., at N) is to L' in formula (3000)), -CH2-NH- (wherein N is attached to L' in formula (3000) [ka] wherein N is attached to L′ in formula (3000), and Ar is an optionally substituted arylene (in some embodiments, [ka] ) or optionally substituted heteroarylene)), -(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is attached to L' in formula (3000), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50ais attached to L' in formula (3000), and each C1-C 10 -alkylene is optionally substituted independently with one or more hydroxy), -C(O)-N(R 35 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -(where X 2 is attached to L' in formula (3000), or [ka] (where X 4 is attached to L' in formula (3000); and / or b) selected from the compounds in Table A below, wherein the compounds in Table A are linked to BA of the compound of formula (III) via the hydroxy of the -C(O)CHOH group, i.e., by -C(O)CH-O-SP-L'-, or via the hydroxy of the mapla collate, i.e., by -O-SP-L'-; X 1 is -N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 is -CH2- and X 3 is -CH2-O-(C1-C 10 -alkylene)-C(O)- (wherein C(O) is X 4 (attached to a 3 is -C(O)-; X 4 is -O-; R 35 is H, -OH, -OCH3, or C 1-6 is alkyl; R 50 and R 50a are independently hydrogen or C1-C6-alkyl; R d , R e , and Rf are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CHOR g where each R g is independently —CHC(O)OH or —CHC(O)O(alkyl); and mm is 0 or 1; n is an integer selected from 1 to 30; L' is a linker; and BA is a binder).

[0227] In some examples of Formula 3000, D is budesonide or any other steroid shown in Table A. In some examples of Formula 3000, D is any budesonide analog described herein. The compounds in Table A are linked to BA of the compound of Formula (III) through the hydroxy of the -C(O)CHOH group, i.e., by -C(O)CH-O-SP-L'-, or through the hydroxy of the mapracolate, i.e., by -O-SP-L'-. In some examples of Formula 3000, the moiety SP-D (or H-SP-D) is referred to herein as a "budesonide-spacer," and includes, for example, the budesonide-spacer shown in Table B, the Examples section, and Scheme 1 of Figure 22, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. Table A. [Table 1] TIFF0007590871000145.tif229170TIFF0007590871000146.tif229170TIFF0007590871000147.tif229170TIFF0007590871000148.tif166170Table B. Budesonide-Spacer (Budesonide-SP) [Table 2] TIFF0007590871000150.tif231170TIFF0007590871000151.tif240170TIFF0007590871000152.tif228170TIFF0007590871000153.tif146170In some instances, in each of the above structures [ka] The n-propyl in is in the R-configuration, i.e., at the carbon indicated by the asterisk. In some instances, [ka] The n-propyl in is in the S-configuration, i.e., at the carbon indicated by the asterisk. In some instances, [ka] The n-propyl in is a mixture of R- and S-configuration, i.e., at the carbon indicated by the asterisk. In some instances, [ka] n-propyl is a mixture of R- and S-configurations, i.e., at the carbon indicated by the asterisk, where the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0228] In various embodiments, Ab-L′-SP-D or -SP-D of formula (3000) [ka] teeth, [ka] Selected from TIFF0007590871000160.tif225170 and TIFF0007590871000161.tif90170, where [ka] is the bond to the linker.

[0229] In some instances, in each of the above structures [ka] The n-propyl in is in the R-configuration, i.e., at the carbon indicated by the asterisk. In some instances, [ka] The n-propyl in is in the S-configuration, i.e., at the carbon indicated by the asterisk. In some instances, [ka] The n-propyl in is a mixture of R- and S-configuration, i.e., at the carbon indicated by the asterisk. In some instances, [ka] n-propyl is a mixture of R- and S-configurations, i.e., at the carbon indicated by the asterisk, where the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0230] In various embodiments, [ka] is selected from Table B, or [ka] is selected from.

[0231] In some embodiments, the payload is a rifamycin analog having the structure of Formula (C): or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof; [ka] (In the formula: X 1c -O-, -S-, and -NR 5c Selected from; R 1c is hydrogen; amino-C 1-6 Alkyl; C 1-6 Alkylamino C 1-6 Alkyl; Di-C 1-6 Alkylamino C 1-6 Alkyl; Hydroxy-C 1-6 Alkyl; HS-C 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-OC 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-SC 1-6 Alkyl; heterocycloalkyl, or heterocycloalkyl-C 1-6 alkyl; wherein heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and wherein heterocycloalkyl is nine Roarke Lu is , Haro, C 1-6 Alkyl, -OH, =O, or -N(R 5c )2 optionally substituted; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; R ac -F; -Cl; -Br; -I; -OH; -NH2; and C 1-6 selected from alkoxy; R bc Each occurrence of is hydrogen; and R 5c is independently at each occurrence hydrogen; and C 1-6 alkyl; However, R 1c is not an n-butyl group; and Furthermore, however, X 1c When is -O-, R 1c is not hydrogen; where the group R 1c is attached to the linker).

[0232] In some embodiments, the payload is a rifamycin analog having the structure of formula (C-1): or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof; [ka] (In the formula: X 1c -S-; -O- and -NR 5c Selected from; R 1c is amino-C 1-6 Alkyl; C 1-6 Alkylamino C 1-6 Alkyl; Di-C 1-6 Alkylamino C 1-6 Alkyl; Hydroxy-C 1-6 Alkyl; HS-C 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-OC 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-SC 1-6Alkyl; heterocycloalkyl, or heterocycloalkyl-C 1-6 alkyl; wherein heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and wherein heterocycloalkyl is nine Roarke Lu is , Haro, C 1-6 Alkyl, -OH, =O, or -N(R 5c )2 optionally substituted; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; Each R ac are, if present, independently -F; -Cl; -Br; -I; -OH; -NH; and C 1-6 alkoxy; and R 5c is independently at each occurrence hydrogen; and C 1-6 alkyl; where the group R 1c is attached to the linker).

[0233] In some embodiments, the payload is a rifamycin analog having the structure of formula (C-2): or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof; [ka] (In the formula: X 1c -S-; -O- and -NR 5c Selected from; R 1c is amino-C 1-6 Alkyl; C 1-6 Alkylamino C 1-6 Alkyl; Di-C 1-6 Alkylamino C 1-6 Alkyl; Hydroxy-C 1-6 Alkyl; HS-C 1-6 Alkyl; (R 5c )2N-C1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-OC 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-SC 1-6 Alkyl; heterocycloalkyl, or heterocycloalkyl-C 1-6 alkyl; wherein heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and wherein heterocycloalkyl is nine Roarke Lu is , Haro, C 1-6 Alkyl, -OH, =O, or -N(R 5c )2 optionally substituted; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; R ac and R bc are independently -F; -Cl; -Br; -I; -OH; -NH; and C 1-6 alkoxy; and R 5c is independently at each occurrence hydrogen; and C 1-6 alkyl; where the group R 1c is attached to the linker).

[0234] In some embodiments, the payload is a rifamycin analog having the structure of formula (C-3): or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof; [ka] (In the formula: R 1c Is Ji-C 1-6 Alkylamino C 1-6 Alkyl; (R 5c )2N-C1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; heterocycloalkyl, or heterocycloalkyl-C 1-6 alkyl; wherein heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and wherein heterocycloalkyl is nine Roarke Lu is , Haro, C 1-6 Alkyl, -OH, =O, or -N(R 5c )2 is optionally substituted; and R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c selected from; and R 5c is hydrogen and C 1-6 alkyl; where the group R 1c is attached to the linker).

[0235] In some embodiments, the payload is a rifamycin analog having the structure of formula (C-4): or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof; [ka] (In the formula: R 1c teeth, [ka] and; where Y is C or N; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c selected from; and R 5c is hydrogen and C 1-6 alkyl; where the group R1c is a wavy line [ka] (which is attached to the linker via a nitrogen atom indicated by

[0236] In some or any embodiments of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4), R bc is hydrogen, and / or R ac is hydrogen. In some or any embodiments of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4), R 2c is methyl, ethyl, propyl, or isopropyl, preferably methyl. In some or any embodiments of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4), R 3c is a CH3-(C=O)-(acetyl) group, CH3CH2-(C=O)-, CH3CH2CH2-(C=O)-, or (CH3)2CH-(C=O)-; preferably, acetyl. In some or any embodiments of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4), R 4c is hydrogen.

[0237] In some embodiments of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4), -OR 1c teeth, [ka] In some embodiments of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4), -OR 1c teeth, [ka] is.

[0238] In some or any embodiments of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4), X 1c is O and -OR 1c contains a tertiary amine, which is converted to a quaternary amine after attachment to the linker. In some such embodiments, -OR 1c teeth, [ka] In such embodiments, when a quaternary amine is formed, a suitable counterion is present, i.e., the rifamycin analog is available as a pharmaceutically acceptable salt containing a quaternary amine that carries a positive charge, and a salt, e.g., a negatively charged, charge-balancing counterion (e.g., I - , Br - , Cl - , or any other suitable counterion).

[0239] In some embodiments, compounds of formula (C-1) and / or (C-2) and / or (C-3) and / or (C-4) are: [ka] TIFF0007590871000180.tif164170; where: [ka] is the bond to the linker.

[0240] (Linker) In some embodiments of Formula (I), (III), or (3000), L is -L 1 -L 2 -(L 3 ) 0-1 - and L 2 teeth, [ka] In some embodiments, L comprises -L 1 -L 2 -(L 3 ) 0-1 - and L 2 teeth, [ka] or CD, or a combination thereof. In some embodiments, L is -L 1 -L 2 -(L 3 ) 0-1 - and L 2 In some embodiments, L and / or L 2 If contains CD, then CD is [ka] TIFF0007590871000185.tif98170.

[0241] In some embodiments of Formula (I), (III), or (3000), L is -L 1 -L 2 -(L 3 ) 0-1 - and L 2 includes HG as described herein. In some embodiments, L and / or L 2 teeth, [ka] In some embodiments, L and / or L 2 teeth, [ka] Includes.

[0242] In some embodiments of Formula (I), (III), or (3000), L is -L 1 -L 2 -(L3 ) 0-1 - and L 1 teeth, [ka] or a positional isomer or mixture of isomers thereof; [ka] or a stereoisomer or mixture of stereoisomers thereof (wherein S represents the S atom on the cysteine ​​residue through which the reactive group residue is attached to BA); and [ka] where N represents the N atom on the lysine residue through which the reactive group residue is attached to the BA.

[0243] In some embodiments, L is -L as described herein. 1 -L 2 -(L 3 ) 0-1 - and -L 2 -(L 3 ) 0-1 In some embodiments, L is L'-SP, as described herein for Formula (III) and Formula (3000). In some embodiments, L is: [ka] Includes TIFF0007590871000192.tif224170TIFF0007590871000193.tif223170TIFF0007590871000194.tif182170TIFF0007590871000195.tif216170.

[0244] In some examples, the compound of formula (I) or (III) or (3000) is [ka] or a stereoisomeric form thereof or a positional isomer thereof or a mixture of positional isomers thereof, where: each Ab is an anti-MSR1 antibody or an antigen-binding fragment thereof; and Each n is an integer from 1 to 4.

[0245] In some examples, the compound of formula (I) or (III) or (3000) is [ka] TIFF0007590871000198.tif211170TIFF0007590871000199.tif234170TIFF0007590871000200.tif207170TIFF0007590871000201.tif222170TIFF0007590871000202.tif131170 or a stereoisomeric form thereof or a positional isomer thereof or a mixture of positional isomers thereof; where: each Ab is an anti-MSR1 antibody or an antigen-binding fragment thereof; Each BA is [ka] where Ab 1 is an anti-MSR1 antibody or an antigen-binding fragment thereof; R is C 2-4 -alkylene; and nn is an integer selected from 2 to 4, inclusive, and Each n is an integer from 1 to 4.

[0246] In some further embodiments, the ADCs described herein can include a linker described in US 9,951,141 B2, filed November 29, 2016, and published April 24, 2018, which linkers are incorporated herein by reference. In some examples, the linker is: [ka] wherein b is an integer from 2 to 8; and [ka] is a bond to a binding agent. In some embodiments, the linker contains two reactive groups and can form bonds with, for example, thiols on two different chains of an antibody or antigen-binding fragment thereof: [ka] where b is an integer from 2 to 8. In further embodiments, the linker comprises two reactive groups and can form bonds with, for example, thiols on two different chains of an antibody or antigen-binding fragment thereof: [ka] where b is an integer from 2 to 8. In some other embodiments, the linker contains two reactive groups and can form bonds with, for example, thiols on two different chains of an antibody or antigen-binding fragment thereof: [ka] where b is an integer from 2 to 8, and R N is a hydrogen atom or alkyl, and R M is alkyl. In further embodiments, the linker comprises two reactive groups and can form bonds with, for example, thiols on two different chains of an antibody or antigen-binding fragment thereof: [ka] where b is an integer from 2 to 8. In certain embodiments, the linker contains two reactive groups and can form bonds with, for example, thiols on two different chains of an antibody or antigen-binding fragment thereof: [ka] where b is an integer from 2 to 8. In some embodiments, the linker contains two reactive groups and can form bonds with, for example, thiols on two different chains of an antibody or antigen-binding fragment thereof: [ka] where b is an integer from 2 to 8; R N is a hydrogen atom or alkyl; and R M is alkyl.

[0247] In formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (III), (3000), (5001), (5002), (5003), (5004), (6001), (6002), (6003), (6004), (6005), (7001), (7002), (7003), (7004), and / or (7005) described herein, and / or BA-[(L) 0-1 -PA] nwherein PA can be linked to BA with any linker L deemed suitable. A linker is any group or moiety that links, connects, or bonds an antibody or antigen-binding protein described herein to a therapeutic moiety, such as a steroid or an LXR modulator. Suitable linkers can be found, for example, in Antibody-Drug Conjugates and Immunotoxins; Phillips, G.L. (ed.); Springer Verlag: New York, 2013; Antibody-Drug Conjugates; Ducry, L. (ed.); Humana Press, 2013; Antibody-Drug Conjugates; Wang, J., Shen, W.-C., and Zaro, J.L. (eds.); Springer International Publishing, 2015, the contents of each of which are incorporated herein by reference in their entirety. Typically, suitable binder linkers for the antibody conjugates described herein are those that are stable enough to take advantage of the circulating half-life of the antibody and, at the same time, are capable of releasing their payload after antigen-mediated internalization of the conjugate. The linker can be cleavable or non-cleavable. Cleavable linkers include linkers that are cleaved by intracellular metabolism after internalization, such as cleavage via hydrolysis, reduction, or enzymatic reaction. Non-cleavable linkers include linkers that release the attached payload via lysosomal degradation of the antibody after internalization. Suitable linkers include, but are not limited to, acid-labile linkers, hydrolytically labile linkers, enzyme-cleavable linkers, reduction-labile linkers, self-immolative linkers / groups, and non-cleavable linkers. Suitable linkers also include, but are not limited to, those that are or contain peptides, glucuronides, succinimide-thioethers, polyethylene glycol (PEG) units, hydrazones, mar-caproyl units, dipeptide units, valine-citrulline units, and para-aminobenzyl (PAB) units.

[0248] Any linker molecule or linker technology known in the art can be used to create or construct the ADCs of the present disclosure. In some embodiments, the linker is a cleavable linker. In other embodiments, the linker is a non-cleavable linker. Exemplary linkers that can be used in the context of the present disclosure include, for example, linkers comprising or consisting of MC (6-maleimidocaproyl), MP (maleimidopropanoyl), val-cit (valine-citrulline), val-ala (valine-alanine), a dipeptide moiety in a protease-cleavable linker, ala-phe (alanine-phenylalanine), a dipeptide moiety in a protease-cleavable linker, PAB (p-aminobenzyloxycarbonyl), SPP (N-succinimidyl 4-(2-pyridylthio)pentanoate), SMCC (N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate), SIAB (N-succinimidyl(4-iodo-acetyl)aminobenzoate), and variants and combinations thereof. Further examples of linkers that can be used in the context of the present disclosure are provided, for example, in U.S. Pat. No. 7,754,681 and Ducry, Bioconjugate Chem., 2010, 21:5-13, the contents of which are incorporated herein by reference in their entirety, and references cited therein.

[0249] In some embodiments, the linker is stable under physiological conditions. In some embodiments, the linker is cleavable, for example, in the presence of an enzyme or at a specific pH range or value, and can release at least the payload portion. In some embodiments, the linker comprises an enzyme-cleavable moiety. Exemplary enzyme-cleavable moieties include, but are not limited to, peptide bonds, ester bonds, hydrazones, and disulfide bonds. In some embodiments, the linker comprises a cathepsin-cleavable linker.

[0250] In some embodiments, the linker comprises a non-cleavable moiety.

[0251] Suitable linkers include, but are not limited to, a single linker that is chemically bonded to two cysteine ​​residues of an antibody, such as an antibody, which can serve to mimic the disulfide bonds of an antibody that are disrupted as a result of the conjugation process.

[0252] In some embodiments, the linker comprises one or more amino acids. Suitable amino acids include natural, non-natural, standard, non-standard, proteinogenic, non-proteinogenic, and L- or D-α-amino acids. In some embodiments, the linker comprises alanine, valine, glycine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline, derivatives thereof, or combinations thereof. In certain embodiments, one or more side chains of the amino acids are linked to the following side chain groups: In some embodiments, the linker comprises valine and citrulline. In some embodiments, the linker comprises lysine, valine, and citrulline. In some embodiments, the linker comprises lysine, valine, and alanine. In some embodiments, the linker comprises valine and alanine.

[0253] In some embodiments, the linker comprises a self-immolative group. The self-immolative group can be any such group known to those skilled in the art. In certain embodiments, the self-immolative group is p-aminobenzyl (PAB) or a derivative thereof. In some embodiments, the self-immolative group is p-aminobenzyloxy. In some embodiments, the self-immolative group comprises a cleavable disulfide group. Useful derivatives include p-aminobenzyloxycarbonyl (PABC). Those skilled in the art will recognize that the self-immolative group can undergo a chemical reaction that releases the remaining atoms of the linker from the payload.

[0254] In some embodiments, the linker is: [ka] where: [ka] is the binding to an antibody or antigen-binding protein (e.g., via a lysine residue), and [ka] is the bond to the payload. In some embodiments, the linker is: [ka] where: [ka] is the binding to an antibody or antigen-binding protein (e.g., via a lysine residue), and [ka] is the bond to the payload. In some embodiments, the linker is: [ka] is.

[0255] In some embodiments, the linker is: [ka] is.

[0256] In some embodiments, the linker is maleimidylmethyl-4-trans-cyclohexanecarboxysuccinate: [ka] It comes from.

[0257] In some embodiments, the linker is: [ka] where: [ka] is the binding to an antibody or antigen-binding protein (e.g., via a lysine residue), and [ka] is the binding with the payload.

[0258] In some embodiments, L is a cleavable linker. In some embodiments, L is a non-cleavable linker. In some embodiments, L comprises a dipeptide. In some embodiments, L comprises a PAB moiety. In some embodiments, L comprises a disulfide moiety.

[0259] In some embodiments, L comprises a moiety having the structure: [ka] .

[0260] In some embodiments, L comprises a moiety having the structure: [ka] .

[0261] In some embodiments, L comprises a moiety having the structure: [ka] .

[0262] In some embodiments, L comprises a moiety having the structure: [ka] .

[0263] In certain embodiments, the linker comprises a cyclodextrin group. In certain embodiments, the linker provides an ADC according to Formula (Ia): [ka] .

[0264] In Formula (Ia), BA is an anti-MSR1 antibody or an antigen-binding fragment thereof, LL is a trivalent linker, RG is a reactive linker residue, SP is, independently in each occurrence, absent or a spacer group, the subscript n is an integer from 1 to 30; and PA is a payload. In some embodiments, n is 1 to 4. In some embodiments, n is 4. In some embodiments, n is 2. In some embodiments, n is 1. In some embodiments, n is 3.

[0265] In certain embodiments, the linker comprises a cyclodextrin group. In certain embodiments, the linker provides an ADC according to Formula (Id): [ka] .

[0266] In formula (Id), BA is an anti-MSR1 antibody or an antigen-binding fragment thereof; RG is a reactive group residue; SP 1 and SP 2 are each, independently in each occurrence, absent or a spacer group residue, and 1 comprises a trivalent linker; AA 1 is a trivalent linker comprising amino acid residues; AA 2 is a dipeptide residue; PEG is a polyethylene glycol residue; PAB is [ka] where: [ka] represents the atom through which PAB is attached to the adjacent group in the formula, CD, independently in each occurrence, is absent or a cyclodextrin residue, where at least one CD is present, subscript n is an integer from 1 to 30; subscript m is an integer from 0 to 5; subscript p is 0 or 1; and PA is a payload moiety. In these examples, subscript m is 0, 1, 2, 3, 4, or 5. In some examples, subscript m is 0. In some examples, subscript m is 1. In some examples, subscript m is 2. In some examples, subscript m is 3. In some examples, subscript m is 4. In some examples, subscript m is 5. In some examples, subscript p is 0. In some examples, subscript p is 1. In some examples, AA 1 or AA 2 In one embodiment, any one of AA, ... 1is an amino acid, derivative thereof, or combination thereof selected from alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline. 1 is lysine. In some embodiments, AA 1 is lysine or a derivative of lysine. In some embodiments, AA 2 is valine-citrulline. In some embodiments, AA 2 is citrulline-valine. In some embodiments, AA 2 is valine-alanine. In some embodiments, AA 2 is alanine-valine. In some embodiments, AA 2 is valine-glycine. In some embodiments, AA 2 is glycine-valine. In some embodiments, AA 1 -AA 2 is glutamine-valine-citrulline. In some embodiments, AA 1 -AA 2 is glutamine-valine-citrulline. In some embodiments, AA 1 -AA 2 is lysine-valine-alanine. In some embodiments, AA 1 -AA 2 is lysine-valine-citrulline. In some embodiments, AA 1 -AA 2 is glutamine-valine-citrulline. In some embodiments, lysine is L-lysine. In some embodiments, lysine is D-lysine. In some examples, SP 1 is, in each case independently, C 1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e , -NH-CH2-CH2-(-O-CH2-CH2) e-C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, and combinations thereof, where subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8. In some examples, SP 2 is, in each case independently, C 1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e , -NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, and combinations thereof, wherein the subscript e is an integer from 0 to 4, the subscript u is an integer from 1 to 8, and the subscript v is an integer from 1 to 8.

[0267] In certain embodiments of formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (III), (3000), (5001), (5002), (5003), (5004), (6001), (6002), (6003), (6004), (6005), (7001), (7002), (7003), (7004), and / or (7005), the linker is: [ka] TIFF0007590871000233.tif212170TIFF0007590871000234.tif187170TIFF0007590871000235.tif 172170TIFF0007590871000236.tif166170TIFF0007590871000237.tif206170TIFF000759087100023 8.tif213170TIFF0007590871000239.tif210170TIFF0007590871000240.tif243170TIFF0007590871000241.tif168170TIFF0007590871000242.tif222170TIFF0007590871000243.tif184170. Also included in these examples are pharmaceutically acceptable salts, solvates, stereoisomeric forms, positional isomers, or mixtures of positional isomers thereof, wherein each [ka] is the bond with the binder; and each [ka] is the binding with the payload.

[0268] In some embodiments, the linker comprises a terminal hydrophilic group (HG). In some embodiments, the linker comprises a taurine group. In some embodiments, the linker comprises a terminal sulfonic acid group. In some embodiments, the linker provides an ADC according to Formula (II): [ka] wherein in formula (II), BA is a binding agent; LL is a trivalent linker; RG 1 and R.G. 2 is a reactive group residue; SP 1 and SP 2is, independently in each occurrence, absent or a spacer group residue; HG is a hydrophilic residue; PA is a payload residue; the subscript n is an integer from 1 to 30; and the subscript q is 0 or 1. In some cases, multiple trivalent linkers LL may be present. In some cases, n is an integer from 1 to 4. In some cases, n is 1. In some cases, n is 2. In some cases, n is 3. In some cases, n is 4. In some cases, HG is a terminal hydrophilic group. In some cases, HG comprises one terminal sulfonic acid group or a salt thereof. In other cases, HG comprises multiple terminal sulfonic acid groups or salts thereof. In some cases, HG comprises one terminal phosphonic acid group or a salt thereof. In other cases, HG comprises multiple terminal phosphonic acid groups or salts thereof. In some cases, HG comprises one terminal tertiary amine group or a salt thereof. In other cases, HG comprises multiple terminal tertiary amine groups or salts thereof. In some instances, the HG comprises one terminal polyol (e.g., glucose, maltose) or a derivative thereof. In other instances, the HG comprises multiple terminal polyols (e.g., glucose, maltose) or a derivative thereof.

[0269] In another example, the compound of formula (II) is according to formula (IV): [ka] .

[0270] In formula (IV), BA, RG 1 , SP 1 , R.G. 2 , SP 2 , and HG are as defined above, and AA 1 is a trivalent linker comprising amino acid residues; AA 2 is a dipeptide residue; and PAB is [ka] where: [ka] indicates the atom through which PAB is attached to the adjacent group in the formula; subscript p is 0 or 1; and subscript q is 0 or 1. In some examples, subscript p is 0 and subscript q is 0. In some examples, subscript p is 1; and subscript q is 0. In some examples, subscript p is 0; and subscript q is 1. In some examples, subscript p is 1; and subscript q is 1. In some examples, SP 1 contains 0 to 5 polyethylene glycol (PEG) residues. In some examples, SP 2 contains 0 to 5 PEG residues. 1 is, in each case independently, C 1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e , -NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, and combinations thereof, where subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8. In some examples, SP 2 is, in each case independently, C 1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e , -NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, and combinations thereof, where subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8. In some examples, AA 1 or AA 2and any one of AA, at each occurrence independently, comprises an amino acid selected from alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline, a derivative thereof, or a combination thereof. 1 is an amino acid, derivative thereof, or combination thereof selected from alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline. 1 is lysine. In some embodiments, AA 1 is lysine or a derivative of lysine. In some embodiments, AA 1 is glutamic acid. In some embodiments, AA 2 is valine-citrulline. In some embodiments, AA 2 is citrulline-valine. In some embodiments, AA 2 is valine-alanine. In some embodiments, AA 2 is alanine-valine. In some embodiments, AA 2 is valine-glycine. In some embodiments, AA 2 is glycine-valine. In some embodiments, AA 1 -AA 2 is glutamine-valine-citrulline. In some embodiments, AA 1 -AA 2 is lysine-valine-citrulline. In some embodiments, AA 1 -AA 2 is lysine-valine-alanine. In some embodiments, AA 1 -AA 2is glutamine-valine-alanine. In some embodiments, the lysine is L-lysine. In some embodiments, the lysine is D-lysine.

[0271] In certain embodiments of formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (III), (3000), (5001), (5002), (5003), (5004), (6001), (6002), (6003), (6004), (6005), (7001), (7002), (7003), (7004), and / or (7005), the linker is: [ka] or a stereoisomeric form thereof or a positional isomer thereof or a mixture of positional isomers thereof, wherein: Each [ka] is a bond with a binder; and Each [ka] is the bond to the payload residue.

[0272] In some examples, the moiety L-PA is attached to a reactive group (RG) to form an RG-L-PA (e.g., a linker payload shown in Table 3). In some examples, a BA (or a modified form of a BA, e.g., a PEG-modified Ab shown in Table 2, or an Ab 1 ) reacts with a linker payload to form an ADC described in Tables 1 and 2. Also contemplated within the scope of the embodiments presented herein are ADCs prepared from any of the linker payloads described in Tables 5A and 5B.

[0273] (Linker payload) Provided herein are linker-steroids according to formula (2000) or pharmaceutically acceptable salts, solvates, or stereoisomers thereof that are useful in the preparation of antibody-drug conjugates; RG-L 2 -(L 3 ) 0-1 -SP-D (In the formula, D is a) [ka] (wherein both R x is hydrogen; R 34 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is —C(O)—C—C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1 -(where X 1 is (L 3 ) 0-1 -C(O)-N(H)-(C1-C 10 -alkylene)-S- (where S is (L 3 ) 0-1 attached to -C(O)-N(C 1-6 Alkyl)-(C1-C 10 -alkylene)-S- (where S is (L 3 ) 0-1 (attached to [ka] (where the attachment point on the right (i.e., at N) is (L 3 ) 0-1 (where N is the same as (L 3 ) 0-1 (attached to [ka] (where N is the (L 3 ) 0-1 and wherein Ar is an optionally substituted arylene (in some embodiments, [ka] ) or optionally substituted heteroarylene), -(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is (L 3 ) 0-1 -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is (L 3 ) 0-1 and wherein each C1-C 10 -alkylene is optionally substituted independently with one or more hydroxy), -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -(where X 2 is (L 3 ) 0-1 (attached to [ka] (where X 4 is (L 3 ) 0-1 (appended to the Here, both R in formula (a) x is fluoro; R 34is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is —C(O)—C—C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1b -(where X 1b is (L 3 ) 0-1 -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -(where X 1b is (L 3 ) 0-1 (attached to [ka] (where the attachment point on the right (i.e., at N) is (L 3 ) 0-1 (where N is the same as (L 3 ) 0-1 (attached to [ka] (where N is the (L 3 ) 0-1 and wherein Ar is an optionally substituted arylene (in some embodiments, [ka] ) or optionally substituted heteroarylene), -(C-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is (L 3 ) 0-1 -C(O)-(C1-C 10 -alkylene)-NR50 C(O)-(C1-C 10 -alkylene)-NR 50a -(where NR 50a is (L 3 ) 0-1 and wherein each C1-C 10 -alkylene is optionally substituted independently with one or more hydroxy), -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -(where X 2 is (L 3 ) 0-1 (attached to [ka] (where X 4 is (L 3 ) 0-1 (attached to); and / or b) a compound of Table A above (wherein the compound of Table A is a compound of the formula: -C(O)CHOH-OH, i.e., -C(O)CH-O-SP-(L 3 ) 0-1 - or via the hydroxy of the mapla collate, i.e., -O-SP-(L 3 ) 0-1 - linked to BA of the compound of formula (2000) by Selected from: X 1 is -N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 is -CH2- or X 3 is -CH2-O-(C1-C 10 -alkylene)-C(O)- (wherein C(O) is X 4 (attached to a3 is -C(O)-; X 34 is -O-; R 35 is H, -OH, -OCH3, or C 1-6 is alkyl; R 50 and R 50a are independently hydrogen or C1-C6-alkyl; R d , R e , and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CHOR g where each R g is independently —CHC(O)OH or —CHC(O)O(alkyl); and mm is 0 or 1; RG is a reactive group residue; L 2 is the connecting linker; and L 3 is a self-immolating group, if present).

[0274] Provided herein are linker-LXR-modulators according to formula (4000), or pharmaceutically acceptable salts, solvates, or stereoisomers thereof, that are useful in the preparation of antibody-drug conjugates; RG-LE type (4000) (In the formula, E is a) a compound of formula (B) as described above and herein; and / or b) a compound of formula (B-1) as described above and herein; and / or c) Payloads described in Table C herein Selected from; L is a linker described herein; and RG is any reactive group residue described herein).

[0275] In some embodiments, the LXR payload is [ka] In some embodiments, the LXR payload is [ka] is.

[0276] In some embodiments, the linker-payload of Formula (4000) has the structure of Formula (4001), (4002), (4003), or (4004): or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof; [ka] (In the formula, SP 1 and SP 2 is, when present, in some and optional embodiments a spacer group as defined herein; Each AA is an amino acid residue; p is an integer from 1 to 10; RG is a reactive group residue; and R B1 , R B2 , R 7 and b are, in some and optional embodiments, as defined herein.

[0277] In some embodiments, the linker-payload of formula (4000), (4001), (4002), (4003), or (4004) is selected from the linker-payloads of Table 3.

[0278] Provided herein is a linker-rifamycin analog according to formula (7000) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof; RG-LF type (7000) (In the formula, F is a rifamycin analog; L is a linker described herein; and RG is any reactive group residue described herein).

[0279] In some embodiments, F is a rifamycin analog described herein. In some embodiments, F is a rifamycin analog: [ka] In some embodiments, F is rifampicin: [ka] is.

[0280] Also provided herein is a linker payload according to formula (D): [ka] .

[0281] Provided herein are linker-steroids, wherein the steroid conjugated to an antibody or antigen-binding fragment thereof via a linker or linker-spacer is a compound of formula (A-1) or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof; [ka] (In the formula, R 1 and R 2 are independently -H, alkyl, alkyl-C(O)-O-, -OH, or halo; or R 1 and R 2 together, [ka] Forming where R 4 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; wherein the alkyl, aryl, arylalkyl, and N-containing heterocycloalkyl are independently in each occurrence -NR Aa R Ab optionally substituted with; R 3 is -O,R Z -C(O)-X-, -heteroalkyl, -piperidinyl, -NR Aa R Ab , -oxyaryl-NR Aa R Ab , or -Z-A'(R P ) t and; R Z is alkyl; X is O or NR Aa and; Z is S, S(O), S(O)2, SO2NR Aa , O, C(O)NR Aa , C(O), or NR Aa and; A' is aryl, arylalkyl, or heteroaryl; R P is independently in each occurrence halo, optionally substituted alkyl, —OH, or —NR Aa R Ab and; R Aa and R Ab is independently at each occurrence —H, optionally substituted alkyl, or optionally substituted aryl; the subscript a is an integer from 0 to 19; and t is an integer from 1 to 3; and R 5A and R 5B are each independently a halo or a hydrogen atom; where the group R 3 or R 4 is attached to the linker).

[0282] Provided herein are antibody-drug conjugates of the formula Ab-L'-SP-D or BA-L'-SP-D, where D is a budesonide prodrug or a prodrug of a budesonide analog or derivative (including fluorinated analogs and derivatives), and where Ab, BA, L', and SP are as defined in any embodiment described herein. In some embodiments, SP is D or [ka] In some embodiments, under physiological conditions, the bond between L and SP is cleaved to release the steroid prodrug, i.e., H-SP-D or [ka] and then release the bond between SP and D, or SP and [ka] The bond between is cleaved, releasing the biologically active steroid.

[0283] In some examples, the ADC of formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (III), or (3000) is an ADC described in Table 1 and / or Table 2 and in the Examples section. In some embodiments, the steroid payload in any antibody drug conjugate described herein is [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

[0284] Provided herein is an antibody-drug conjugate of any LXR-modulator compound described herein of formula (5001), (5002), (5003), or (5004): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein L, in some or any embodiments, is any linker described herein; n is an integer from 1 to 30; BA is a binding agent or a PEG-modified binding agent; and R B1 , R B2 , R 7 and b are, in some and optional embodiments, as defined herein.

[0285] Provided herein is an antibody-drug conjugate of any LXR-modulator compound described herein of formula (6001), (6002), (6003), or (6004): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] (In the formula, SP 1 and SP, if present, is in some or any embodiment a spacer group as defined herein; Each AA is an amino acid residue; p is an integer from 1 to 10; n is an integer from 1 to 30; BA is a binding agent or a PEG-modified binding agent; and R B1 , R B2 , R 7 and b are, in some and optional embodiments, as defined herein.

[0286] Provided herein is an antibody-drug conjugate of any LXR-modulator compound described herein of formula (6005): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] (In the formula, R B1 , R B2 , R 7 , b, BA, RG 1 , SP 1 , A.A. 1 , and A.A. 2 is, in some or any embodiments, as defined herein).

[0287] In some examples, the ADC of formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (5001), (5002), (5003), (5004), (6001), (6002), (6003), (6004), or (6005) is an ADC described in Table 1 and / or Table 2 and in the Examples section. In some embodiments, the LXR modulator payload in any antibody drug conjugate described herein is [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0288] Provided herein are antibody-drug conjugates of any rifamycin analog described herein and having the structure of formula (7001), or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] (In the formula: X 1c -S-; -O- and -NR 5c Selected from; R1c is amino-C 1-6 Alkyl; C 1-6 Alkylamino C 1-6 Alkyl; Di-C 1-6 Alkylamino C 1-6 Alkyl; Hydroxy-C 1-6 Alkyl; HS-C 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-OC 1-6 Alkyl; (R 5c )2N-C 1-6 Alkylene-SC 1-6 Alkyl; heterocycloalkyl, or heterocycloalkyl-C 1-6 alkyl; wherein heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and wherein heterocycloalkyl is nine Roarke Lu is , Haro, C 1-6 optionally substituted with alkyl, -OH, or =O; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; Each R ac are, if present, independently -F; -Cl; -Br; -I; -OH; -NH; and C 1-6 alkoxy; and R 5c is independently at each occurrence hydrogen; and C 1-6 alkyl; L is a linker; BA is a binder; and The subscript n is an integer from 1 to 30.

[0289] Provided herein is an antibody-drug conjugate of any rifamycin analog described herein and having the structure of formula (7002): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] (Wherein, BA, RG 1 , SP 1 , A.A. 1 , A.A. 2 , R 1c , R bc , R ac , X 1c , R 2c , R 3c , R 4c and n is, in some or any embodiments, as defined herein.

[0290] Provided herein is an antibody-rifamycin analog conjugate having the structure of formula (7003): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] (In the formula: X 1c is selected from -S-; -O-; and c; R 1c teeth, [ka] where Y is C or N; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; R 5c is, independently at each occurrence, absent or hydrogen; and C 1-6 alkyl; each AA is an independently selected amino acid; SP 1 is absent or a spacer; RG 1 is a reactive group residue; BA is an anti-MSR1 antibody or an antigen-binding fragment thereof; The subscript n is an integer from 1 to 30; The subscript w is 2, 3, or 4; where R 1c is a wavy line [ka] (which is attached to the linker via a nitrogen atom indicated by

[0291] In various embodiments of formula (7003), SP 1 , R.G. 1 and AA are, in some and / or any particular embodiment, as defined herein.

[0292] In some embodiments of Formula (7003), X 1c is O. In some embodiments of Formula (7003), X 1c is S. In some embodiments of Formula (7003), X 1c teeth C In some embodiments of Formula (7003), X 1c is NR 5c is.

[0293] In some embodiments of Formula (7003), BA comprises an N297Q mutation; is an anti-MSR1 antibody or antigen-binding fragment thereof.

[0294] In some embodiments of Formula (7003), the subscript w is 2.

[0295] In some embodiments of Formula (7003), (AA)2 is valine-citrulline.

[0296] In some embodiments of Formula (7003), SP 1 teeth, [ka] In some embodiments of Formula (7003), SP 1 teeth, [ka] Includes.

[0297] In some embodiments of Formula (7003), RG 1 teeth, [ka] Includes.

[0298] In some embodiments of Formula (7003), X 1c is O; R 1c teeth, [ka] where Y is C or N; where R 1c is R 1c is attached to the linker via a quaternary nitrogen atom of R 5c is C 1-6 alkyl; and R 6c is the counter ion.

[0299] In some such embodiments, R 1c teeth, [ka] In some such embodiments, R 1c teeth, [ka] In some such embodiments, R 1c teeth, [ka] In some such embodiments, R 6c I - , Cl - , or Br - and in some instances, R 6c I - is.

[0300] In some embodiments of Formula (7003), the rifamycin analog is: [ka] In some embodiments of Formula (7003), the rifamycin analog is:

[0301] [ka] In some embodiments of Formula (7003), the rifamycin analog is: [ka] is.

[0302] Further provided herein is an antibody-drug conjugate comprising a rifamycin compound (e.g., rifampicin) according to Formula (7004): [ka] .

[0303] Further provided herein is an antibody-drug conjugate comprising a rifamycin compound (e.g., rifampicin) according to Formula (7005): [ka] wherein L and BA are, in some or any embodiments, as defined herein.

[0304] In some examples, the ADC of formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (7001), (7002), (7003), (7004), and / or (7005) is an ADC described in Table 2 and / or the Examples section.

[0305] Also included in these examples of ADCs are pharmaceutically acceptable salts, solvates, stereoisomeric forms, positional isomers, or mixtures of positional isomers thereof, wherein each [ka] is the bond with the binder; and each [ka] is the binding with the payload.

[0306] In certain embodiments, provided herein is an ADC comprising an anti-MSR1 antibody or antigen-binding fragment thereof disclosed herein, or a PEG-modified anti-MSR1 antibody or antigen-binding fragment thereof, and a linker-payload (LP) selected from the group consisting of a linker-payload in Table 3, or a stereoisomeric form thereof, or a positional isomer thereof, or a mixture of positional isomers thereof.

[0307] Also provided herein are antibody-radionuclide conjugates (ARCs) comprising an anti-MSR1 antibody conjugated to one or more radionuclides. Exemplary radionuclides that can be used in connection with this aspect of the disclosure include, for example: 225 Ac, 212 Bi, 213 Bi, 131 I, 186 Re, 227 Th, 222 Rn, 223 Ra, 224Ra, and 90 Examples include, but are not limited to, Y. Table 1: List of ADCs and their structures [Table 3] TIFF0007590871000298.tif207170TIFF0007590871000299.tif219170TIFF0007590871000300.tif244170TIFF0007590871 000301.tif241170TIFF0007590871000302.tif243170TIFF0007590871000303.tif233170TIFF0007590871000304.tif43170

[0308] In the ADCs of Table 1, Ab is an anti-MSR1 antibody or antigen-binding fragment thereof provided herein. In certain embodiments, Ab is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a PEG group on a glutamine side chain described herein. [ka] (herein referred to as a PEG-modified antibody). In some embodiments, the PEG group terminates in an azide group, facilitating reaction with a linker-payload described herein (e.g., a linker-payload described in Table 3 and the Examples). In some embodiments, the PEG group is linked to the linker-payload via a triazole or triazole derivative described herein. In the ADC, n is an integer from 1 to 10, e.g., 1, 2, 3, or 4. In the PEG group, nn is an integer from 1 to 10, e.g., 1, 2, 3, 4, or 5. In other embodiments, each BA in the ADC of Table 1 is [ka] where Ab 1 is an anti-MSR1 antibody or an antigen-binding fragment thereof; R is C 2-4-alkylene; and nn is an integer selected from 2 to 4, and each n is an integer from 1 to 10, for example, 1, 2, 3, or 4.

[0309] In certain embodiments, provided herein is an ADC comprising an antibody disclosed herein and a linker-payload (LP) selected from the group consisting of a linker-payload in Table 2, or a stereoisomeric form thereof, or a positional isomer thereof, or a mixture of positional isomers thereof. Table 2: List of ADCs and their structures [Table 4] TIFF0007590871000308.tif214170TIFF0007590871000309.tif201170TIFF0007590871000310.tif211170TIF F0007590871000311.tif213170TIFF0007590871000312.tif226170TIFF0007590871000313.tif239170TIFF000 7590871000314.tif244170TIFF0007590871000315.tif207170TIFF0007590871000316.tif231170TIFF0007590 871000317.tif207170TIFF0007590871000318.tif213170TIFF0007590871000319.tif194170TIFF00075908710 00320.tif198170TIFF0007590871000321.tif183170TIFF0007590871000322.tif228170TIFF00075908710003 23.tif237170TIFF0007590871000324.tif241170TIFF0007590871000325.tif241170TIFF0007590871000326.t if183170TIFF0007590871000327.tif176170TIFF0007590871000328.tif181170TIFF0007590871000329.tif23 0170TIFF0007590871000330.tif229170TIFF0007590871000331.tif244170TIFF0007590871000332.tif167170

[0310] In the ADCs in Table 2, Ab is an anti-MSR1 antibody or antigen-binding fragment thereof provided herein. In certain embodiments, Ab is modified with a PEG group on the glutamine side chain described herein. In the ADCs, n is an integer from 1 to 10, e.g., 1, 2, 3, or 4.

[0311] Provided herein are payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a N297Q mutation.

[0312] Provided herein are antibodies comprising a set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) of Table 4, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof is conjugated to a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a set of six complementarity-determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4 and an N297Q mutation.

[0313] Provided herein are antibody fragments comprising a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO:52; an HCDR2 comprising SEQ ID NO:54; an HCDR3 comprising SEQ ID NO:56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO:60; an LCDR2 comprising SEQ ID NO:62; and an LCDR3 comprising SEQ ID NO:64, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; a HCDR2 comprising SEQ ID NO: 54; a HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; a LCDR2 comprising SEQ ID NO: 62; and a LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0314] Provided herein are antibodies that contain a set of heavy chain variable regions (HCVRs) and a set of light chain variable regions (LCVRs) that are variable regions of Table 4, and that deliver a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain variable region (HCVR) set and a light chain variable region (LCVR) set that are variable regions in Table 4, and an N297Q mutation.

[0315] Provided herein is a antibody comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and a payload [ka] Conjugated to An anti-MSR1 antibody or an antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and an N297Q mutation.

[0316] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof. In some of such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises an N297Q mutation.

[0317] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4 and an N297Q mutation.

[0318] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0319] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are the variable regions of Table 4. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are the variable regions of Table 4, and an N297Q mutation.

[0320] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and an N297Q mutation.

[0321] Provided herein are payload [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a N297Q mutation.

[0322] Provided herein are antibodies comprising a set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) of Table 4, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a set of six complementarity-determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4 and an N297Q mutation.

[0323] Provided herein are antibody fragments comprising a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO:52; an HCDR2 comprising SEQ ID NO:54; an HCDR3 comprising SEQ ID NO:56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO:60; an LCDR2 comprising SEQ ID NO:62; and an LCDR3 comprising SEQ ID NO:64, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; a HCDR2 comprising SEQ ID NO: 54; a HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; a LCDR2 comprising SEQ ID NO: 62; and a LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0324] Provided herein are antibodies that contain a set of heavy chain variable regions (HCVRs) and a set of light chain variable regions (LCVRs) that are variable regions of Table 4, and that deliver a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain variable region (HCVR) set and a light chain variable region (LCVR) set that are the variable regions of Table 4, and an N297Q mutation.

[0325] Provided herein is a antibody comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and an N297Q mutation.

[0326] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof. In some of such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises an N297Q mutation.

[0327] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4 and an N297Q mutation.

[0328] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0329] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are the variable regions in Table 4. In some of such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are the variable regions in Table 4, and an N297Q mutation.

[0330] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and an N297Q mutation.

[0331] Provided herein are payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a N297Q mutation.

[0332] Provided herein are antibodies comprising a set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) of Table 4, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a set of six complementarity-determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4 and an N297Q mutation.

[0333] Provided herein are antibody fragments comprising a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO:52; an HCDR2 comprising SEQ ID NO:54; an HCDR3 comprising SEQ ID NO:56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO:60; an LCDR2 comprising SEQ ID NO:62; and an LCDR3 comprising SEQ ID NO:64, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; a HCDR2 comprising SEQ ID NO: 54; a HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; a LCDR2 comprising SEQ ID NO: 62; and a LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0334] Provided herein are antibodies that contain a set of heavy chain variable regions (HCVRs) and a set of light chain variable regions (LCVRs) that are variable regions of Table 4, and that deliver a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain variable region (HCVR) set and a light chain variable region (LCVR) set that are the variable regions of Table 4, and an N297Q mutation.

[0335] Provided herein is a antibody comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and an N297Q mutation.

[0336] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof. In some of such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises an N297Q mutation.

[0337] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4 and an N297Q mutation.

[0338] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0339] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are the variable regions in Table 4. In some of such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are the variable regions in Table 4, and an N297Q mutation.

[0340] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and an N297Q mutation.

[0341] Provided herein are payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a N297Q mutation.

[0342] Provided herein are antibodies comprising a set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) of Table 4, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a set of six complementarity-determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) in Table 4 and an N297Q mutation.

[0343] Provided herein are antibody fragments comprising a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO:52; an HCDR2 comprising SEQ ID NO:54; an HCDR3 comprising SEQ ID NO:56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO:60; an LCDR2 comprising SEQ ID NO:62; and an LCDR3 comprising SEQ ID NO:64, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; a HCDR2 comprising SEQ ID NO: 54; a HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; a LCDR2 comprising SEQ ID NO: 62; and a LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0344] Provided herein are antibodies that contain a set of heavy chain variable regions (HCVRs) and a set of light chain variable regions (LCVRs) that are variable regions of Table 4, and that deliver a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to a heavy chain variable region (HCVR) set and a light chain variable region (LCVR) set that are the variable regions of Table 4, and an N297Q mutation.

[0345] Provided herein is a antibody comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and a payload [ka] In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, is conjugated to: In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58, and an N297Q mutation.

[0346] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] where X - is a pharmaceutically acceptable counterion, and wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a N297Q mutation.

[0347] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] where X -is a pharmaceutically acceptable counterion, and wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) of Table 4. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises the set of six complementarity determining regions (CDRs) (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) of Table 4 and an N297Q mutation.

[0348] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] where X -is a pharmaceutically acceptable counterion, and wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof, comprising: a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 52; an HCDR2 comprising SEQ ID NO: 54; an HCDR3 comprising SEQ ID NO: 56; a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 60; an LCDR2 comprising SEQ ID NO: 62; and an LCDR3 comprising SEQ ID NO: 64, and an N297Q mutation.

[0349] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] where X - is a pharmaceutically acceptable counterion, and wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are variable regions in Table 4. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a pair of heavy chain variable regions (HCVRs) and a pair of light chain variable regions (LCVRs) that are variable regions in Table 4, and an N297Q mutation.

[0350] An antibody-drug conjugate (ADC) according to the formula: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, or positional isomer thereof, or a mixture thereof; [ka] where X - is a pharmaceutically acceptable counterion, and wherein the antibody is an anti-MSR1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR) comprising SEQ ID NO: 50 and a light chain variable region (LCVR) of SEQ ID NO: 58. In some such embodiments, the drug-antibody ratio (DAR) is 1 to 4. In some embodiments, the DAR is 1. In some embodiments, the DAR is 2. In some embodiments, the DAR is 3. In some embodiments, the DAR is 4. In some embodiments, the anti-MSR1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 50; a light chain variable region (LCVR) of SEQ ID NO: 58; and a N297Q mutation.

[0351] As used herein, in certain embodiments, an amino acid is a nucleotide, e.g., a nucleotide, such as the moiety -SP 1 -AA 1 -AA 2 -Middle spacer SP 1 When bound to the amino acid AA 1 is connected to the spacer SP via its amino group. 1 The spacer residue comprises a functional group portion that forms a bond with the amino group in the amino acid. By way of example only, the following structure: [ka] In the example, the valine residue is SP as shown. 1 binds to SP 1 The residue, in this example, contains a (C=O) moiety. Also, in this example, SP 1 The residue contains a functional group suitable for forming a bond with a reactive group, and 1The residue contains an -NH- moiety. One of skill in the art will recognize that similar classifications can be applied to all other formulas described herein.

[0352] The antibody-drug conjugates described herein can be prepared using conjugation conditions known to those skilled in the art (see, e.g., Doronina et al., Nature Biotechnology 2003, 21, 7, 778, incorporated herein by reference in its entirety). In some embodiments, the ADC is prepared by reacting an anti-MSR1 antibody or antigen-binding fragment thereof with a compound comprising a desired linker and payload, where the linker carries a moiety that reacts with an antibody or antigen-binding protein, e.g., at a desired residue of the antibody or antigen-binding protein. Exemplary conditions are described in the Examples below.

[0353] (Preparation of antibody-drug conjugates) In some embodiments, provided herein is a process for preparing an antibody-drug conjugate, the process comprising contacting an anti-MSR1 antibody or a PEG-modified anti-MSR1 antibody, or an antigen-binding fragment thereof, with a linker-payload or linker-spacer-payload selected from Table 3. Also provided herein is an antibody-drug conjugate, or a stereoisomeric form or positional isomer thereof, or a mixture of positional isomers thereof, prepared by conjugating an anti-MSR1 antibody or a PEG-modified anti-MSR1 antibody, or an antigen-binding fragment thereof, with a linker-payload or linker-spacer-payload selected from Table 3. Table 3: List of linker-payload (LP) and their structures [Table 5] TIFF0007590871000375.tif216170TIFF0007590871000376.tif218170TIFF0007590871000377.tif210170TIFF000 7590871000378.tif216170TIFF0007590871000379.tif238170TIFF0007590871000380.tif244170TIFF00075908710 00381.tif223170TIFF0007590871000382.tif233170TIFF0007590871000383.tif185170TIFF0007590871000384.t if228170TIFF0007590871000385.tif221170TIFF0007590871000386.tif234170TIFF0007590871000387.tif211170

[0354] The compounds in the table above can be prepared as described in the Examples herein.

[0355] Also provided herein is a method for preparing an antibody-drug conjugate of a rifamycin analog (e.g., rifampicin), comprising coupling an anti-MSR1 antibody, or antigen-binding fragment thereof, to a linker payload according to Formula (D): [ka] under conditions suitable for forming a bond between the anti-MSR1 antibody or antigen-binding fragment thereof.

[0356] (Epitope mapping and related techniques) The epitope to which the antibody of the present invention binds can consist of a single contiguous sequence of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) amino acids of the MSR1 protein. Alternatively, the epitope can consist of multiple discontinuous amino acids (or amino acid sequences) of MSR1. In some embodiments, the epitope is located in or near the modified LDL-binding domain of MSR1. In other embodiments, the epitope is located outside the modified LDL-binding domain of MSR1, e.g., at a location on the surface of MSR1 that does not interfere with the binding of modified LDL to MSR1 when the antibody binds to such an epitope.

[0357] Various techniques known to those skilled in the art can be used to determine whether an antibody "interacts with one or more amino acids" within a polypeptide or protein. Exemplary techniques include routine cross-blocking assays, such as those described in Harlow and Lane, Antibodies (Cold Spring Harbor Press, Cold Spring Harbor, NY), alanine scanning mutation analysis, peptide blot analysis (Reineke, 2004, Methods Mol Biol 248:443-463), and peptide truncation analysis. Additionally, methods such as epitope excision, epitope extraction, and chemical modification of antigens can be utilized (Tomer, 2000, Protein Science 9:487-496). Another method that can be used to identify amino acids within a polypeptide with which an antibody interacts is hydrogen / deuterium exchange, detected by mass spectrometry. Generally, hydrogen / deuterium exchange involves deuterium-labeling the protein of interest and then binding the antibody to the deuterium-labeled protein. The protein / antibody complex is then transferred to water, allowing hydrogen-deuterium exchange to occur at all residues except those protected by the antibody (which remain deuterium-labeled). After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry analysis, revealing deuterium-labeled residues corresponding to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) Analytical Biochemistry 267(2):252-259; Engen and Smith (2001) Anal. Chem. 73:256A-265A.

[0358] Embodiments include anti-MSR1 antibodies that bind to the same epitope as any of the specific exemplary antibodies described herein (e.g., antibodies comprising any of the amino acid sequences set forth in Table 4 herein). Similarly, embodiments include anti-MSR1 antibodies that compete for binding to MSR1 with any of the specific exemplary antibodies described herein (e.g., antibodies comprising any of the amino acid sequences set forth in Table 4 herein).

[0359] Using routine methods known in the art and exemplified herein, for example, in Example 7, it is easy to determine whether an antibody binds to the same epitope as a reference anti-MSR1 antibody or competes for binding with the reference anti-MSR1 antibody. For example, to determine whether a test antibody binds to the same epitope as a reference anti-MSR1 antibody disclosed herein, the reference antibody is bound to an MSR1 protein. The ability of the test antibody to bind to the MSR1 molecule is then evaluated. If the test antibody can bind to MSR1 after saturation binding with the reference anti-MSR1 antibody, it can be concluded that the test antibody binds to a different epitope than the reference anti-MSR1 antibody. On the other hand, if the test antibody cannot bind to the MSR1 molecule after saturation binding with the reference anti-MSR1 antibody, the test antibody can bind to the same epitope as the epitope bound by the reference anti-MSR1 antibody of the present invention. Further routine experiments (e.g., peptide mutagenesis and binding analysis) can then be performed to confirm whether the observed lack of binding of the test antibody is indeed due to binding to the same epitope as the reference antibody, or whether steric blocking (or another phenomenon) is responsible for the observed lack of binding. These types of experiments can be performed using ELISA, RIA, Biacore, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art. According to certain embodiments of the invention, two antibodies bind to the same (or overlapping) epitope if a 1-, 5-, 10-, 20-, or 100-fold excess of one antibody inhibits binding of the other by at least 50%, but preferably 75%, 90%, or even 99%, as measured, for example, in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 1990:50:1495-1502). Alternatively, two antibodies are considered to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other. Two antibodies are considered to have "overlapping epitopes" if only a subset of the amino acid mutations that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other.

[0360] To determine whether an antibody competes for binding (or cross-competes for binding) with a reference anti-MSR1 antibody, the above binding method is performed in two ways. In the first way, the reference antibody is bound to the MSR1 protein under saturating conditions, and then the binding of the test antibody to the MSR1 molecule is evaluated. In the second way, the test antibody is bound to the MSR1 molecule under saturating conditions, and then the binding of the reference antibody to the MSR1 molecule is evaluated. If the first (saturating) antibody can bind to the MSR1 molecule in both ways, it is concluded that the test antibody and the reference antibody compete for binding to MSR1. As will be understood by those skilled in the art, an antibody that competes for binding with a reference antibody may not necessarily be able to bind to the same epitope as the reference antibody, but may sterically block the binding of the reference antibody by binding to an overlapping or adjacent epitope.

[0361] (Preparation of human antibodies) The anti-MSR1 antibody disclosed herein can be a fully human antibody. Methods for producing monoclonal antibodies, including fully human monoclonal antibodies, are known in the art. Any such known method can be used in the context of the present invention to produce a human antibody that specifically binds to human MSR1.

[0362] For example, using VELOCIMMUNE™ technology or any other similar known method for generating fully human monoclonal antibodies, high-affinity chimeric antibodies against MSR1 having human variable regions and mouse constant regions are first isolated. As described in the experimental section below, the antibodies are characterized and selected for desired characteristics, including affinity, ligand-blocking activity, selectivity, epitope, etc. If necessary, the mouse constant region is replaced with a desired human constant region, such as wild-type or modified IgG1 or IgG4, to generate a fully human anti-MSR1 antibody. The constant region selected may vary depending on the specific application, but high-affinity antigen binding and target specificity characteristics reside in the variable region. In some instances, fully human anti-MSR1 antibodies are isolated directly from antigen-positive B cells.

[0363] (biological equivalent) The anti-MSR1 antibodies and antibody fragments disclosed herein include proteins having amino acid sequences that differ from the amino acid sequences of the described antibodies but retain the ability to bind to human MSR1. Such variant antibodies and antibody fragments contain one or more amino acid additions, deletions, or substitutions when compared to the parent sequence, but exhibit biological activity essentially equivalent to that of the described antibody. Similarly, DNA sequences encoding the anti-MSR1 antibodies disclosed herein include sequences that contain one or more nucleotide additions, deletions, or substitutions when compared to the disclosed sequences, but encode anti-MSR1 antibodies or antibody fragments that are essentially biologically equivalent to the anti-MSR1 antibodies or antibody fragments disclosed herein. Examples of such variant amino acid and DNA sequences are discussed above.

[0364] For example, two antigen-binding proteins or antibodies are considered to be bioequivalent if they are pharmaceutical equivalents or pharmaceutical substitutes whose rate and extent of absorption do not differ significantly when administered at the same molar dose, either in single or multiple doses, under similar experimental conditions. Some antibodies may be considered equivalents or pharmaceutical substitutes and still be considered bioequivalent if their extent of absorption is equivalent but their absorption rate is not, because such differences in absorption rate are intended and reflected in the labeling, are not essential to achieving effective body drug concentrations, for example, during chronic use, and are not considered medically significant for the particular drug being tested.

[0365] In one embodiment, two antigen binding proteins are bioequivalent if they have no clinically meaningful differences in terms of their safety, purity, and potency.

[0366] In one embodiment, two antigen binding proteins are bioequivalent if a patient can be made to switch between the reference product and the biological product without an expected increased risk of adverse effects, including clinically important changes in immunogenicity or reduced efficacy, compared to continuous therapy without one or more switches.

[0367] In one embodiment, two antigen binding proteins are biologically equivalent if they both act by a common mechanism(s) of action for the condition(s) of use, to the extent such mechanisms are known.

[0368] Bioequivalence can be demonstrated by in vivo and in vitro methods. Measures of bioequivalence include, for example, (a) in vivo studies in humans or other mammals in which the concentration of an antibody or its metabolites is measured as a function of time in blood, plasma, serum, or other biological fluid; (b) in vitro studies that correlate with and reasonably predict human in vivo bioavailability data; (c) in vivo studies in humans or other mammals in which the relevant acute pharmacological effect of the antibody (or its target) is measured as a function of time; and (d) well-controlled clinical trials that establish the safety, efficacy, or bioavailability or bioequivalence of the antibody.

[0369] Biologically equivalent variants of the anti-MSR1 antibodies disclosed herein can be constructed, for example, by making various substitutions of residues or sequences or by deleting terminal or internal residues or sequences not required for biological activity. For example, cysteine ​​residues not essential for biological activity can be deleted or replaced with other amino acids to prevent unnecessary or incorrect intramolecular disulfide bridge formation during renaturation. In other contexts, biologically equivalent antibodies can include anti-MSR1 antibody variants containing amino acid changes that modify the glycosylation characteristics of the antibody, for example, mutations that abolish or eliminate glycosylation.

[0370] (Species selectivity and species cross-reactivity) In certain embodiments, provided herein are anti-MSR1 antibodies that bind to human MSR1 but not to MSR1 from other species. Embodiments also include anti-MSR1 antibodies that bind to human MSR1 and MSR1 from one or more non-human species. For example, the anti-MSR1 antibodies disclosed herein can bind to human MSR1 and, optionally, may or may not bind to one or more of mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, macaque, marmoset, rhesus, or chimpanzee MSR1. In certain exemplary embodiments, anti-MSR1 antibodies are provided that specifically bind to human MSR1 and macaque (e.g., cynomolgus) MSR1. Other anti-MSR1 antibodies disclosed herein bind to human MSR1 but do not bind, or only weakly bind, to macaque MSR1.

[0371] (multispecific antibody) The antibodies disclosed herein can be monospecific or multispecific (e.g., bispecific). Multispecific antibodies may be specific for different epitopes of a single target polypeptide or may contain antigen-binding domains specific for multiple target polypeptides. See, for example, Tutt et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol. 22:238-244. The anti-MSR1 antibodies disclosed herein can be linked to or co-expressed with another functional molecule, such as another peptide or protein. For example, an antibody or fragment thereof can be operatively linked (e.g., by chemical coupling, genetic fusion, noncovalent association, or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment, to produce a bispecific or multispecific antibody having a second binding specificity.

[0372] Embodiments include bispecific antibodies in which one arm of the immunoglobulin binds to human MSR1 and the other arm of the immunoglobulin is specific for a second antigen. The MSR1-binding arm can comprise any of the HCVR / LCVR or CDR amino acid sequences shown in Table 4 herein. In certain embodiments, the MSR1-binding arm binds to human MSR1 and blocks modified LDL binding to MSR1. In other embodiments, the MSR1-binding arm binds to human MSR1 but does not block modified LDL binding to MSR1. In some embodiments, the MSR1-binding arm binds to human MSR1 and activates MSR1 signaling. In other embodiments, the MSR1-binding arm blocks MSR1-mediated receptor stimulation. Embodiments also include bispecific antibodies in which one arm of the antibody binds to a first epitope of human MSR1 and the other arm of the antibody binds to a second, different epitope of human MSR1.

[0373] An exemplary bispecific antibody format that can be used in the context of the present invention is a first immunoglobulin (Ig) C H 3 domain and second Ig C H the use of three domains, wherein the first and second Ig C H The three domains differ from each other by at least one amino acid, and wherein the at least one amino acid difference reduces binding of the bispecific antibody to Protein A when compared to a bispecific antibody lacking the amino acid difference. H The 3 domain binds to protein A and the second Ig C H The third domain contains a mutation that reduces or eliminates Protein A binding, for example, the H95R modification (according to IMGT exon numbering; H435R according to EU numbering). H 3 may further comprise a Y96F modification (according to IMGT; Y436F according to EU). HFurther modifications that may be found within 3 include: for IgG1 antibodies, D16E, L18M, N44S, K52N, V57M, and V82I (according to IMGT; D356E, L358M, N384S, K392N, V397M, and V422I according to EU); for IgG2 antibodies, N44S, K52N, and V82I (according to IMGT; N384S, K392N, and V422I according to EU); and for IgG4 antibodies, Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I (according to IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I according to EU). Variations on the above bispecific antibody formats are contemplated within the scope of the present invention.

[0374] Other exemplary bispecific formats that can be used in the context of the present invention include, but are not limited to, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadroma, knobs-into-holes, common light chain (e.g., common light chain with knobs-into-holes), CrossMab, CrossFab, (SEED) body, leucine zipper, duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab. 2 Bispecific formats include those described in, for example, Klein et al., 2012, mAbs 4:6, 1-11, and references cited therein, for a review of such formats. Bispecific antibodies can also be constructed using peptide / nucleic acid conjugation, for example, using unnatural amino acids with orthogonal chemical reactivity to generate site-specific antibody-oligonucleotide conjugates that subsequently self-assemble into multimeric complexes with defined composition, valency, and shape (see, for example, Kazane et al., J. Am. Chem. Soc. [Epub: Dec. 4, 2012]).

[0375] Therapeutic Formulations and Administration Embodiments relate to pharmaceutical compositions comprising the anti-MSR1 antibodies or antigen-binding fragments thereof disclosed herein. The pharmaceutical compositions of the present invention are formulated with suitable carriers, excipients, and other agents that result in improved transfer, delivery, tolerability, etc. Many suitable formulations can be found in a formulary known to all pharmacists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, gels, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (e.g., LIPOFECTIN™, Life Technologies, Carlsbad, CA), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, carbowax emulsions (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al., "Compendium of excipients for parenteral formulations," PDA (1998) J Pharm Sci Technol 52:238-311.

[0376] The dose of an antibody administered to a patient may vary depending on the patient's age and size, the target disease, condition, route of administration, etc. A preferred dose is usually calculated according to body weight or body surface area. For adult patients, it may be advantageous to administer the antibody of the present invention intravenously at a single dose of typically about 0.01 to about 20 mg / kg body weight, more preferably about 0.02 to about 7, about 0.03 to about 5, or about 0.05 to about 3 mg / kg body weight. The frequency and duration of treatment can be adjusted depending on the severity of the disease. Effective dosages and schedules for administering anti-MSR1 antibodies can be determined empirically; for example, the patient's progress can be monitored by periodic evaluation, and the dosage can be adjusted accordingly. Furthermore, interspecies scaling of dosages can be performed using methods well known in the art (e.g., Mordenti et al., 1991, Pharmaceut. Res. 8:1351).

[0377] Various delivery systems are known and can be used to administer the pharmaceutical compositions disclosed herein, including, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, and receptor-mediated endocytosis (e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous layers (e.g., oral mucosa, rectal, and intestinal mucosa), and can be administered together with other biologically active agents. Administration can be systemic or local.

[0378] The pharmaceutical compositions disclosed herein can be delivered subcutaneously or intravenously with a standard needle and syringe. Furthermore, for subcutaneous delivery, pen delivery devices are readily adapted to deliver the pharmaceutical compositions of the present invention. Such pen delivery devices can be reusable or disposable. Reusable pen delivery devices typically utilize a replaceable cartridge containing the pharmaceutical composition. Once the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be readily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. Disposable pen delivery devices do not have a replaceable cartridge. Instead, disposable pen delivery devices are pre-filled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0379] A number of reusable pen and autoinjector delivery devices are adapted for subcutaneous delivery of the pharmaceutical compositions disclosed herein. Examples include, but are not limited to, AUTOPEN™ (Owen Mumford Ltd., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75 / 25™ pen, HUMALOG™ pen, HUMALIN 70 / 30™ pen (Eli Lilly and Co., Indianapolis, IN), NOVOPEN™ I, II, and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™ (sanofi-aventis, Frankfurt, Germany), to name a few. Examples of disposable pen delivery devices adapted for subcutaneous delivery of the pharmaceutical compositions of the present invention include, but are not limited to, the SOLOSTAR™ pen (sanofi-aventis), FLEXPEN™ (Novo Nordisk), and KWIKPEN™ (Eli Lilly), SURECLICK™ Autoinjector (Amgen, Thousand Oaks, CA), PENLET™ (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP), and HUMIRA™ pen (Abbott Labs, Abbott Park IL), to name a few.

[0380] In some situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, a polymeric material can be used; see Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, the controlled release system can be placed in proximity to the target of the composition, so that only a fraction of the systemic dose is required (see, e.g., Goodson, 1984, Medical Applications of Controlled Release, supra, Vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.

[0381] Injectable formulations may include dosage forms for intravenous, subcutaneous, intradermal, and intramuscular injections, infusions, and the like. These injectable preparations can be prepared by known methods. For example, injectable preparations can be prepared by dissolving, suspending, or emulsifying the above-mentioned antibody or its salt in a sterile aqueous or oily medium conventionally used for injections. Aqueous media for injection include, for example, saline, isotonic solutions containing glucose, and other auxiliary agents, which may be used in combination with suitable solubilizers such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol), and nonionic surfactants [e.g., polysorbate 80, polyoxyethylene (50 mol) adduct of HCO-50 (hydrogenated castor oil)]. Oily media include, for example, sesame oil, soybean oil, and the like, which may be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol. The injectable preparations prepared in this manner are preferably filled into appropriate ampoules.

[0382] Advantageously, the above-mentioned pharmaceutical compositions for oral or parenteral use are prepared into a unit dosage form suitable for the dosage of the active ingredient. Examples of such unit dosage forms include tablets, pills, injections (ampoules), suppositories, etc. The amount of the antibody contained is usually about 5 to about 500 mg per unit dosage form; particularly, in the form of an injection, the amount of the antibody is preferably about 5 to about 100 mg, and in the case of other dosage forms, the amount is preferably about 10 to about 250 mg.

[0383] Therapeutic Uses of Antibodies Embodiments include methods comprising administering to a subject in need thereof a therapeutic composition comprising an anti-MSR1 antibody or an antibody-drug conjugate comprising an anti-MSR1 antibody (e.g., an anti-MSR1 antibody or ADC comprising any of the HCVR / LCVR or CDR sequences described in Table 4 herein). Therapeutic compositions can include any of the anti-MSR1 antibodies, antigen-binding fragments thereof, or ADCs disclosed herein (e.g., ADCs of formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (III), (3000), (5001), (5002), (5003), (5004), (6001), (6002), (6003), (6004), (6005), (7001), (7002), (7003), (7004), and / or (7005)) and a pharmaceutically acceptable carrier or diluent.

[0384] The antibodies and ADCs disclosed herein are useful, inter alia, for the treatment, prevention, and / or amelioration of any disease or disorder associated with or mediated by MSR1 expression or activity, or treatable by binding to MSR1 without competing for modified LDL and / or promoting MSR1 receptor internalization and / or reducing the number of cell surface receptors. For example, the antibodies and ADCs disclosed herein are useful for treating, arresting, or ameliorating atherosclerosis, proliferative disorders, neurodegenerative disorders, and inflammation by targeting cells that express MSR1 and / or respond to MSR1-mediated signaling, such as macrophages.

[0385] In the context of the therapeutic methods described herein, the anti-MSR1 antibody or ADC thereof can be administered as a monotherapy (i.e., as the only therapeutic agent) or in combination with one or more additional therapeutic agents (examples of which are described elsewhere herein).

[0386] Provided herein are methods for treating a proliferative disease, a metabolic disease, an inflammation, a neurodegenerative disease, or a disease, disorder, or condition associated with glucocorticoid receptor signaling in a subject, comprising administering to the subject an effective therapeutic amount of a compound described herein (e.g., an anti-MSR1 ADC), or a pharmaceutical composition comprising a compound described herein.

[0387] In some embodiments, when the payload is a steroid, the disease, disorder, or condition is an allergic condition, including, but not limited to, asthma, atopic dermatitis, contact dermatitis, allergic dermatitis, drug hypersensitivity reactions, anaphylactic rhinitis, perennial or seasonal allergic rhinitis, and serum sickness; a skin condition, including, but not limited to, pruritus, seborrheic dermatitis, neurodermatitis, eczema, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome); Endocrine disorders, including but not limited to primary or secondary adrenal insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis; gastrointestinal disorders; blood disorders, including but not limited to acquired (autoimmune) hemolytic anemia, congenital (erythroblastic) aplastic anemia (Diamond-Blackfan anemia), adult idiopathic thrombocytopenic purpura, pure red cell aplasia, and secondary thrombocytopenia; trichinosis; tuberculous meningitis with subarachnoid block or impending block; neoplastic diseases, including but not limited to leukemia and lymphoma; nervous system disorders, including but not limited to acute exacerbation of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumors, craniotomy, or head injury; ophthalmologic diseases, including but not limited to sympathetic ophthalmia, temporal arteritis, uveitis, xerophthalmia, and ocular inflammatory conditions refractory to topical corticosteroids; renal diseases, including but not limited to, for diuresis or induction of remission of proteinuria in idiopathic nephrotic syndrome or for diuresis or induction of remission of proteinuria due to lupus erythematosus; beryllium disease, respiratory diseases, including fulminant or disseminated pulmonary tuberculosis, idiopathic eosinophilic pneumonia, and symptomatic sarcoidosis when used concomitantly with effective anti-tuberculosis chemotherapy; and rheumatic disorders, including for short-term administration (to get patients through an acute episode or exacerbation) in rheumatoid arthritis, including, but not limited to, acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis, as well as for use as adjunctive therapy in dermatomyositis, polymyositis, stomatitis, and systemic lupus erythematosus. In certain embodiments, provided herein are methods for treating or preventing arthritis.

[0388] In some embodiments, described herein are methods of treating a disease, disorder, or condition selected from an autoimmune disease, allergy, arthritis, asthma, a respiratory disorder, a blood disorder, cancer, a collagen disease, a connective tissue disorder, a skin disorder, an eye disorder, an endocrine disorder, an immune disorder, an inflammatory disease, an intestinal disorder, a gastrointestinal disorder, a neurological disorder, an organ transplant disease, a rheumatoid disorder, a skin disorder, a swelling condition, a wound healing condition, and combinations thereof, comprising administering a steroid payload or a conjugate thereof described herein.

[0389] The autoimmune disease is selected from multiple sclerosis, autoimmune hepatitis, shingles, systemic lupus erythematosus (i.e., lupus), myasthenia gravis, Duchenne muscular dystrophy, and sarcoidosis. In some embodiments, the respiratory disorder is selected from asthma, chronic respiratory disease, chronic obstructive pulmonary disease, bronchial inflammation, and acute bronchitis. In some embodiments, the cancer is selected from leukemia, lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), and multiple myeloma. In some embodiments, the collagen disease is systemic lupus erythematosus. In some embodiments, the ophthalmological disease is keratitis. In some embodiments, the endocrine disorder is selected from Addison's disease, adrenal insufficiency, adrenal cortical insufficiency, adrenal cortical hyperplasia, and congenital adrenal hyperplasia. In some embodiments, the inflammatory disease is selected from inflammation after cataract surgery, joint inflammation, immune inflammation, tendon inflammation, bursitis, epicondylitis, Crohn's disease, inflammatory bowel disease, fatty pneumonitis, thyroiditis, urticaria (hives), pericarditis, nephrotic syndrome, and uveitis. In some embodiments, the bowel disease is selected from collagenous colitis, ulcerative colitis, Crohn's disease, and inflammatory bowel disease. In some embodiments, the rheumatic disorder is selected from rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus. In some embodiments, the skin disorder is selected from psoriasis, eczema, and poison ivy. In some embodiments, the neurological disorder is chronic inflammatory demyelinating polyneuropathy.

[0390] In some embodiments, the compounds described herein are administered to patients to treat acute inflammatory events, including, but not limited to, shock, cerebral edema, and graft-versus-host disease. In some embodiments, the compounds described herein are administered to treat lymphocytolytic events, including, but not limited to, those associated with hematological malignancies, such as leukemia, lymphoma, and myeloma.

[0391] In some embodiments, described herein are methods of reducing inflammation in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof described herein. In some embodiments, described herein are methods of modulating the immune system in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof described herein. In some embodiments, described herein are methods of modulating cortisol levels in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof described herein. In some embodiments, described herein are methods of reducing lymphocyte migration in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof described herein. In some embodiments, described herein is a method for treating cancer-induced hypercalcemia, Meniere's disease, migraine, cluster headache, severe aphthous ulcers, laryngitis, severe tuberculosis, Herxheimer reaction to syphilis, decompensated heart failure, allergic rhinitis, or nasal polyps, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or a conjugate thereof described herein. In some embodiments, the compounds disclosed herein can be used to treat inflammatory bowel disease, Crohn's disease, or ulcerative colitis. In some embodiments, the disease, disorder, or condition is a chronic inflammatory disease, including, but not limited to, asthma, skin infections, and eye infections. In some embodiments, the compounds described herein can be used for immunosuppression in patients undergoing organ transplantation.

[0392] In some embodiments, the steroid payloads and conjugates thereof described herein are administered to a patient to treat neurological disorders associated with GR signaling, including, but not limited to, psychiatric disorders such as schizophrenia, drug addiction, post-traumatic stress disorder (PTSD), and mood disorders, substance abuse, stress, and anxiety.

[0393] In some embodiments, the steroid payloads and conjugates thereof described herein are administered to a patient to treat a visual system disorder, including, but not limited to, ocular inflammation (e.g., conjunctivitis, keratitis, uveitis), macular edema, and macular degeneration. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to a patient to treat a cardiovascular disorder. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to a patient to treat a glucose and / or liver metabolism disorder. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to a patient to treat a musculoskeletal disorder. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to a patient to treat a skin inflammatory condition, such as eczema and psoriasis.

[0394] The protein conjugates described herein provide a means for targeted delivery of their steroid payload to specific cells or organ systems, thereby reducing or preventing side effects resulting from administration of the free, unconjugated steroid payload. Examples of such potential side effects to be reduced or prevented include Decadron® (dexamethasone), which is incorporated herein by reference in its entirety. hmmIn some embodiments, the side effects to be reduced or prevented include elevated blood pressure; sodium retention; water / fluid retention (edema, angioedema, pulmonary edema); increased potassium excretion; reversible hypothalamic-pituitary-adrenal (HPA) axis suppression; potential corticosteroid deficiency after withdrawal of treatment; susceptibility to infections; exacerbation of systemic fungal infections; worsening of the severity of chickenpox in pediatric and adult patients; worsening of the severity of measles in pediatric and adult patients; posterior subcapsular cataracts; glaucoma with potential damage to the optic nerve; promotion of the establishment of secondary bacterial, fungal, or viral ocular infections; new episodes of optic neuritis. increased risk of perforation in the presence of active or latent peptic ulcer, diverticulitis, fresh intestinal anastomosis, and nonspecific ulcerative colitis; peritoneal irritation after gastrointestinal perforation; decreased bone formation; increased bone resorption; inhibition of osteoblast function; inhibition of bone growth in pediatric patients; development of osteoporosis at any age; acute myopathy (possibly involving the ocular and respiratory muscles, potentially causing quadriplegia); elevated creatine kinase; psychiatric episodes manifested by euphoria, insomnia, mood swings, personality changes, and severe depression. Persistent mental confusion; worsening of pre-existing emotional lability or psychotic tendencies; increased intraocular pressure; bradycardia; cardiac arrest; cardiac arrhythmia; cardiac hypertrophy; circulatory collapse; congestive heart failure; fat embolism; hypertension; hypertrophic cardiomyopathy in premature infants; cardiac rupture after subacute myocardial infarction; syncope; tachycardia; thromboembolism; thrombophlebitis; vasculitis; acne; allergic dermatitis; shark skin; ecchymoses and petechiae; erythema; impaired wound healing; hyperhidrosis; rash; striae; depressed response to skin tests; thin, brittle skin; thinning of scalp hair; urticaria; decreased carbohydrate and glucose tolerance; development of a Cushingoid state; hyperglycemia; glucose intolerance. Urinary; hirsutism; hypertrichosis; increased insulin or oral hypoglycemic agent requirements in diabetes (insulin resistance); signs of latent diabetes; menstrual irregularities; secondary adrenal and pituitary refractoriness (especially in times of stress, trauma, surgery, or illness); growth restriction in pediatric patients; congestive heart failure in susceptible patients; fluid retention; hypokalemic alkalosis; potassium loss; sodium retention; abdominal distension; elevated serum liver enzyme levels (usually reversible on discontinuation); hepatomegaly; increased appetite; nauseapancreatitis; peptic ulcer with the possibility of perforation and bleeding; perforation of the small and large intestine (especially in patients with inflammatory bowel disease); ulcerative esophagitis; negative nitrogen balance due to protein catabolism; aseptic necrosis of the femoral and humeral heads; muscle loss; muscle weakness; osteoporosis; pathologic fractures of long bones; steroid myopathy; tendon rupture; vertebral compression fractures; convulsions; depression; emotional lability; euphoria; headache; increased intracranial pressure usually with papilledema after discontinuation of treatment (pseudotumor cerebri); insomnia; mood swings; neuritis; neuropathy; paresthesia; personality changes; psychiatric disturbances; vertigo; exophthalmos; glaucoma; increased intraocular pressure; posterior subcapsular cataract; abnormal fat accumulation; decreased resistance to infection; hiccups; increased or decreased sperm motility and count; fatigue; anticholinesterase agents; and weight gain; and side effects associated with drug-drug interactions. In some embodiments, the side effects to be reduced or prevented are those associated with drug-drug interactions. In some embodiments, the side effects to be reduced or prevented include drug-drug interactions resulting from the use of corticosteroids and aminoglutethimide, including attenuation of adrenal suppression by corticosteroids; drug-drug interactions resulting from the use of amphotericin B injections and potassium-depleting agents, including the development of hypokalemia, cardiac hypertrophy, and congestive heart failure; drug-drug interactions resulting from the use of antibiotics, including a significant decrease in corticosteroid clearance; drug-drug interactions resulting from the use of anticholinesterase agents, including resulting in severe weakness in patients with myasthenia gravis; and drug-drug interactions resulting from the use of oral anticoagulants, including an inhibition of response to warfarin. Drug-drug interactions with the use of antidiabetic agents, including increased blood glucose levels; drug-drug interactions with the use of antituberculosis drugs, including decreased serum concentrations of isoniazid; drug-drug interactions with the use of cholestyramine, including increased clearance of corticosteroids; drug-drug interactions with the use of cyclosporine, including increased activity of both cyclosporine and corticosteroids and an increased incidence of seizures; drug-drug interactions with the use of dexamethasone suppression test (DST) interference, including false-negative results in patients treated with indomethacin; drug-drug interactions with the use of digitalis glycosides, including an increased risk of arrhythmia due to hypokalemia;Drug-drug interactions due to the use of ephedrine, including increased metabolic clearance of corticosteroids, resulting in decreased blood levels and decreased physiological activity; drug-drug interactions due to the use of estrogens, including oral contraceptives, including decreased hepatic metabolism of certain corticosteroids and a concomitant increase in their effects; drug-drug interactions due to the use of hepatic enzyme inducers, inhibitors, and substrates (drugs that induce cytochrome P450 3A4 (CYP 3A4) enzyme activity, e.g., barbiturates, phenytoin, carbamazepine, rifampin), including increased metabolism of corticosteroids; drug-drug interactions due to the use of drugs that inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics, e.g., erythromycin), including the potential for increased plasma concentrations of corticosteroids; drug-drug interactions due to the use of drugs that inhibit CYP 3A4, including increased clearance, resulting in decreased plasma concentrations of corticosteroids; Drug-drug interactions associated with the use of drugs metabolized by 3A4 (e.g., indinavir, erythromycin); drug-drug interactions associated with the use of ketoconazole, including up to a 60% decrease in the metabolism of certain corticosteroids resulting in an increased risk of corticosteroid side effects and inhibition of adrenal corticosteroid synthesis, which may lead to adrenal insufficiency during corticosteroid withdrawal; drug-drug interactions associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDS), including an increased risk of gastrointestinal side effects and increased clearance of salicylate; drug-drug interactions associated with the use of phenytoin, including increased or decreased phenytoin levels and altered seizure control; drug-drug interactions associated with the use of skin testing, including suppressed skin test response; drug-drug interactions associated with the use of thalidomide, including toxic epidermal necrolysis; and drug-drug interactions associated with the use of vaccines, including decreased response to toxoids and live or inactivated vaccines due to inhibition of antibody responses or enhanced replication of some organisms contained in live-attenuated vaccines.

[0395] Accordingly, provided herein is a method of treating a disease, disorder, or condition associated with the glucocorticoid receptor, comprising administering a conjugate of Formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), Formula (III), or Formula (3000) to a patient having the disease, disorder, or condition, wherein side effects associated with administering the free steroid payload of the conjugate are reduced. Further provided herein is a method of delivering a compound of Formula (III) or Formula (3000) to a cell, comprising contacting the cell with a protein conjugate of a compound of Formula (III) or Formula (3000), wherein the protein conjugate comprises an antibody or antigen-binding fragment thereof that binds to a surface antigen of the cell.

[0396] In some examples where the payload is an LXR modulator, described herein are methods of treating a disease, disorder, or condition, comprising administering to a patient having the disorder a therapeutically effective amount of a compound and / or ADC (e.g., an ADC of Formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (5001), (5002), (5003), (5004), (6001), (6002), (6003), (6004), or (6005)) or a pharmaceutical composition thereof.

[0397] In some examples, described herein are methods for preventing a disease, disorder, or condition, comprising administering to a patient having the disorder a prophylactically effective amount of a compound and / or ADC (e.g., an ADC of Formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (5001), (5002), (5003), (5004), (6001), (6002), (6003), (6004), or (6005) or a pharmaceutical composition thereof).

[0398] In some instances, described herein are methods of treating or preventing any disease, disorder, or condition responsive to modulation of LXR signaling. In some instances, the disease or disorder is associated with LXR function, LXR polymorphisms, LXR agonist activity, or LXR antagonist activity. In some instances, described herein are methods of treating or preventing a disease, disorder, or condition selected from the group consisting of a proliferative disorder, a neurodegenerative disorder, an immunological disorder, an autoimmune disease, an inflammatory disorder, a skin disorder, a metabolic disorder, a cardiovascular disease, and a gastrointestinal disorder.

[0399] The proliferative disorder can be any proliferative disorder known to those of skill in the art. In certain embodiments, the proliferative disorder includes, but is not limited to, an oncology disorder, wherein the oncology disorder can be any cancer disorder known to those of skill in the art. In certain embodiments, provided herein is a method of treating or preventing melanoma. In certain embodiments, provided herein is a method of treating or preventing metastatic melanoma. In certain embodiments, provided herein is a method of treating or preventing lung cancer. In certain embodiments, provided herein is a method of treating or preventing EGFR-tyrosine kinase inhibitor-resistant lung cancer. In certain embodiments, provided herein is a method of treating or preventing oral cancer. In certain embodiments, provided herein is a method of treating or preventing oral squamous cell carcinoma. In certain embodiments, provided herein is a method of treating or preventing prostate cancer. In certain embodiments, provided herein is a method of treating or preventing Hodgkin's lymphoma. In certain embodiments, provided herein is a method of treating or preventing breast cancer.

[0400] The neurodegenerative disorder can be any neurodegenerative disorder known to one of skill in the art. In certain embodiments, provided herein is a method of treating or preventing Alzheimer's disease. In certain embodiments, provided herein is a method of treating or preventing Parkinson's disease. In certain embodiments, provided herein is a method of treating or preventing Huntington's disease. In certain embodiments, provided herein is a method of treating or preventing amyotrophic lateral sclerosis. In certain embodiments, provided herein is a method of treating or preventing myelin gene expression. In certain embodiments, provided herein is a method of treating or preventing a disease, disorder, or disorder of myelination and remyelination.

[0401] The immunological disorder can be any immunological disorder known to those skilled in the art. In certain embodiments, provided herein is a method for treating or preventing inflammatory bowel disease. In certain embodiments, provided herein is a method for treating or preventing ulcerative colitis. In certain embodiments, provided herein is a method for treating or preventing Crohn's disease.

[0402] The inflammatory disorder can be any inflammatory disorder known to those skilled in the art. In some embodiments, provided herein is a method for treating or preventing arthritis. In some embodiments, provided herein is a method for treating or preventing rheumatoid arthritis.

[0403] The metabolic disease can be any metabolic disease known to those skilled in the art. In some embodiments, the metabolic disease is dyslipidemia. The dyslipidemia can be any dyslipidemia known to those skilled in the art. In some embodiments, the dyslipidemia is selected from the group consisting of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperlipoproteinemia, HDL deficiency, ApoA-I deficiency, and cardiovascular disease, for example, coronary artery disease (including, for example, the treatment and prevention of angina pectoris, myocardial infarction, and sudden cardiac death); atherosclerosis (including, for example, the treatment and prevention of atherosclerotic plaques resulting from medical procedures such as balloon angioplasty). In some embodiments, provided herein is a method for treating or preventing diabetes.

[0404] The cardiovascular disease can be any cardiovascular disease known to those skilled in the art. In certain embodiments, provided herein is a method for treating or preventing atherosclerosis. In certain embodiments, provided herein is a method for treating or preventing atherosclerosis resulting from abnormal macrophage processing. In certain embodiments, provided herein is a method for treating or preventing atherosclerosis resulting from the formation of oxidized low-density lipoprotein (oxLDL) when macrophages are unable to process oxLDL. In certain embodiments, provided herein is a method for treating or preventing ischemic heart disease. In certain embodiments, provided herein is a method for treating or preventing stroke. In certain embodiments, provided herein is a method for treating or preventing hypertensive heart disease. In certain embodiments, provided herein is a method for treating or preventing aortic aneurysm. In certain embodiments, provided herein is a method for treating or preventing endocarditis. In certain embodiments, provided herein is a method for treating or preventing peripheral arterial disease. In certain embodiments, provided herein is a method of treating or preventing any combination of the diseases provided in this paragraph.

[0405] In some instances, described herein are methods of modulating a function of a nuclear receptor. By way of non-limiting example, the function may be selected from expression / secretion of inflammatory mediators (e.g., cytokines, chemokines), cholesterol regulation, cholesterol uptake, cholesterol efflux, cholesterol oxidation, migration, chemotaxis, apoptosis and necrosis, inflammatory activity, lipid regulation, apoptosis, migration, chemotaxis, gene transcription, and protein expression.

[0406] In some examples, described herein are methods for preventing a disease, disorder, or condition, comprising administering to a patient having the disorder a therapeutically effective amount of a compound and / or ADC of Formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (7001), (7002), (7003), (7004), and / or (7005), or a pharmaceutical composition thereof.

[0407] S. aureus is a facultative intracellular bacterium that can survive phagocytosis by macrophages and other cell types (Horn, J. et al., Inside job: Staphylococcus aureus host-pathogen interactions. Int J Med Microbiol, 2018. 308(6): pp. 607-624; Jubrail, J. et al., Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages. Cell Microbiol, 2016. 18(1): pp. 80-96). Intravital imaging has shown that macrophages can serve as reservoirs where S. aureus replicates and subsequently disseminates to other organs during infection (Surewaard, BG et al., Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med, 2016. 213(7): pp. 1141-51). Most antibiotics poorly penetrate cells, including macrophages, indicating that intracellular S. aureus reservoirs can evade standard-of-care antibiotic treatment (Lehar, SM et al., Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature, 2015. 527(7578): pp. 323-8).However, liposomal formulations of vancomycin increased antibiotic penetration into macrophages and reduced S. aureus organ burden more effectively than standard-of-care vancomycin (Surewaard, BG et al., Identification and treatment of the Staphylococcus aureus reservoir in vivo. J Exp Med 2016. 213(7): pp. 1141-51). Collectively, these data indicate that delivery of antibiotics to macrophages may be an effective method to eliminate intracellular S. aureus reservoirs.

[0408] In the United States, antibiotic-resistant Staphylococcus aureus continues to be a public health problem, with approximately 40% of bloodstream infections caused by methicillin-resistant Staphylococcus aureus (MRSA). FDA-approved treatment options are largely nonexistent for MRSA bloodstream infections, with vancomycin remaining the antibiotic of choice. Despite appropriate antibiotic treatment, the mortality rate from S. aureus bloodstream infections is ~18%, prompting research into combinations that may improve treatment.

[0409] The rifamycin class of antibiotics inhibits bacterial RNA polymerase (RNAP) and has potent activity against Staphylococcus aureus. However, monotherapy with this class of antibiotics can lead to the selection of resistant populations during treatment. Therefore, rifamycin antibiotics can be used in combination with first-line antibiotics to improve outcomes in infections commonly associated with prosthetics or exogenous devices.

[0410] The ADCs described herein that comprise rifamycin analogs are useful for preventing or treating bacterial growth and / or bacterial infection in a subject. In some instances, the bacteria is a gram-positive bacteria (gram-positive bacteria are the cause of bacterial infections). In some instances, the bacteria is a pemycin-positive bacteria. D Siri Resistant toIn some examples, the bacterium is a penicillin-resistant bacterium (a penicillin-resistant bacterium is the cause of the bacterial infection). In some examples, the bacterium is Staphylococcus aureus, a methicillin-resistant Staphylococcus aureus (MRSA) bacterium (a MRSA bacterium is the cause of the bacterial infection). In some examples, the bacterium is a methicillin-sensitive Staphylococcus aureus (MSSA) bacterium (a MSSA bacterium is the cause of the bacterial infection). In some examples, the bacterium is a vancomycin-resistant Staphylococcus aureus (VRSA) bacterium (a VRSA bacterium is the cause of the bacterial infection). In some examples, the bacterium is a multidrug-resistant Mycobacterium tuberculosis bacterium (a multidrug-resistant Mycobacterium tuberculosis bacterium is the cause of the bacterial infection). In further examples, the bacterium is, for example, a Chlamydia trachomatis resistant to azithromycin (e.g., a Chlamydia trachomatis resistant to azithromycin is the cause of the bacterial infection). In further examples, the bacteria is, for example, Clostridium difficile resistant to metronidazole, vancomycin, and / or fidaxomicin (e.g., Clostridium difficile resistant to metronidazole, vancomycin, and / or fidaxomicin is the cause of the bacterial infection).

[0411] Provided herein are methods for preventing or treating cellulitis, bacteremia, dermonecrosis, eyelid infection, eye infection, neonatal conjunctivitis, osteomyelitis, impetigo, inflammatory boils, scalded skin syndrome, food poisoning, pneumonia, surgical infection, urinary tract infection, post-burn infection, meningitis, endocarditis, sepsis, toxic shock syndrome, septic arthritis, mastitis, infections associated with prosthetic joints, infections associated with catheters, or infections associated with implants in a subject, the method comprising administering to the subject a therapeutically effective amount of an antibody-drug conjugate comprising a rifamycin analog (e.g., an ADC of Formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (7001), (7002), (7003), (7004), and / or (7005)). Also provided herein is a method of preventing or treating an intracellular bacterial infection in a subject, comprising administering to the subject a therapeutically effective amount of an antibody-drug conjugate comprising a rifamycin analog (e.g., an ADC of Formula (I), (IA), (IB), (IB-1), (IB-2), (IC), (ID), (IE), (7001), (7002), (7003), (7004), and / or (7005)).

[0412] In some examples, provided herein are therapeutic methods comprising administering to a subject in need thereof an anti-MSR1 antibody, an antigen-binding portion of an MSR1 antibody, or an ADC comprising an anti-MSR1 antibody or its MSR1-antigen-binding fragment, which is useful for treating and / or preventing a disease, disorder, or condition associated with a bacterial infection and / or a staphylococcal infection, e.g., a Staphylococcus aureus infection, and / or ameliorating at least one symptom of such a disease, disorder, or condition. Such a disease, disorder, or condition can be cellulitis, bacteremia, skin necrosis, eyelid infection, eye infection, neonatal conjunctivitis, osteomyelitis, impetigo, inflammatory boils, scalded skin syndrome, food poisoning, pneumonia, surgical infection, urinary tract infection, post-burn infection, meningitis, endocarditis, sepsis, toxic shock syndrome, or septic arthritis. In some examples, the subject has a prosthetic joint, and the antibodies disclosed herein are used to treat and / or prevent a Staphylococcus aureus infection of tissues surrounding the prosthetic joint. In some examples, the subject has a catheter, and the antibodies disclosed herein are used to treat and / or prevent Staphylococcus aureus infection of the catheter and / or tissue surrounding the catheter. In some examples, the subject has an implanted foreign body, and the antibodies disclosed herein are used to treat and / or prevent Staphylococcus aureus infection of the foreign body and / or tissue surrounding the foreign body. In some examples, the subject has mastitis, and the antibodies disclosed herein are useful for treating mastitis.

[0413] In some examples, the rifamycin analog and / or anti-MSR1 ADC thereof is administered in combination with one or more additional antibiotics (e.g., antibiotics that can be used to treat MRSA infections), such as vancomycin, trimethoprim-sulfamethoxazole, tetracycline, doxycycline / minocycline, clindamycin, cephalosporins (e.g., cephalexin), natriuretic peptides (e.g., natriuretic peptides), or natriuretic peptides (e.g., natriuretic peptides). Fushi R hmm,and / or any other suitable antibiotic. In some instances, the ADCs described herein that comprise rifamycin analogs are administered in combination with vancomycin and are useful for preventing or treating a bacterial infection in a subject.

[0414] Combination Therapies and Formulations Embodiments include compositions and therapeutic formulations comprising any of the anti-MSR1 antibodies described herein in combination with one or more additional therapeutically active ingredients, as well as methods of treatment comprising administering such combinations to a subject in need thereof.

[0415] The anti-MSR1 antibodies disclosed herein can be co-formulated and / or administered in combination with one or more additional therapeutically active ingredients selected from the group consisting of: cytokine inhibitors, including small molecule cytokine inhibitors and antibodies that bind to cytokines such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-12, IL-13, IL-17, IL-18, or their respective receptors.

[0416] The anti-MSR1 antibodies disclosed herein can also be administered and / or co-formulated in combination with anti-inflammatory agents, immunomodulators, analgesics, corticosteroids, steroids, antioxidants, COX inhibitors, cardioprotective agents, metal chelators, IFN-γ, and / or NSAIDs. In some embodiments, the anti-MSR1 antibodies can be administered and / or co-formulated in combination with anti-PCSK9 antibodies, anti-ANGPTL3 antibodies, statins, ezetimibe, and other lipid-lowering therapies.

[0417] The additional therapeutically active ingredient, e.g., any of the above-mentioned agents or derivatives thereof, can be administered immediately before, simultaneously with, or immediately after administration of the anti-MSR1 antibody disclosed herein; (For purposes of this disclosure, such an administration regimen will be considered administration of the anti-MSR1 antibody "in combination with" the additional therapeutically active ingredient.) Embodiments include pharmaceutical compositions in which the anti-MSR1 antibody disclosed herein is co-formulated with one or more of the additional therapeutically active ingredients described elsewhere herein.

[0418] (Dosage regimen) According to certain embodiments, multiple doses of an anti-MSR1 antibody (or a pharmaceutical composition comprising an ADC or a combination of an anti-MSR1 antibody and any of the additional therapeutically active agents mentioned herein) can be administered to a subject over a defined time course. The method comprises sequentially administering to a subject multiple doses of an anti-MSR1 antibody disclosed herein. As used herein, "sequentially administering" means that each dose of an anti-MSR1 antibody is administered to a subject at a different time point, for example, on different days separated by a predetermined interval (e.g., hour, day, week, or month). Embodiments include methods comprising sequentially administering to a patient a single initial dose of an anti-MSR1 antibody, followed by one or more secondary doses of an anti-MSR1 antibody, and optionally thereafter one or more tertiary doses of an anti-MSR1 antibody.

[0419] The terms "initial dose," "secondary dose," and "tertiary dose" refer to the time sequence of administration of the anti-MSR1 antibody disclosed herein. Thus, an "initial dose" is a dose administered at the beginning of a treatment regimen (also known as a "baseline dose"); a "secondary dose" is a dose administered after the initial dose; and a "tertiary dose" is a dose administered after the secondary dose. The initial, secondary, and tertiary doses may all contain the same amount of anti-MSR1 antibody, but may differ from each other, typically in terms of frequency of administration. In certain embodiments, the amount of anti-MSR1 antibody contained in the initial, secondary, and / or tertiary doses varies from each other during the course of treatment (e.g., adjusted upward or downward as needed). In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered as "loading doses" at the beginning of a treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered at a less frequent frequency.

[0420] In certain exemplary embodiments, each secondary and / or tertiary dose is administered 1 to 26 weeks (e.g., 1, 1 1 / 2, 2, 2 1 / 2, 3, 3 1 / 2, 4, 4 1 / 2, 5, 5 1 / 2, 6, 6 1 / 2, 7, 7 1 / 2, 8, 8 1 / 2, 9, 9 1 / 2, 10, 10 1 / 2, 11, 11 1 / 2, 12, 12 1 / 2, 13, 13 1 / 2, 14, 14 1 / 2, 15, 15 1 / 2, 16, 16 1 / 2, 17, 17 1 / 2, 18, 18 1 / 2, 19, 19 1 / 2, 20, 20 1 / 2, 21, 21 1 / 2, 22, 22 1 / 2, 23, 23 1 / 2, 24, 24 1 / 2, 25, 25 1 / 2, 26, 26 1 / 2 weeks, or longer). As used herein, the phrase "the immediately preceding dose" refers to a dose of an anti-MSR1 antibody that is administered to a patient prior to the administration of the very next dose in a series of multiple doses, in a sequence with no intervening doses.

[0421] The method according to this aspect of the present disclosure can include administering any number of secondary and / or tertiary doses of an anti-MSR1 antibody to a patient. For example, in certain embodiments, only a single secondary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to a patient. Similarly, in certain embodiments, only a single tertiary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to a patient. The administration regimen can be carried out indefinitely for the life of a particular subject, or until such treatment is no longer therapeutically necessary or beneficial.

[0422] In embodiments comprising multiple secondary doses, each secondary dose may be administered at the same frequency as the other secondary doses. For example, each secondary dose may be administered to a patient 1 to 2 weeks or 1 to 2 months after the immediately preceding dose. Similarly, in embodiments comprising multiple tertiary doses, each tertiary dose may be administered at the same frequency as the other tertiary doses. For example, each tertiary dose may be administered to a patient 2 to 12 weeks after the immediately preceding dose. In certain embodiments, the frequency with which the secondary and / or tertiary doses are administered to a patient may vary over the course of a treatment regimen. The frequency of administration may also be adjusted by a physician during the course of treatment depending on the needs of an individual patient after clinical testing.

[0423] Embodiments include dosing regimens in which two to six loading doses are administered to a patient at a first frequency (e.g., once weekly, once every two weeks, once every three weeks, once monthly, once every two months, etc.), followed by two or more maintenance doses administered to the patient at a less frequent frequency. For example, according to this aspect of the invention, if the loading dose is administered monthly, the maintenance doses may be administered to the patient once every six weeks, once every two months, once every three months, etc.

[0424] Diagnostic Uses of Antibodies The anti-MSR1 antibodies disclosed herein can also be used to detect and / or measure MSR1 or MSR1-expressing cells in a sample, for example, for diagnostic purposes. For example, an anti-MSR1 antibody or a fragment thereof can be used to diagnose a disease or disorder characterized by abnormal expression of MSR1 (e.g., overexpression, underexpression, absence of expression, etc.). An exemplary diagnostic assay for MSR1 can include, for example, contacting a sample obtained from a patient with an anti-MSR1 antibody disclosed herein, wherein the anti-MSR1 antibody is labeled with a detectable label or reporter molecule. Alternatively, an unlabeled anti-MSR1 antibody can be used for diagnostic purposes in combination with a secondary antibody that is itself detectably labeled. The detectable label or reporter molecule can be a radioisotope, e.g., 3 H, 14 C. 32 P, 35 S, or 125 1; a fluorescent or chemiluminescent moiety, such as fluorescein or rhodamine; or an enzyme, such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure MSR1 in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immuno-PET (e.g., 89 Zr, 64 Cu), and fluorescence activated cell sorting (FACS).

[0425] Samples that can be used in the MSR1 diagnostic assays of the present invention include any tissue or fluid sample obtainable from a patient that contains a detectable amount of MSR1 protein or a fragment thereof under normal or pathological conditions. Typically, the level of MSR1 in a particular sample obtained from a healthy patient (e.g., a patient not suffering from a disease or disorder associated with abnormal MSR1 levels or activity) is measured to first establish a baseline or standard level of MSR1. This baseline level of MSR1 can then be compared with the level of MSR1 in a sample obtained from an individual suspected of having an MSR1-related disease or disorder. [Example]

[0426] (Example) The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions provided herein, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric. The examples should not be construed as limiting, as they merely provide a specific understanding and practice of the embodiments and various aspects thereof.

[0427] As used herein, symbols and conventions used in the processes and examples herein are consistent with those used in contemporary scientific literature, e.g., the Journal of the American Chemical Society or the Journal of Biological Chemistry, unless otherwise specified to the contrary. Specifically, but without limitation, the following abbreviations may be used in the examples and throughout this specification: [Table 6] TIFF0007590871000390.tif188170

[0428] Unless otherwise expressly stated, reagents and solvents were obtained from commercial sources, such as Sinopharm Chemical Reagent Co. (SCRC), Sigma-Aldrich, Alfa, or other suppliers.

[0429] 1 H NMR and other NMR spectra were recorded on a Bruker AVIII 400 or Bruker AVIII 500. Data were processed with Nuts or MestReNova software, and proton shifts were measured in parts per million (ppm) downfield from the internal standard tetramethylsilane (TMS).

[0430] HPLC-MS measurements were performed on an Agilent 1200 HPLC / 6100 SQ system using the following conditions:

[0431] Method A for HPLC-MS measurement included the following mobile phases: A: water (0.01% trifluoroacetic acid (TFA)), B: acetonitrile (0.01% TFA); gradient phase: 5% B increased to 95% B within 15 minutes (min); flow rate: 1.0 mL / min; column: SunFire C18, 4.6 × 50 mm, 3.5 μm; column temperature: 50 °C; detectors: analog-to-digital converter (ADC), evaporative light scattering detector (ELSD), diode array detector (DAD) (214 nm and 254 nm), electrospray ionization-ambient ionization (ES-API).

[0432] Method B for HPLC-MS determination included the following mobile phases: A: water (10 mM NH4HCO3), B: acetonitrile; gradient phase: 5% to 95% B within 15 min; flow rate: 1.0 mL / min; column: XBridge C18, 4.6 × 50 mm, 3.5 μm; column temperature: 50 °C; detector: ADC ELSD, DAD (214 nm and 254 nm), mass selective detector (MSD) (ES-API).

[0433] LC-MS measurements were performed on an Agilent 1200 HPLC / 6100 SQ system using the following conditions:

[0434] Method A for LC-MS measurement included the following equipment: WATERS 2767; Column: Two connected in series, Shimadzu Shim-Pack, PRC-ODS, 20 × 250 mm, 15 μm; Mobile phase: A: water (0.01% TFA), B: acetonitrile (0.01% TFA); Gradient phase: 5% B increased to 95% B within 3 min; Flow rate: 1.8-2.3 mL / min; Column: SunFire C18, 4.6 × 50 mm, 3.5 μm; Column temperature: 50 °C; Detector: ADC ELSD, DAD (214 nm and 254 nm), ES-API.

[0435] Method B for LC-MS measurement included: equipment: Gilson GX-281; ​​column: Xbridge Prep C18 10 μm OBD, 19 × 250 mm; mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile; gradient phase: 5% to 95% B within 3 min; flow rate: 1.8–2.3 mL / min; column: XBridge C18, 4.6 × 50 mm, 3.5 μm; column temperature: 50 °C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API).

[0436] Preparative high-pressure liquid chromatography (prep HPLC) with acidic or basic solvent systems was performed on a Gilson GX-281 instrument. For the acidic solvent system, a Waters SunFire 10 μm C18 column (100 Å, 250 × 19 mm) was used; solvent A for preparative HPLC was water / 0.05% TFA, and solvent B was acetonitrile. The elution conditions were a linear gradient increase of solvent B from 5% to 100% over 20 min at a flow rate of 30 mL / min. For the basic solvent system, a Waters Xbridge 10 μm C18 column (100 Å, 250 × 19 mm) was used; solvent A for preparative HPLC was water / 10 mM ammonium bicarbonate (NH4HCO3), and solvent B was acetonitrile. The elution conditions were a linear gradient increase of solvent B from 5% to 100% over 20 min at a flow rate of 30 mL / min.

[0437] Flash chromatography was performed on a Biotage instrument using Agela flash column silica-CS cartridges; reversed-phase flash chromatography was performed on a Biotage instrument using Boston ODS or Agela C18 cartridges.

[0438] (Analytical chiral HPLC method - SFC conditions:) a) Apparatus: SFC method station (Thar, Waters) b) Column: CHIRALPAK AD-H / AS-H / OJ-H / OD-H 4.6 x 100 mm, 5 μm (Daicel) c) Column temperature: 40°C d) Mobile phase: CO2 / IPA(0.1%DEA)=55 / 45 e) Flow rate: 4.0ml / min f) Back pressure: 120 bar g) Injection volume: 2μL.

[0439] Preparative Chiral HPLC Method - SFC Conditions: a) Apparatus: SFC-80 (Thar, Waters) b) Column: CHIRALPAK AD-H / AS-H / OJ-H / OD-H 20×250mm, 10μm (Daicel) c) Column temperature: 35°C d) Mobile phase: CO2 / IPA (0.2% methanol ammonia) = 30 / 70 e) Flow rate: 80g / min f) Back pressure: 100 bar g) Detection wavelength: 214nm h) Cycle time: 6.0 minutes i) Sample solution: 1500 mg dissolved in 70 mL of methanol j) Injection volume: 2 mL (loading: 42.86 mg / injection).

[0440] As used herein, the symbols and conventions used in these processes, schemes, and examples are consistent with those used in the contemporary scientific literature, e.g., the Journal of the American Chemical Society or the Journal of Biological Chemistry, regardless of whether a particular abbreviation is specifically defined.

[0441] Example 1: Preparation o...

Claims

1. 1. An isolated antibody or antigen-binding fragment thereof that binds to macrophage scavenger receptor 1 (MSR1), the antibody or antigen-binding fragment thereof comprising: (i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 52; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 60; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 62; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 64; or (ii) HCDR1 comprising the amino acid sequence of SEQ ID NO:4; HCDR2 comprising the amino acid sequence of SEQ ID NO:6; HCDR3 comprising the amino acid sequence of SEQ ID NO:8; LCDR1 comprising the amino acid sequence of SEQ ID NO:12; LCDR2 comprising the amino acid sequence of SEQ ID NO:14; and LCDR3 comprising the amino acid sequence of SEQ ID NO:

16. The isolated antibody or antigen-binding fragment thereof.

2. 2. The isolated antibody or antigen-binding fragment thereof of claim 1, which binds to macrophage scavenger receptor 1 (MSR1), wherein the antibody or antigen-binding fragment thereof has the following characteristics: (i) a K of less than about 1.4 nM at 37° C. as measured by surface plasmon resonance; D Binding to human MSR1 at (ii) binds to human MSR1 with a half-life t of greater than about 4 minutes at 37°C, as measured by surface plasmon resonance; (iii) an IC of less than about 10 nM as measured by a ligand uptake assay; 50 exhibiting less than about 90% maximal inhibition of modified LDL uptake by human MSR1; (iv) blocks modified LDL binding to human MSR1 by <50% as measured by a competitive ELISA assay; and / or (v) exhibiting binding of human MSR1 and internalization of greater than about 10% of the bound complex when assayed by binding in THP-1 cells; The isolated antibody or antigen-binding fragment thereof,

3. The antibody or antigen-binding fragment thereof has an IC of less than 3.5 nM 50 The isolated antibody or antigen-binding fragment thereof of claim 1, which blocks the inhibition of modified LDL uptake by MSR1 by less than 60%.

4. the antibody or antigen-binding fragment thereof (i) a HCVR comprising the amino acid sequence of SEQ ID NO: 50; and a LCVR comprising the amino acid sequence of SEQ ID NO: 58; or (ii) an HCVR comprising the amino acid sequence of SEQ ID NO:2; and an LCVR comprising the amino acid sequence of SEQ ID NO:

10. The anti-MSR1 antibody or antigen-binding fragment thereof of claim 1,

5. 5. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, optionally conjugated to a payload moiety via a linker or via a linker-spacer.

6. 6. The antibody-drug conjugate of claim 5, having the structure of formula (I), or a pharma- ceutically acceptable salt, solvate, stereoisomeric form, positional isomer, or mixture of positional isomers thereof: [Formula 1] (In the formula: BA is a binder; L is a linker; PA is a payload moiety selected from the group consisting of a steroid residue, an LXR modulator residue, or a rifamycin residue; and The subscript n is an integer from 1 to 30.

7. The antibody-drug conjugate of claim 5 or claim 6, having the structure of formula (IA): [Case 2] (In the formula, SP 1 is absent or a spacer; R.G. 1 is a reactive group residue; AA 1 is absent or a bivalent or trivalent linker optionally comprising an amino acid residue directly or indirectly bonded to the group HG; AA 2 is absent or a dipeptide, tripeptide, or tetrapeptide residue; Q, if present, is a connector group residue; SP is absent or a spacer; and HG, if present, is a hydrophilic group).

8. The antibody-drug conjugate of any one of claims 5 to 7, having the structure of formula (IB-1): [C3] (In the formula, SP 1 is absent or a spacer; R.G. 1 is a reactive group residue; Q, if present, [C4] and SP is absent or a spacer; Where: [C5] indicates the atom through which the referenced group is attached to the adjacent group in the formula).

9. The antibody-drug conjugate of any one of claims 5 to 7, having the structure of formula (IB-2): [C6] (In the formula, SP 1 is absent or a spacer; R.G. 1 is a reactive group residue; AA 1 is absent or a bivalent or trivalent linker optionally comprising an amino acid residue directly or indirectly bonded to the group HG; AA 2is absent or a dipeptide, tripeptide, or tetrapeptide residue; Q, if present, [C7] and; SP is absent or a spacer; and HG, if present, [C8] and Where: [C9] indicates the atom through which the referenced group is attached to the adjacent group in the formula).

10. The antibody-drug conjugate of any one of claims 5 to 7 and 9, having a structure of formula (IC), formula (ID), or formula (IE): [C10] (In the formula, SP 1 is absent or a spacer; R.G. 1 is a reactive group residue; SP 2 is absent or a spacer; R.G. 2 is a reactive group residue; AA 1 is a bivalent or trivalent linker comprising an amino acid residue; AA 2 is a dipeptide, tripeptide, or tetrapeptide residue; Q, if present, [C11] and; SP is absent or a spacer; and H.G. [C12] and Where: [C13] indicates the atom through which the referenced group is attached to the adjacent group in the formula).

11. AA 1 -AA 2 The antibody-drug conjugate of any one of claims 7, 9 and 10, wherein said antibody-drug conjugate is according to formula (LL1): [C14] (In the formula, R AA1 , R AA2 , and R AA3 are each independently at least one of -(RG 2 )-SP 2 -HG, -(RG 2 )-HG, or an amino acid side chain linked to HG; [C15] AA through it 1 -AA 2 indicates the atom bonded to the adjacent group in the formula).

12. R AA1 is a lysine, glutamine, glutamic acid, or aspartic acid side chain attached directly or indirectly to HG, and R AA2 and R AA3 are either valine and alanine or valine and citrulline side chains, respectively.

13. AA 1 -AA 2 but, [C16] where: [C17] But through it, AA 1 -AA 2 The antibody-drug conjugate of any one of claims 7 and 9 to 12, wherein indicates an atom attached to an adjacent group in said formula.

14. R.G. 1 and R.G. 2 The residue is, independently in each occurrence: [C18] selected from the group consisting of; Where: [C19] However, through it, the RG 1 or R.G. 2 The antibody-drug conjugate of any one of claims 7 to 13, wherein the residues indicate the atoms that are attached to adjacent groups in said formula.

15. SP, SP 1 , and S.P. 2 is, independently in each occurrence, absent or C 1-6 Alkylene, -NH-, -S-, -O-, -C(O)-, (-CH 2 -CH 2 -O) e , -NH-CH 2 -CH 2 -(-O-CH 2 -CH 2 ) e -C(O)-, -C(O)-(CH 2 ) u -C(O)-, -C(O)-NH-(CH 2 ) v -,(glycine) 4 -serine, and combinations thereof, wherein subscript e is an integer from 0 to 4, subscript u is an integer from 1 to 8, and subscript v is an integer from 1 to 8.

16. The antibody-drug conjugate of any one of claims 5 to 15, wherein n is 1, 2, 3, or 4.

17.

20. but, [C21] [ka] [ka] [ka] [ka] The antibody-drug conjugate of any one of claims 7 to 16,

18. The antibody-drug conjugate of claim 5, wherein the antibody or antigen-binding fragment thereof is conjugated to a steroid payload via a linker or linker-spacer.

19. The antibody-drug conjugate of claim 5, wherein the antibody or antigen-binding fragment thereof is conjugated to an LXR modulator payload via a linker.

20. The antibody-drug conjugate of claim 5, wherein the antibody or antigen-binding fragment thereof is conjugated to a rifamycin payload via a linker.

21. 19. The antibody-drug conjugate of claim 18, wherein the steroid conjugated to the antibody or antigen-binding fragment thereof via a linker or linker-spacer is a compound of formula (A-1): [C22] (In the formula, R 1 and R 2 is independently -H, alkyl, alkyl-C(O)-O-, -OH, or halo; or R 1 and R 2 Together, [C23] Forming Here, R 4 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; wherein the alkyl, aryl, arylalkyl, and N-containing heterocycloalkyl are independently selected from each occurrence: -NR Aa R Ab is optionally substituted with; R 3 -O,R Z-C(O)-X-, -heteroalkyl, -piperidinyl, -NR Aa R Ab , -oxyaryl-NR Aa R Ab , or -Z-A'(R P ) t and; R Z is alkyl; X is O or NR Aa and; Z is S, S(O), S(O) 2 , S.O. 2 NR Aa , O, C(O)NR Aa , C(O), or NR Aa and; A' is aryl, arylalkyl, or heteroaryl; R P is independently, at each occurrence, halo, optionally substituted alkyl, —OH, or —NR Aa R Ab and; R Aa and R Ab is independently at each occurrence -H, optionally substituted alkyl, or optionally substituted aryl; The subscript a is an integer from 0 to 19; and t is an integer from 1 to 3; and R 5A and R 5B are each independently a halo or a hydrogen atom; Here, the group R 3 or R 4 is attached to the linker).

22. 20. The antibody-drug conjugate of claim 18, having the structure of formula (3000), or a pharma- ceutically acceptable salt, solvate, or stereoisomeric form thereof: BA-(L′-SP-D) n Expression(3000) (In the formula, D is a) [C24] (wherein both R x is hydrogen; R 34 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is -C(O)-C 1 -C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C 1 -C 10 -Alkylene-X 1 -(where X 1 is attached to L' in formula (3000), -C(O)-N(H)-(C 1 -C 10 -alkylene)-S- (wherein S is attached to L' in formula (3000)), -C(O)-N(C 1-6 Alkyl)-(C 1 -C 10 -alkylene)-S- (wherein S is attached to L' in formula (3000)); [C25] (wherein the point of attachment to the right (i.e., at N) is to L' in formula (3000)), -CH 2 -NH- (wherein N is attached to L' in formula (3000)), [C26] wherein N is attached to L' in formula (3000), and wherein Ar is an optionally substituted arylene (in some embodiments, [C27] ) or optionally substituted heteroarylene), -(C 1 -C 10 -alkylene)-NR 50 C(O)-(C 1 -C 10 -alkylene)-NR 50a - (where NR 50a is attached to L' in formula (3000), -C(O)-(C 1 -C 10 -alkylene)-NR 50C(O)-(C 1 -C 10 -alkylene)-NR 50a - (where NR 50a is added to L' in formula (3000), and where each C 1 -C 10 -alkylene is optionally substituted with one or more hydroxyl, -C(O)-N(R 35 )-C 1 -C 10 -Alkylene-C(O)NH-X 2 -(where X 2 is attached to L' in formula (3000), or [C28] (where X 4 is attached to L' in formula (3000); or Here, both R x is fluoro; R 34 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is -C(O)-C 1 -C 10 -Alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C 1 -C 10 -Alkylene-X 1b -(where X 1b is attached to L' in formula (3000), -C(O)-N(H)-(C 1 -C 10 -alkylene)-X 1b -(where X 1b is added to L' in formula (3000), [C29] (wherein the point of attachment to the right (i.e., at N) is to L' in formula (3000)), -CH 2 -NH- (wherein N is attached to L' in formula (3000)), [C30] wherein N is attached to L' in formula (3000), and wherein Ar is an optionally substituted arylene (in some embodiments, [C31] ) or optionally substituted heteroarylene), -(C 1 -C 10 -alkylene)-NR 50 C(O)-(C 1 -C 10 -alkylene)-NR 50a - (where NR 50a is attached to L' in formula (3000), -C(O)-(C 1 -C 10 -alkylene)-NR 50 C(O)-(C 1 -C 10 -alkylene)-NR 50a - (where NR 50a is added to L' in formula (3000), and where each C 1 -C 10 -alkylene is optionally substituted with one or more hydroxyl, -C(O)-N(R 35 )-(C 1 -C 10 -alkylene)-C(O)NH-X 2 -(where X 2 is attached to L' in formula (3000), or [C32] (where X 4 is added to L' in formula (3000); and / or b) a compound consisting of: [Table 1] [ka] [ka] [ka] [ka] (wherein the compound is -C(O)CH 2via the hydroxy of the OH group or via the hydroxy of the maplacorat to the BA of the compound of formula (3000) Selected from; X 1 is -N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 is -CH 2 - and X 3 is -CH 2 -O-(C 1 -C 10 -alkylene)-C(O)- (wherein C(O) is X 4 (bonded to X) or 3 is -C(O)-; X 4 is -O-; R 35 are H, -OH, -OCH 3 , or C 1-6 is alkyl; R 50 and R 50a are independently hydrogen or C 1 -C 6 - alkyl; R d , R e , and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH 2 OR g where each R g are independently -CH 2 C(O)OH or -CH 2 C(O)O(alkyl); and mm is 0 or 1; n is an integer selected from 1 to 30; L' is a linker; and BA is a binding agent).

23. The steroid payload comprises: [C33] [ka] [ka] is selected from the group consisting of Where: [C34] The antibody-drug conjugate of claim 18, wherein the bond to the linker is

24. The steroid payload comprises: [C35] 20. The antibody-drug conjugate of claim 18, wherein the antibody-drug conjugate is selected from the group consisting of:

25. 20. The antibody-drug conjugate of claim 19, wherein the LXR modulator conjugated to the antibody or antigen-binding fragment thereof via a linker is a compound of formula (B): [C36] (In the formula, W is -CH 2 -, -N(H)-, or -O-; R B1 -H, -OH, -NH 2 , alkyl, or -OP(O)(OR 6 ) 2 and; R B2 -H, -OH, -CH 2 NH 2 , R B3 , R B4 , R B5 -OR B5 where R B1 and R B2 is not simultaneously -H; R B3 is -N(R 6 ) 2 and; R B4 is -XYZ; X is selected from the group consisting of -O- and -N(H)-; Y is selected from the group consisting of alkylene, substituted alkylene (including but not limited to, oxo-substituted, i.e., =O), heteroalkylene, and substituted heteroalkylene (including but not limited to, oxo-substituted, i.e., =O); Z is -OH and -NH 2 selected from the group consisting of; R B5 is alkyl, heterocycloalkyl, or substituted heterocycloalkyl, where each heterocycloalkyl or substituted heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from nitrogen and oxygen and at least one of -OH and -CH 2 Contains an OH substituent or at least one primary or secondary nitrogen, e.g., O-glucose; Each R 6 is, at each occurrence, -H, an amino acid residue, an N-alkyl amino acid residue, a peptide, or an alkyl; and Each R 7 are independently, halo, C 1-6 Alkyl, C 1-6 Alkoxy, -CN, O-glucose, O-amino acid residues, and O-PEG b where each subscript b is an integer from 0 to 3; Here, the group R B1 or R B2 is attached to the linker).

26. 20. The antibody-drug conjugate of claim 19, wherein the LXR modulator conjugated to the antibody or antigen-binding fragment thereof via a linker is a compound of formula (B-1): [C37] (In the formula: R B1 is -N(H)R 8 Or -N(R 9 ) 2 and; R B2 is -N(H)R 8 and; Each R 8 is independently, at each occurrence, hydrogen, an amino acid residue, an N-alkyl amino acid residue, a peptide residue, a biodegradable moiety, or an alkyl; R 9 is alkyl, aryl, arylalkyl, heterocycloalkyl, or substituted heterocycloalkyl, where each heterocycloalkyl or substituted heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from nitrogen and oxygen, and when substituted, contains at least one of -OH and -CH 2 Contains OH or contains at least one primary or secondary nitrogen; Each R 7 are independently, halo, C 1-6 Alkyl, C 1-6 Alkoxy, -CN, O-glucose, O-amino acid residue, or O-PEG b where each subscript b is an integer from 0 to 3; Here, the group R B1 or R B2 is attached to the linker).

27. The antibody-drug conjugate of any one of claims 5 to 17, 19, 25 and 26, having the structure of formula (6005): [C38] .

28. The LXR modulator comprises: [C39] is selected from the group consisting of Where: [C40] The antibody-drug conjugate of claim 19, wherein the bond to the linker is

29. The LXR modulator comprises: [C41] [ka] [ka] [ka] is selected from the group consisting of Where: [C42] The antibody-drug conjugate of claim 19, wherein the bond to the linker is

30. The LXR modulator is [C43] and; Where: [C44] The antibody-drug conjugate of claim 19, wherein the bond to the linker is

31. 21. The antibody-drug conjugate of claim 20, wherein the rifamycin is a compound of formula (C-1), or a pharma- ceutically acceptable salt, solvate, or stereoisomeric form thereof: [C45] (In the formula: X 1c -S-; -O- and -NR 5c Selected from; R 1c is amino-C 1-6 Alkyl; C 1-6 Alkylamino C 1-6 Alkyl; Di-C 1-6 Alkylamino C 1-6 Alkyl;Hydroxy-C 1-6 Alkyl; HS-C 1-6 Alkyl; (R 5c ) 2 NC 1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; (R 5c ) 2 NC 1-6 Alkylene-OC 1-6 Alkyl; (R 5c ) 2 NC 1-6 Alkylene-SC 1-6 Alkyl; Heterocycloalkyl, or Heterocycloalkyl-C 1-6 alkyl; where heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and where heterocycloalkyl is halo, C 1-6 Alkyl, -OH, =O, or -N(R 5c ) 2 is optionally substituted with; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; Each R ac are, when present, independently: -F; -Cl; -Br; -I; -OH; -NH 2 ; and C 1-6 alkoxy; and R 5c represents independently at each occurrence hydrogen; and C 1-6 alkyl; Here, the group R 1c is attached to the linker).

32. 21. The antibody-drug conjugate of claim 20, wherein the rifamycin is a compound of formula (C-2): [C46] (In the formula: X 1c -S-; -O- and -NR 5c Selected from; R 1c is amino-C 1-6 Alkyl; C 1-6 Alkylamino C 1-6 Alkyl; Di-C 1-6 Alkylamino C 1-6 Alkyl;Hydroxy-C 1-6 Alkyl; HS-C 1-6 Alkyl; (R 5c ) 2 NC 1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; (R 5c ) 2 NC 1-6 Alkylene-OC 1-6 Alkyl; (R 5c ) 2 NC 1-6 Alkylene-SC 1-6 Alkyl; Heterocycloalkyl, or Heterocycloalkyl-C 1-6 alkyl; where heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and where heterocycloalkyl is halo, C 1-6 Alkyl, -OH, =O, or -N(R 5c ) 2 is optionally substituted with; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; R ac and R bc are independently: -F; -Cl; -Br; -I; -OH; -NH 2 ; and C 1-6 alkoxy; and R 5c represents independently at each occurrence hydrogen; and C 1-6 alkyl; Here, the group R 1c is attached to the linker).

33. 21. The antibody-drug conjugate of claim 20, wherein the rifamycin is a compound of formula (C-3): [C47] (In the formula: R 1c , Ji-C 1-6Alkylamino C 1-6 Alkyl; (R 5c ) 2 NC 1-6 Alkylene-N(R 5c )-C 1-6 Alkyl; Heterocycloalkyl, or Heterocycloalkyl-C 1-6 alkyl; where heterocycloalkyl contains 1, 2, or 3 heteroatoms selected from O, N, and S; and where heterocycloalkyl is halo, C 1-6 Alkyl, -OH, =O, or -N(R 5c ) 2 is optionally substituted with; and R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c selected from; and R 5c is hydrogen and C 1-6 alkyl; Here, the group R 1c is attached to the linker).

34. 21. The antibody-drug conjugate of claim 20, wherein the rifamycin is a compound of formula (C-4): [C48] (In the formula: R 1c teeth, [C49] where Y is C or N; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c selected from; and R 5c is independently at each occurrence absent or selected from hydrogen and C 1-6 alkyl; Here, the group R 1c is a wavy line [50] The linker is attached via a nitrogen atom represented by the formula:

35. The antibody-drug conjugate of any one of claims 5 to 7, 9, 13 to 17, 20, and 31 to 34, having the structure of formula (7002): [C51] .

36. The rifamycin is: [C52] [ka] is selected from the group consisting of Where: [C53] The antibody-drug conjugate of any one of claims 6, 7, 9, 13-17, 20, and 31-35, wherein the bond to the linker is

37. An antibody-rifamycin conjugate having the structure of formula (7003), or a pharma- ceutically acceptable salt, solvate, or stereoisomeric form thereof: [C54] (In the formula: X 1c -S-; -O- and -NR 5c Selected from; R 1c teeth, [C55] where Y is C or N; R 2c , R 3c , and R 4c are independently hydrogen, C 1-6 Alkyl, and -(C=O)-R 5c Selected from; R 5c is, independently at each occurrence, absent or hydrogen; and C 1-6 alkyl; each AA is an independently selected amino acid; SP 1 is absent or a spacer; R.G. 1 is a reactive group residue; The BA is the anti-MSR1 antibody or antigen-binding fragment thereof according to claim 1; The subscript n is an integer from 1 to 30; The subscript w is 2, 3, or 4; Here, R 1c is a wavy line [C56] (bonded to -CH 2 - through the nitrogen atom represented by the formula:

38. X 1c The antibody-rifamycin conjugate of claim 37, wherein is O.

39. 39. The antibody-rifamycin conjugate of claim 37 or claim 38, wherein BA is an anti-MSR1 antibody or an antigen-binding fragment thereof comprising a N297Q mutation.

40. The antibody-rifamycin conjugate of any one of claims 37 to 39, wherein the subscript w is 2.

41. (AA) 2 The antibody-rifamycin conjugate of any one of claims 37 to 40, wherein is valine-citrulline.

42. SP 1 but, [C57] 42. The antibody-rifamycin conjugate of any one of claims 37 to 41, comprising:

43. SP 1 but, [C58] 42. The antibody-rifamycin conjugate of any one of claims 37 to 41, comprising:

44. R.G. 1 but, [C59] 44. The antibody-rifamycin conjugate of any one of claims 37 to 43, comprising:

45. X 1c is O; R 1c but, [60] where Y is C or N; where R 1c is R 1c is attached to the linker via a quaternary nitrogen atom of R 5c C 1-6 is alkyl; and R 6c is the counter ion, The antibody-rifamycin conjugate of any one of claims 37 to 43.

46. The rifamycin is: [61] The antibody-rifamycin conjugate of any one of claims 37 to 45,

47. The following: [62] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] wherein: each Ab is an anti-MSR1 antibody or an antigen-binding fragment thereof; Each BA, [63] and where Ab 1 is an anti-MSR1 antibody or an antigen-binding fragment thereof; R is C 2-4 -alkylene; and nn is an integer selected from 2 to 4, inclusive; each n is an integer from 1 to 4; 21. The antibody-drug conjugate of any one of claims 5 to 20, or a stereoisomeric form thereof or a positional isomer thereof or a mixture of positional isomers thereof.

48. The following [64] where: each Ab is an anti-MSR1 antibody or an antigen-binding fragment thereof according to claim 1; and each n is an integer from 1 to 4; An antibody-drug conjugate or a stereoisomeric form thereof or a positional isomer thereof or a mixture of positional isomers thereof.

49. An antibody-drug conjugate according to one of the following formulas or a stereoisomeric form thereof or a positional isomer thereof or a mixture of positional isomers thereof: [65] [ka] [ka] [ka] [ka] (In the formula, Each Ab is an anti-MSR1 antibody or an antigen-binding fragment thereof according to claim 1; Each B.A. [66] where Ab 1 is the anti-MSR1 antibody or antigen-binding fragment thereof according to claim 1; R is C 2-4 -alkylene; and nn is an integer selected from 2 to 4, and Each n is an integer from 1 to 4.

50. The antibody-drug conjugate of any one of claims 5, 6 and 20 according to the formula (7004): [67] .

51. An antibody-drug conjugate prepared by conjugating the anti-MSR1 antibody or PEG-modified anti-MSR1 antibody or antigen-binding fragment thereof according to claim 1 with a linker payload or a stereoisomeric form thereof or a positional isomer thereof or a mixture of positional isomers thereof selected from the group consisting of: [68] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] .

52. The anti-MSR1 antibody or PEG-modified anti-MSR1 antibody, or an antigen-binding fragment thereof, is reacted with a compound represented by the formula (D): [69] The antibody-drug conjugate of claim 5, prepared by contacting a linker payload according to the formula (I) or a stereoisomeric form or positional isomer thereof with an anti-MSR1 antibody or an antigen-binding fragment thereof under conditions suitable for forming a bond between the linker payload according to the formula (I) or a stereoisomeric form or positional isomer thereof with an anti-MSR1 antibody or an antigen-binding fragment thereof.

53. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 and a pharma- ceutical acceptable carrier.

54. A pharmaceutical composition comprising the antibody-drug conjugate of any one of claims 5 to 50 and a pharma- ceutical acceptable carrier.

55. 55. The pharmaceutical composition of claim 53 or 54, for treating a proliferative disease, a metabolic disease, an inflammatory disease, a neurodegenerative disease, or a disease, disorder, or condition associated with glucocorticoid receptor signaling in a subject.

56. 56. The pharmaceutical composition of claim 55, for treating atherosclerosis.

57. 56. The pharmaceutical composition of claim 55, wherein the disease, disorder, or condition associated with glucocorticoid receptor signaling is an inflammatory disease, disorder, or condition.

58. 56. The pharmaceutical composition of claim 55 for treating arthritis.

59. 56. The pharmaceutical composition of claim 55, which reduces side effects associated with administration of a steroid payload that is not conjugated to an antibody.

60. 56. The pharmaceutical composition of claim 55, wherein the metabolic disorder is dyslipidemia.

61. 55. A pharmaceutical composition according to claim 53 or 54 for preventing or treating a bacterial infection in a subject.

62. 62. The pharmaceutical composition of claim 61, wherein the bacterium is a gram-positive bacterium, a penicillin-resistant bacterium Staphylococcus aureus, a methicillin-resistant Staphylococcus aureus (MRSA), a methicillin-sensitive Staphylococcus aureus (MSSA), or a vancomycin-resistant Staphylococcus aureus (VRSA), or a multidrug-resistant Mycobacterium tuberculosis.

63. 62. The pharmaceutical composition of claim 61, wherein the pharmaceutical composition is administered in combination with vancomycin.

64. 55. The pharmaceutical composition of claim 53 or 54 for preventing or treating cellulitis, bacteremia, skin necrosis, eyelid infection, eye infection, neonatal conjunctivitis, osteomyelitis, impetigo, inflammatory boils, scalded skin syndrome, food poisoning, pneumonia, surgical infection, urinary tract infection, post-burn infection, meningitis, endocarditis, sepsis, toxic shock syndrome, septic arthritis, mastitis, infections associated with artificial joints, infections associated with catheters, or infections associated with implants in a subject.

65. 55. A pharmaceutical composition according to claim 53 or 54, for preventing or treating an intracellular bacterial infection in a subject.

Citation Information

Patent Citations

  • SR-a antagonists

    WO2005119266A1

  • Amino acid sequences directed against multitarget scavenger receptors and polypeptides

    WO2010010119A1

  • Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases

    WO2011103389A1

  • Fused heterocyclic compound and application thereof

    WO2012011591A1

  • Phosphate based linkers for intracellular delivery of drug conjugates

    WO2015153401A1